Document:

<PAGE>   1
                                                                    EXHIBIT 10.5

[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION.
THESE PORTIONS HAVE BEEN MARKED WITH THE CLAUSE "CONFIDENTIAL TREATMENT
REQUESTED" AND/OR TWO ASTERISKS ENCLOSED IN BRACKETS (i.e., [**]). THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

<PAGE>   2

                                                                    Confidential

                           CONTRACT SERVICES AGREEMENT
              RE: GENE EXPRESSION PROFILES IN RHEUMATOID ARTHRITIS

                THIS SERVICES AGREEMENT (this "Agreement"), is entered into as
of June 12, 2001, by and between Encode ehf., a corporation formed under the
laws of Iceland and wholly owned indirect subsidiary of deCODE genetics, Inc.,
having principal offices at Geirsgotu 9, 101 Reykjavik, Iceland ("Encode"), and
Genmab A/S, a public limited liability company (aktieselskab) incorporated under
the laws of Denmark having principal offices at Bredgade 23A 3rd Floor, DK-1260
Copenhagen K, Denmark (the "Client") (Encode and Client collectively, the
"Parties" or each a "Party").

        WHEREAS, the Client wishes Encode to perform, and Encode wishes to
perform, certain services as more particularly provided for, and upon the terms
and conditions stated, in this Agreement.

        NOW, THEREFORE, in consideration of the promises and mutual covenants
contained in this Agreement, the Parties hereto agree as follows:

1.      SERVICES.

        1.1.1   Encode shall perform the services for the Client (the
                "Services") as set forth and described in Schedule A attached
                hereto (the "Study Plan") and in Schedule B attached hereto (the
                "Target Development Plan"), including: (a) the Part I Subject
                Drug Study upon the terms set forth in Section 1.1.2; (b) the
                Part IA CD4 Study upon the terms set forth in Section 1.1.3; (c)
                upon the Successful Completion of the Part I Subject Drug Study
                and upon the terms set forth in Section 1.1.4, the Part II
                Subject Drug Study; (d) the Part IB CD4 Study upon the terms set
                forth in Section 1.1.5; (e) upon the Successful Completion of
                the Part I CD4 Study and upon the terms set forth in Section
                1.1.6, the Part II CD4 Study; and (f) upon the initiation of
                each of the Part II Subject Drug Study and the Part II CD4
                Study, those portions of the Target Development Study relating
                to Subject Drug and CD4, respectively. (The Target Development
                Study and the Drug Studies, including the Part I Subject Drug
                Study, Part II Subject Drug Study, Part IA CD4 Study, Part IB
                CD4 Study and Part II CD4 Study, as such terms are defined in
                Schedule A, Schedule B, the Study Plan or the Target Development
                Plan, collectively referred to herein as the "Studies"). Each of
                the Study Plan and Target Development Plan sets forth the
                Services to be performed, the fees (the "Fees") for such
                Services and the timeline (the "Timeline") for the progress and
                completion of such Services. Encode shall exercise commercially
                reasonable efforts to perform the Services set forth in each of
                the Study Plan and the Target Development Plan in a timely
                manner consistent with the Timeline for such Study. In
                connection with the conduct of the Studies, Encode shall
                maintain complete records of patient identification in
                accordance with applicable EU and U.S. requirements, clinical
                observations, laboratory tests and receipt and disposition of
                the drugs administered during the Studies in accordance with
                Section 3.1 hereof.

                                      -1-
<PAGE>   3

        1.1.2   Upon the execution of this agreement, the Parties shall, in
                accordance with Section 1.2, secure all necessary government
                approvals, including, but not limited to, those set forth by
                applicable institutional review boards and/or ethical
                committees, required in connection with identifying and
                enrolling the cohort of patients for the Part I Subject Drug
                Study. Upon the receipt of all such approvals, Encode will
                promptly initiate the Part I Subject Drug Study as set forth in
                the Study Plan.

        1.1.3   Upon the execution of this agreement, the Parties shall, in
                accordance with Section 1.2, secure all necessary government
                approvals, including, but not limited to, those set forth by
                applicable institutional review boards and/or ethical
                committees, required in connection with identifying and
                enrolling the cohort of patients for the Part IA CD4 Study.
                Within 90 days of receipt of all such approvals, Client will
                provide the Materials and Information relating to the
                identification and enrollment of the cohort of patients for the
                Part IA CD4 Study. Upon receipt of such Materials and
                Information, Encode will promptly initiate the Part IA CD4 Study
                as set forth in the Study Plan. If the patients for the for the
                Part IA CD4 Study are not enrolled by Client within the time
                frame set forth above, then Encode may, in its sole discretion,
                require Client to pay it [**] of the Fee set forth on Schedule
                A, which amount paid by Client will be credited against the
                amount which would be owed by Client in the event it later cures
                its non-performance by enrolling the required patients within
                one (1) year of the execution of this Agreement.

        1.1.4   Within thirty (30) days of Client receiving written report from
                Encode detailing the Successful Completion of the Part I Subject
                Drug Study, Client shall send to Encode its written response to
                such report in the event Client disagrees with the findings of
                the report or otherwise believes the Part I Subject Drug Study
                has not been completed successfully and the matter will be
                resolved through the dispute resolution procedures set forth in
                Section 12 hereof. In the event in the time frame set forth
                above that no response is received from Client or Client's
                response is in agreement with the findings of the report, the
                Part I Subject Drug Study shall be deemed to have succeeded (the
                "Success of the Part I Subject Drug Study"). Upon receipt of
                notice from Encode of the Success of the Part I Subject Drug
                Study, the Parties shall, in accordance with Section 1.2, secure
                all necessary government approvals, including, but not limited
                to, those set forth by applicable institutional review boards
                and/or ethical committees, required in connection with
                identifying and enrolling the cohort of patients for the Part II
                Subject Drug Study. Within 90 days of receipt of all such
                approvals, Client will provide the Materials and Information
                relating to the identification and enrollment of the cohort of
                patients for the Part II Subject Drug Study as set forth on
                Schedule A. Upon receipt of such Materials and Information,
                Encode will promptly initiate (a) the Part II Subject Drug Study
                as set forth in the Study Plan and (b) the Target Development
                Study as to Subject Drug as set forth in the Target Development
                Plan. If the patients for the Part II Subject Drug Study are not
                enrolled by Client within the time frame set forth above, then
                Encode may, in its sole discretion, require Client to pay it
                [**] of the Fee set forth on Schedule A, which amount paid by
                Client will be credited against the amount which would be owed
                by Client in the event it later cures its non-performance by
                enrolling the

                                      -2-
<PAGE>   4

                required patients within one (1) year of Client receiving notice
                from Encode of the Successful Completion of the Part I Subject
                Drug Study.

        1.1.5   Upon the unblinding of the Phase II HuMAX-CD4 study currently
                being undertaken by Client (the "CD4 Start Date"), the Parties
                shall, in accordance with Section 1.2, secure all necessary
                government approvals, including, but not limited to, those set
                forth by applicable institutional review boards and/or ethical
                committees, required in connection with identifying and
                enrolling the cohort of patients for the Part IB CD4 Study.
                Within 90 days of receipt of all such approvals, Client will
                provide the Materials and Information relating to the
                identification and enrollment of the cohort of patients for the
                Part IB CD4 Study as set forth on Schedule A. Upon receipt of
                such Materials and Information, Encode will promptly initiate
                the Part IB CD4 Study as set forth in the Study Plan. If the
                patients for the for the Part IB CD4 Study are not enrolled by
                Client within the time frame set forth above, then Encode may,
                in its sole discretion, require Client to pay it [**] of the Fee
                set forth on Schedule A, which amount paid by Client will be
                credited against the amount which would be owed by Client in the
                event it later cures its non-performance by enrolling the
                required patients within one (1) year of the CD4 Start Date.

        1.1.6   Within thirty (30) days of Client receiving written report from
                Encode detailing the Successful Completion of the Part I CD4
                Study, Client shall send to Encode its written response to such
                report in the event Client disagrees with the findings of the
                report or otherwise believes the Part I CD4 Study has not been
                completed successfully and the matter will be resolved through
                the dispute resolution procedures set forth in Section 12
                hereof. In the event in the time frame set forth above that no
                response is received from Client or Client's response is in
                agreement with the findings of the report, the Part I CD4 Study
                shall be deemed to have succeeded (the "Success of the Part I
                CD4 Study"). Upon receipt of notice from Encode of the Success
                of the Part I CD4 Study, the Parties shall, in accordance with
                Section 1.2, secure all necessary government approvals,
                including, but not limited to, those set forth by applicable
                institutional review boards and/or ethical committees, required
                in connection with identifying and enrolling the cohort of
                patients for the Part II CD4 Study. Within 90 days of receipt of
                all such approvals, Client will provide the Materials and
                Information relating to the identification and enrollment of the
                cohort of patients for the Part II CD4 Study as set forth on
                Schedule A. Upon receipt of such Materials and Information,
                Encode will promptly initiate (a) the Part II CD4 Study as set
                forth in the Study Plan and (b) the Target Development Study as
                to CD4 as set forth in the Target Development Plan. If the
                patients for the Part II CD4 Study are not enrolled by Client
                within the time frame set forth above, then Encode may, in its
                sole discretion, require Client to pay it [**] of the Fee set
                forth on Schedule A, which amount paid by Client will be
                credited against the amount which would be owed by Client in the
                event it later cures its non-performance by enrolling the
                required patients within one (1) year of Client receiving notice
                from Encode of the Successful Completion of the Part I CD4
                Study.

                                      -3-
<PAGE>   5

        1.2     Client shall use commercially reasonable efforts to secure all
necessary non-Icelandic government approvals, including, but not limited to,
those set forth by applicable non-Icelandic institutional review boards and/or
non-Icelandic ethical committees, required in connection with identifying and
enrolling the cohort of patients for the each of the Drug Studies. Encode shall
use commercially reasonable efforts to secure all necessary Icelandic government
approvals, including, but not limited to, those set forth by applicable
Icelandic institutional review boards and/or Icelandic ethical committees,
required in connection with identifying and enrolling the cohort of patients for
the each of the Drug Studies. In addition, Encode, through its investigators,
will be responsible for the content and implementation of the final patient
consent form which prior to use will be approved (i) by an institutional review
board established pursuant to 21 C.F.R. Part 56 ("IRB"), if the Study will be
conducted in the United States, and by any required governmental agency or
comparable organization, if the study will be conducted outside the United
States, and (ii) by the Client. Each Party will give reasonable assistance to
the other Party in connection with obtaining any such approvals.

        1.3     Encode will track the overall safety of the Studies and will
alert the Client to any actual or potential safety concerns, reporting all
adverse reactions and side effects to Client in accordance with the Study Plan
and Target Development Plan, as applicable, and all applicable laws, rules and
regulations.

        1.4     It is agreed that Client's scientific and/or quality assurance
personnel may visit Encode upon reasonable advance notice at any mutually
convenient time(s) for the purpose of monitoring the Services; provided that
such visits do not materially interfere with Encode's business. Encode will
promptly notify Client's Principal Scientist (set forth on Schedule A and
Schedule B, respectively) of any unforeseen or unusual happenings which may
affect the outcome of the Services.

        1.5     Encode warrants that the Services shall be provided in
accordance with: (a) the Study Plan; and (b) in good scientific manner and in
accordance with current good clinical practice; and (c) all applicable national,
federal, state and local laws, regulations and guidelines, including, without
limitation, all applicable health and environmental standards.

2.      CLIENT'S MATERIAL AND INFORMATION.

        2.1     The Client shall provide to Encode the relevant information and
materials required to perform the Services as described in Schedule A and
Schedule B, respectively (the "Materials and Information"), at Client's sole
cost and expense. Title to the Materials and Information shall remain with
Client at all times.

        2.2     Client warrants, as of the date hereof, that to the best of its
knowledge it is the owner of the Materials and Information or is otherwise
permitted to transfer the Materials and Information to Encode for the purposes
contemplated by this Agreement without infringing any intellectual property
rights of any other party; provided, such warranty does not extend to Encode's
use of such Materials and Information.

        2.3     The Materials will be used by Encode in compliance with the
terms and conditions of this Agreement, and all applicable laws and regulations.
Upon termination of this Agreement, Encode

                                      -4-
<PAGE>   6

shall, at its option, either dispose of the Materials in the manner described in
the Information provided by Client, or return the Materials to Client for its
disposal, at Client's expense.

        2.4     Encode will at all times retain possession or control of the
Materials and will provide the Materials only to Encode's employees and/or
consultants, including its investigators) who are directly involved in providing
Services under this Agreement. Pursuant to Section 9.3, such employees and/or
consultants of Encode shall be bound by obligations of confidentiality no less
restrictive than those contained in this Agreement.

3.      RECORDS AND REPORTING.

        3.1     Encode shall keep complete and accurate records, including
reports of all Services performed by it under this Agreement. Such records shall
be available at all reasonable times during normal business hours for
inspection, examination or copying by or on behalf of the Client at Client's
expense. Encode agrees to retain all such records other than such records
relating to clinical trials, including all raw data, at any site selected from
time to time by Encode for a period of not less than two (2) years from the date
of termination of this Agreement. Encode agrees to retain all records relating
to clinical trials undertaken in the Studies, including all raw data, at the
site where such clinical studies are performed for a period of not less than
five (5) years from the date of termination of this Agreement. Encode alone
shall pay for all such storage costs during such time periods. However, after
the expirations of such two (2) and five (5) year time periods, respectively,
Client may, at its option, either have Encode submit all such records to Client
or pay a data storage charge at the rate Encode charges for data storage for
Encode to continue to retain such records. (No raw data will be discarded by
Encode without prior written notice to Client.)

        3.2     Encode shall provide data and information as specified in
Schedule A and Schedule B, respectively (the "Deliverables") and a final report
summarizing the Results (as defined in Section 7.10) of the Services at the
completion of the Services (the "Final Report").

4.      COMPENSATION; PAYMENT. As consideration for the Services provided by
Encode under this Agreement, Encode shall receive the Fees according to the
terms set forth on Schedule A and Schedule B, respectively, and in accordance
with the payment schedule set forth on Schedule A and Schedule B, respectively.
For late payment (more than 30 days) Encode shall charge a monthly late payment
fee, on the first day of each month, calculated as a percentage of the total
amount then outstanding, at the rate of ten (10%) percent plus the last interest
rate set by the European Central Bank in the month for which the fee is
calculated.

5.      TERMINATION.

        5.1     In the event that either Party is in material breach of the
Agreement, the other Party may terminate the Agreement upon 60 days' prior
written notice, during which time the Party in breach may cure such default. In
the event of such a termination due to the Client's material breach (unless
otherwise provided in Section 5.2), the Client shall pay Encode all compensation
for Services that shall

                                      -5-
<PAGE>   7

have accrued, in accordance with the Fees and payment terms set forth in
Schedule A and Schedule B, respectively, as of the effective date of such
termination.

        In the event that such notice is given by Encode, Encode shall
immediately use reasonable efforts to reduce loss and cost to the Client as the
result of such termination. Additionally, in such a case the Client's
obligations will be to pay the balance of any Encode fees incurred as of the
date of termination, including any uncancellable legal obligations to third
parties relating to the performance of the Services under this Agreement, such
as, by way of example, purchase orders which were entered into prior to
receiving the notice of termination.

        5.2     In the event that Encode is not able to provide any of the
Services required in connection with completing any one of the Studies, and such
event is due to Encode's gross negligence or willful misconduct in its
performance of the Services in connection with the Study in question, Encode
will reimburse the Client for fees paid to Encode in connection with those
Services rendered for the Study in question.

6.      SCHEDULE REVISIONS. It is understood by the Parties that certain tasks
involved in the performance of the Services may need to be confirmed and/or
modified as the Services progress and Schedule A and/or Schedule B may require
amendment to meet the Client's objectives. Schedule A and/or Schedule B may be
revised by agreement between the Parties, provided that the Party suggesting the
revision communicates the same in a signed writing to the other Party, and
within ten days thereafter, the other Party indicates acceptance thereof in a
signed writing. In the event that the revision has an impact on the Fees in
Schedule A or Schedule B, Encode shall promptly advise the Client of adjustments
thereto. No change to the Services in Schedule A or Schedule B shall be
implemented before Encode has received written concurrence from Client to the
change to the Services in Schedule A or Schedule B and to any consequent change
in the Fees in Schedule A or Schedule B.

7.      OWNERSHIP OF RESULTS AND DATA RETENTION.

        7.1     "Diagnostic Invention" shall mean any patentable invention or
discovery conceived or reduced to practice during and as a part of the Drug
Studies performed pursuant to this Agreement by Encode's investigators,
employees, or consultants or jointly by such an individual or individuals with
one or more employees of Client. Here and throughout this Agreement, the terms
"conceived" and "reduced to practice" shall be given the meaning of those terms
as they appear in 35 USC Section 102(g). Inventions made solely by Encode's
investigators, employees or consultants shall be the sole property of Encode.
Inventions made jointly by Encode's investigators, employees or consultants with
one or more employee of Client shall be owned jointly by Encode and Client.

        7.2     Encode will offer the Client the first opportunity to enter into
a royalty-bearing license agreement to practice such Diagnostic Invention for
use in diagnostic applications, by exercise of the option provided for in
Section 7.6.1. Encode shall retain all rights to practice such Diagnostic
Invention for all purposes other than for use in diagnostic applications. Such
license shall be [**] in which patents are valid and enforceable for which the
Client does not reasonably assume out-of-pocket costs associated with obtaining
and maintaining letters patent in [**]. All remaining terms of the license,

                                      -6-
<PAGE>   8

including payment (in U.S. dollars) to Encode of running royalties on a
percentage of net sales, to be at least [**] and at most [**], and aggregate
milestone payments, to be at least [**] and at most [**], shall be established
in good faith negotiation by the Parties; provided that the Parties intend that
such terms, royalties, and payments will be determined based on the customary
standards in agreements between commercial entities, taking into account (1) the
type of product that will be developed from such Diagnostic Invention; (2) the
level of contribution of each Party to the development of such product; (3)
whether such Diagnostic Invention is solely owned by Encode or jointly by Encode
and the Client; (4) the degree to which the product will contain active
components covered by intellectual property other than the Diagnostic Invention;
(5) the expected size of the market for such product; and (6) the projected cost
of developing such product.

        7.3     In the event Client exercises its option under Section 7.2 and a
definitive agreement is reached for such license pursuant to Sections 7.6.1 and
7.7, Encode shall have an option under such definitive agreement to elect to
retain or reacquire a [**] right to practice such Diagnostic Invention for use
in diagnostic applications except such applications relating to HuMAX-CD4
(including, without limitation, diagnostic applications relating to the Subject
Drug). In the event Encode exercises such option, (a) the license granted under
the definitive agreement shall be [**] and (b) Encode shall pay Client
("Encode's Payments") [**] of the payments made by Client hereunder (which
payments have not been reimbursed under other such licenses or in connection
with Section 7.7) prior to and including the stage of the Drug Studies in which
such Diagnostic Invention was discovered. [**] of Encode's Payments shall be
made as milestone payments under such license corresponding to the milestones
under which Client will be making payments to Encode. Up to [**] of Encode's
Payments shall be made as royalty payments under such license corresponding to
the royalty payments under which Client will be making payments to Encode.

        7.4     "Therapeutic Invention" shall mean any patentable invention or
discovery conceived or reduced to practice during and as a part of the Target
Development Study performed pursuant to this Agreement by Encode's
investigators, employees, or consultants or jointly by such an individual or
individuals with one or more employees of Client. Here and throughout this
Agreement, the terms "conceived" and "reduced to practice" shall be given the
meaning of those terms as they appear in 35 USC Section 102(g). Inventions made
solely by Encode's investigators, employees or consultants shall be the sole
property of Encode. Inventions made jointly by Encode's investigators, employees
or consultants with one or more employee of Client shall be owned jointly by
Encode and Client. (Diagnostic Invention and Therapeutic Invention may be
collectively and individually referred to as an "Invention").

        7.5     Encode will offer the Client the first opportunity to enter into
a royalty-bearing license agreement to practice such Therapeutic Invention for
use in human monoclonal antibody products, by exercise of the option provided
for in Section 7.6.2. Encode shall retain all rights to practice such Diagnostic
Invention for all purposes other than for use in diagnostic applications. Such
license shall be

                                      -7-
<PAGE>   9

[**] in which patents are valid and enforceable for which the Client does not
reasonably assume out-of-pocket costs associated with obtaining and maintaining
letters patent in [**]. All remaining terms of the license, including payment
(in U.S. dollars) to Encode of running royalties on a percentage of net sales,
to be at least [**] and at most [**], and aggregate milestone payments, to be at
least [**] and at most [**], shall be established in good faith negotiation by
the Parties; provided that the Parties intend that such terms, royalties, and
payments will be determined based on the customary standards in agreements
between commercial entities, taking into account (1) the type of product that
will be developed from such Therapeutic Invention; (2) the level of contribution
of each Party to the development of such product; (3) whether such Therapeutic
Invention is solely owned by Encode or jointly by Encode and the Client; (4) the
degree to which the product will contain active components covered by
intellectual property other than the Therapeutic Invention; (5) the expected
size of the market for such product; and (6) the projected cost of developing
such product.

        7.6.1   Encode shall promptly notify the Client, in writing, of any
Diagnostic Invention. The notice shall provide a reasonably detailed written
description of the Diagnostic Invention. The Client shall have the option to
obtain the license identified in Section 7.2 with respect to the identified
Diagnostic Invention by written notification to Encode at any time prior to
[**]; provided, however that if, at any time after the completion of the
Services set forth in the Study Plan (regardless of the results obtained in any
of the Studies in the Study Plan or whether or not the Part II Subject Drug
Study or the Part II CD4 Study were undertaken pursuant to Sections 1.1.2 and
1.1.4, respectively, provided the various time periods for the delivery of the
Materials and Information by Client have expired), Encode receives a bona fide
offer from [**] such Diagnostic Invention, then Client shall have [**] from
receipt of notice of such [**] from Encode to [**] in accordance with Section
7.7. In the event of [**], a failure by the Client to timely notify Encode shall
be deemed a waiver of the [**] with respect to the identified Diagnostic
Invention, but not with respect to other Inventions subject to this Agreement.
In the event Encode enters into license negotiations with a third party with
regard to a Diagnostic Invention pursuant to Sections 7.6.1 or 7.7, Encode shall
use reasonable efforts to ensure that such third party licensee shall (a) grant
to Client the right to use such Diagnostic Invention during clinical trials of
HuMAX-CD4, and (b) to market any diagnostic product resulting from such
Diagnostic Invention in the United States.

        7.6.2   Encode shall promptly notify the Client, in writing, of any
Therapeutic Invention. The notice shall provide a reasonably detailed written
description of the Therapeutic Invention. The Client shall have [**] after
receipt of such notice to exercise the option to obtain the license identified
in Section 7.5 with respect to the identified Therapeutic Invention by written
notification to Encode. A failure by the Client to timely notify Encode shall be
deemed a waiver of the Client's option with respect to the identified
Therapeutic Invention, but not with respect to other Inventions subject to this
Agreement.

        7.7     If the Client exercises an option pursuant to Sections 7.6.1 or
7.6.2, the Parties shall immediately enter into negotiations for the definitive
license agreement. If a license has not been executed within [**] of the
Client's exercise of the option, Client shall reduce to a writing a summary of
the terms last offered by Client (the "Minimum Terms"). After the passage of
such [**] period of time, Encode shall have the right to grant such license
rights to a third party, provided that if the terms of such license sets forth
the same terms as the Minimum Terms or terms more favorable to

                                      -8-
<PAGE>   10
 such third party than the Minimum Terms, then Encode will present such terms to
Client and Client shall have the right to accept such terms, and further
provided that, within [**] after the execution of such a third party license,
Encode shall reimburse Client for [**] of (a) the payments made by Client
hereunder (which payments have not been reimbursed under other such licenses or
in connection with Section 7.3) prior to and including the stage of the Drug
Studies in which such Diagnostic Invention was discovered, in the case of a
license to a Diagnostic Invention, or (b) the payments made by Client to Encode
in connection with the Target Development Study (which payments have not been
reimbursed under other such licenses), in the case of a license to a Therapeutic
Invention.

        7.8     The right of publication by Encode, as indicated in Section 10,
shall not be affected by a license to any Invention. Further, Encode shall
retain all rights to practice any Diagnostic Invention for all purposes other
than for use in diagnostic applications, and Encode shall retain all rights to
practice any Therapeutic Invention for all purposes other than for use in human
monoclonal antibody products.

        7.9     At any time that Encode is providing information to Client
regarding an Invention, if Encode is interested in entering into a collaborative
development and marketing arrangement with respect to either a Diagnostics
Invention or a Therapeutic Invention for which Client has an option as described
above, Encode shall so advise Client. If Client is interested in pursuing such
an arrangement in lieu of exercising its option for a license, then Client shall
advise Encode within [**] thereafter (or such longer period if such time is
otherwise extended by written agreement of Encode and Client), the option
exercise right shall be deferred, and the Parties shall enter into good faith
negotiations for such an arrangement. If the Parties do not enter into
definitive documents for such an arrangement within [**] thereafter, then Client
will have [**] to advise Encode of its desire to exercise its option to acquire
a license, in which case the Parties will follow the procedure for such
negotiations set forth in Section 7.2 or 7.5, as the case may be.

        7.10    For purposes of this Agreement, "Study Results" with respect to
each of the Target Development Study and the Drug Studies, including the Part I
Subject Drug Study, Part II Subject Drug Study, Part IA CD4 Study, Part IB CD4
Study and Part II CD4 Study, shall mean any and all data, results and
information, other than Inventions, generated by or arising from the conduct of
each of such Studies pursuant to this Agreement. For purposes of this Agreement,
"Results" shall mean the Study Results for all of the Studies.

        7.11    Encode shall own the Study Results with respect to Part I
Subject Drug Study, Part II Subject Drug Study, and the Target Development
Study, (collectively, "Encode's Study Results"), and shall have the right to use
Encode's Study Results for any purposes and in any manner without obligation to
the Client, except that with respect to any Encode's Study Results relating to
any Materials provided by the Client that are proprietary to the Client, Encode
shall not have the right to publish Encode's Study Results except as provided in
Section 10. The Client shall have the right to (i) use Encode's Study Results
for the purpose of developing, marketing and selling HuMAX-CD4, or products
developed therefrom, that are proprietary to the Client, including the right of
publication pursuant to Section 10, (ii) include Encode's Study Results in
submissions to the FDA and other regulatory authorities, and (iii) include
Encode's Study Results in marketing materials to the extent permitted by law.

                                      -9-
<PAGE>   11

        7.12    Client shall own the Study Results with respect to Part IA CD4
Study, Part IB CD4 Study and Part II CD4 Study, (collectively, "Client's Study
Results"), and shall have the right to use Client's Study Results for any
purposes and in any manner without obligation to Encode. Encode shall have the
right to (i) exploit Client's Study Results for its internal research and
discovery purposes (as opposed to the development, commercialization or other
exploitation of products or technology resulting therefrom), without the consent
of the Client; and (ii) store and use Client's Study Results in the Icelandic
Health Sector Database and the genealogical and genotypic databases of deCODE
genetics, Inc. and its affiliates (collectively, "deCODE") and such other
databases as may be created or developed by deCODE from time to time during the
term of this Agreement.

        7.13    Except as expressly set forth in this agreement or any
subsequent license agreement that is executed between the Parties pursuant to
Section 7.7, the Parties will follow United States laws of inventorship with
respect to ownership and patenting rights.

8.      NO OTHER RIGHTS. Except as otherwise provided in this Agreement and as
necessary for Encode to conduct the Study, under no circumstances will either
Party, as a result of this Agreement, obtain any ownership, license or other
interest or rights in any technology, material or intellectual property of the
other Party, including any items transferred by such other Party to such Party
at any time pursuant to this Agreement, except as specifically provided in this
Agreement.

9.      CONFIDENTIALITY.

        9.1     For the purposes of this Agreement, the term "Client's
Confidential Material" shall mean: (a) the Materials; (b) any information
specifically relating to the Materials that (i) is provided by Client to Encode
in accord with the provisions of this Agreement; or, (ii) arises from the
Services; or (c) any information specifically relating to Client's Study
Results. The term "Encode's Confidential Material" shall mean (a) any
information specifically relating to Encode's Study Results; or (b) relates to
Encode's operations, including without limitation, Encode's proprietary
inventions, processes and other assets, including but not limited to proprietary
methods, procedures and techniques, procedure manuals, personal and scientific
data, financial information, computer technical expertise and software which
have been independently developed by Encode. The term "Confidential Material"
shall refer to Client's Confidential Material and/or Encode's Confidential
Material collectively and/or separately as the case might be.

        9.2     To be considered Confidential Material, information must either
be supplied in written, graphic, photographic, electronic or other tangible
form, marked "Confidential" and identified as being disclosed under this
Agreement, or initially disclosed in oral or another non-tangible form and
subsequently reduced to writing and marked "Confidential" by the Party making
the disclosure (the "Disclosing Party") within thirty (30) days of the date of
initial disclosure. Client's Confidential Material shall include the
Information. Notwithstanding the foregoing, Confidential Material shall not
include information that: (a) can be demonstrated by the Party receiving the
disclosure (the "Receiving Party") to have been publicly known at the time of
the Disclosing Party's disclosure of such Confidential Material to the Receiving
Party; or, (b) can be demonstrated to have been in the possession of the
Receiving Party prior to the Disclosing Party's disclosure of such Confidential
Material to the Receiving Party; or, (c) is obtained by the Receiving Party from
a third party who has a lawful right to disclose such

                                      -10-
<PAGE>   12

information free of any obligation to the Disclosing Party; or (d) becomes part
of the public domain or publicly known, by publications or otherwise, not due to
any unauthorized act or omission by the Receiving Party; or, (e) can be
demonstrated as independently developed or acquired by the Receiving Party
without reference to or reliance upon such Confidential Material, as evidenced
by the Receiving Party's written records.

        9.3     During the term of this Agreement and for a period of five (5)
years thereafter, each Receiving Party shall: (a) maintain in strict confidence
all of the Disclosing Party's Confidential Material; (b) limit access to the
Disclosing Party's Confidential Material to those of its employees, affiliates
and consultants who reasonably need to know the Disclosing Party's Confidential
Material, and who are bound by obligations of confidentiality no less
restrictive than those contained in this Agreement; (c) advise any and all such
employees, affiliates and consultants of the confidential nature of the other
Party's Confidential Material; (d) use the Disclosing Party's Confidential
Material solely for the performance of its obligations hereunder; (e) ensure
that any Party to which the Disclosing Party's Confidential Material is
disclosed shall abide by the provisions of this Agreement; and (f) except as is
provided for by this Agreement, not disclose any of the Disclosing Party's
Confidential Material to any third party for any reason without the prior
written consent of the Disclosing Party.

        9.4     The foregoing obligations of confidentiality not withstanding,
the Receiving Party shall be entitled to disclose the Disclosing Party's
Confidential Material when such disclosure is required by law, governmental
regulation, or court order, provided that (a) the Receiving Party notifies the
Disclosing Party in advance of any such disclosure, with sufficient notice to
permit the Disclosing Party to seek a protective order, and the Receiving Party
shall assist the Disclosing Party to obtain such protective order at the
Disclosing Party's expense, and (b) in the event that time is not available to
notify the Disclosing Party as set forth in (a) above, the Receiving Party shall
seek such protective order itself at the Disclosing Party's reasonable expense,
and (c) such disclosure is limited to the Disclosing Party's Confidential
Material requested and only to the extent necessary to comply with the order,
and (d) the Receiving Party shall continue to treat as Confidential all such
information with respect to other third parties.

        9.5     All Confidential Material shall remain the exclusive property of
the Disclosing Party and shall be promptly returned or destroyed by the
Receiving Party upon request of the Disclosing Party and, in any event,
following the expiration or termination of this Agreement (provided that the
Receiving Party shall be entitled to retain a single copy thereof for archival
purposes only).

        9.6     Nothing in this Section 9 shall be construed to prevent each of
the Parties from disclosing the existence of the relationship with the other
Party pursuant to this Agreement, including the right to use the name of the
other Party in any such disclosure.

        9.7     This provision shall supercede any prior agreements between the
Parties relating to confidentiality obligations.

        10      PRESS RELEASES; PUBLICATIONS.

                                      -11-
<PAGE>   13

        10.1    PRESS RELEASES. Press releases or other similar public
communication by any Party relating to this Agreement, shall be approved in
advance by the other Party, which approval shall not be unreasonably withheld or
delayed, except for those communications required by applicable law (which shall
be provided to the other Party as soon as practicable after the release or
communication thereof), disclosures of information for which consent has
previously been obtained, and information of a similar nature to that which has
been previously disclosed publicly with respect to this Agreement, each of which
shall not require advance approval.

        10.2    PUBLICATIONS. The Parties acknowledge that scientific lead-time
is a key element of the value of the research and development activities under
this Agreement and further agree that scientific publications must be strictly
monitored to prevent any adverse effect from premature publication of results of
the research or development activities hereunder. At least sixty (60) days prior
to submission of any material related to the research or development activities
hereunder for publication or presentation, the submitting Party shall provide to
the other Party a draft of such material for its review and comment. The
receiving Party shall provide any comments to the submitting Party within thirty
(30) days of receipt of such materials. No publication or presentation with
respect to the research or development activities hereunder which relate to
Client's proprietary Materials shall be made by Encode unless and until Client's
comments on the proposed publication or presentation have been addressed,
changes have been agreed upon, and any information determined by Client to be
Confidential Material has been removed. With respect to any other publication or
presentation with respect to the research and development activities undertaken
hereunder, neither Party shall make any publication or presentation without the
prior review of the other Party, which shall not be unreasonably delayed and the
publishing party shall take into consideration any comments made by the other
party on the proposed publication or presentation. In all cases, each Party
agrees that such Party shall provide appropriate representation and
acknowledgement of the other Party in any publication or presentation for the
respective contributions of the scientists employed by the other Party with
regard to the subject matter of such publication or presentation. If requested
in writing by the other Party, the submitting Party shall withhold material from
submission for publication or presentation for an additional sixty (90) days to
allow for the filing of a patent application or the taking of such measures to
establish and preserve proprietary rights in the information in the material
being submitted for publication or presentation.

11.     INDEMNIFICATION.

        11.1    The Client agrees that it will indemnify and hold harmless
Encode, its directors, officers, employees and agents against any and all
amounts paid or payable to third parties (including reasonable attorneys' fees)
arising out of actions, suits, claims, demands or prosecutions ("Actions")
arising from this Agreement that may be brought or instituted against Encode,
its directors, officers, employees and agents, unless such Action is the result
of Encode's gross negligence or willful misconduct in connection with the
Services. Notwithstanding the foregoing Client shall not be liable to Encode for
any amount exceeding the aggregate fees actually paid by the Client to Encode
under this Agreement.

        11.2    Encode agrees that it will indemnify and hold harmless the
Client, its directors, officers, employees and agents against any and all
amounts paid or payable to third parties (including reasonable attorneys' fees)
arising out of Actions arising from this Agreement that may be brought or
instituted

                                      -12-
<PAGE>   14

against the Client, its directors, officers, employees and agents, unless such
Action is the result of Client's gross negligence or willful misconduct in
connection with the Services. Notwithstanding the foregoing Encode shall not be
liable to the Client for any amount exceeding the aggregate fees actually paid
by the Client to Encode under this Agreement.

        11.3    Each of Encode and the Client, at its own expense, will maintain
insurance coverage (including appropriate tail coverage) of a type and amount to
cover any and all costs, demands, losses, liabilities and expenses with respect
to which such Party is obligated to indemnify the other Party under this
Agreement. Either Party, upon the request of the other Party, will provide
written evidence of such coverage.

        11.4    Any person seeking indemnification under this Section 11 (an
"indemnified Party"): (i) will give the Party obligated to indemnify (the
"indemnifying Party") prompt notice of any Action as soon as practicable; (ii)
will permit the indemnifying Party to control any litigation or dispute
resolution concerning, and the disposition of, such Actions, so long as such
disposition does not materially adversely affect the indemnified Party or its
affiliates; and (iii) will fully cooperate with the indemnifying Party and its
legal representatives in the investigation of any matter that is the subject of
indemnification.

        11.5    Encode warrants that the Services shall be conducted with
reasonable care in accordance with Schedule A and Schedule B. In the event that
Encode defaults on this warranty with respect to the Services or any portion
thereof, the Client's sole and exclusive remedy shall be to have Encode correct
or re-perform such Services or, if Encode reasonably determines that such remedy
is not economically or technically feasible, to obtain an equitable partial or
full refund of amounts paid with respect to the defective Services. This
warranty is in lieu of any and all other warranties relating to the Services,
expressed or implied, including, without limitation, any implied warranties of
merchantability or fitness for a particular purpose.

12.     USE OF NAMES. Each Party may use the name, insignia, symbol, trademark,
trade name or logotype of another Party only (a) in connection with
announcements and other permitted disclosures relating to this Agreement and the
activities contemplated hereby, (b) as required by Applicable Law, and (c)
otherwise as agreed in writing by such other Party.

13.     DISPUTES. Any dispute that may arise relating to the terms of this
Agreement or the activities of the Parties hereunder shall be referred to the
Chief Executive Officers of each of the Parties (or their respective designees)
who shall use their good faith efforts to mutually agree upon the proper course
of action to resolve the dispute. If any dispute is not resolved by the Chief
Executive Officers (or their designees) within ten (10) business days after an
issue is referred to them, or such longer period as the Chief Executive Officers
(or their respective designees) may collectively agree, then either Party shall
have the right to pursue arbitration in accordance with Section 23 or to pursue
such other dispute resolution mechanism as the Parties may agree.

14.     DELAYS. During the term of this Agreement, if either Party ("Delayed
Party") experiences any delays in its performance of any of the Services as a
result, in whole or in part, due to the other Party's ("Delaying Party")
inability to provide Delayed Party with the required Materials and/or
Information, Delayed Party reserves the right to adjust the Timeline and the
Fees, if appropriate, to compensate

                                      -13-
<PAGE>   15

Delayed Party for loss of use of resources and permit Delayed Party to
reschedule such Services in a manner consistent with its obligations under other
contracts. In such event, Delayed Party shall promptly notify Delaying Party of
any such adjustments.

15.     FORCE MAJEURE. Neither Party shall be held liable or responsible to the
other Party nor be deemed to be in default under, or in breach of any provision
of, this Agreement for failure or delay in fulfilling or performing any
obligation of this Agreement when such failure or delay is due to force majeure,
and without the fault or negligence of the Party so failing or delaying. For
purposes of this Agreement, force majeure is defined as causes beyond the
control of the Party, including, without limitation, acts of God; acts,
regulations, or laws of any government; war; civil commotion; destruction of
production facilities or materials by fire, flood, earthquake, explosion or
storm; labor disturbances; epidemic; and failure of public utilities or common
carriers. In such event Encode or the Client, as the case may be, shall
immediately notify the other Party of such inability and of the period for which
such inability is expected to continue. The Party giving such notice shall
thereupon be excused from such of its obligations under this Agreement as it is
thereby disabled from performing for so long as it is so disabled and the 30
days thereafter. To the extent possible, each Party shall use reasonable efforts
to minimize the duration of any force majeure. Notwithstanding the foregoing,
this provision shall not excuse any obligation of either Party to make any
payment under this Agreement when due.

16.     SURVIVAL. The respective rights and obligations of the Parties hereto
contained in Sections 1.3, 2.2, 3.1, 4, 7, 8, 9, 10, 11, 12, 13, 19 and 24 shall
survive the expiration or earlier termination of this Agreement.

17.     INDEPENDENT CONTRACTOR. The relationship between Encode and the Client
is one of independent contractor and not one of partnership, principal and
agent, employer and employee, joint venturers or otherwise. Neither Party shall
have the power or right to bind or obligate the other.

18.     NOTICE. Any notice or other communication required or permitted to be
given under this Agreement shall be in writing and shall be deemed given on the
date actually received if delivered personally, by facsimile (receipt
confirmed), by e-mail (receipt confirmed) or if sent by overnight mail by a
courier guaranteeing overnight delivery (signature required). No notices or
other communications made pursuant to this Agreement shall be made via e-mail if
such notice or other communication contains any Confidential Information of
either Party. Notices and other communications to each of the Parties shall be
addressed to the Parties at the following addresses:

        If to Encode, to:

               Encode
               Geirsgotu 9, 101
               Reykjavik, Iceland
               Attention:    Thor Sigthorsson
                             cc: Hakon Hakonarson
               Tel:  354 510 9900
               Fax:  354 510 9901

                                      -14-
<PAGE>   16

               E-mail:  thor@encode.is
                        cc: hakonh@decode.is

        If to Client, to:

               Genmab A/S
               Bredgade 23, 3rd Floor
               1260 Copenhagen
               Denmark
               Attention: President
               Tel:  45 7020 2728
               Facsimile:  45 7020 2729
               E-mail: ldrakeman@aol.com

19.     GOVERNING LAW. This Agreement shall be construed under the laws of the
State of New Jersey without regard to principles of conflicts of law.

20.     SEVERABILITY. If one or more provisions of this Agreement shall be found
to be illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or
impaired thereby, provided the surviving Agreement materially comports with the
original intent of the Parties.

21.     WAIVER. Waiver by either Party of any breach of this Agreement shall not
constitute a waiver of any subsequent breach of this Agreement.

22.     AMENDMENTS. This Agreement shall be modified or amended only by a
writing signed by the Parties.

23.     ASSIGNMENT. Except in connection with the transfer or sale by either
Party of all or substantially all of its assets to which this Agreement applies,
or the merger or consolidation of a Party hereto with a third party, this
Agreement may not be assigned by either Party without the prior written consent
of the other. In the event of a transfer, sale, merger, or consolidation in
which a Party hereto is not the surviving Party, this Agreement will be assigned
without modification to said Party's successor, and the Agreement shall continue
unaltered for its remaining term unless otherwise agreed upon between the
Parties at the time of any such occurrence.

24.     ARBITRATION. If a dispute shall arise between the Parties concerning
this Agreement, the Parties shall submit such dispute to binding arbitration by
a single arbitrator, who shall be appointed and act in accordance with the then
current commercial arbitration rules promulgated by the CPR Institute for
Dispute Resolution. Any such arbitration shall be conducted exclusively in New
York, New York. The decision of such arbitrator shall be in writing and shall be
final and binding upon the Parties.

                                      -15-
<PAGE>   17

25.     ENTIRE AGREEMENT. This Agreement constitutes the entire Agreement
between the Parties with respect to the subject matter hereof and supersedes all
prior negotiations, representations and agreements, oral or written, with
respect to the subject matter hereof. All of the terms and provisions of this
Agreement shall be binding upon, inure to the benefit of and be enforceable by
the Parties hereto and their respective permitted successors and assigns.

26.     COUNTERPARTS; FACSIMILE SIGNATURES. This Agreement may be executed in
two or more counterparts, each of which shall constitute an original document,
and all of which together shall constitute one and the same instrument. This
Agreement may be executed by facsimile signatures and such signatures shall be
deemed to bind each party hereto as if they were original signatures.

                                      * * *

                                      -16-
<PAGE>   18

    IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed by its duly authorized representative as of the Effective Date.

Encode ehf.

        By:    /s/ Thor Sigthorsson
               ------------------------------------
        Name:  Thor Sigthorsson
        Title: Managing Director

Genmab A/S

        By:    /s/ Dr. Lisa N. Drakeman
               ------------------------------------
        Name:  Dr. Lisa N. Drakeman
        Title: Chief Executive Officer

        By:    /s/ Michael Wolff Jensen
               ------------------------------------
        Name:  Michael Wolff Jensen
        Title: Chief Financial Officer & Head of Legal Department

<PAGE>   19

                                   SCHEDULE A

CONTRACT INFORMATION
<TABLE>
<S>                       <C>
---------------------------------------------------------------------------------------------------------------------------
Description of Study      The study plan entitled "Pharmacogenomics of [**] and [**] Failures and HuMAX-CD4 Responders
Plan:                     and Diagnostic Tests" dated June 12, 2001 (the "Study Plan").
---------------------------------------------------------------------------------------------------------------------------
Services to be
Performed by Encode:      The drug studies as set forth in the Study Plan (the "Drug Studies").
---------------------------------------------------------------------------------------------------------------------------
Materials and             1.   [**] and [**] inhibitor and HuMAX-CD4 monoclonal antibody for in vitro studies.
Information to be         2.   Identification and enrollment of patient cohort for Part I CD4 Study.
provided by Client:       3.   Upon the occurrence of the Successful Completion of the Part I Subject Drug Study, as
                               such term is defined in the Drug Studies, identification and enrollment of patient cohort
                               for Part II Subject Drug Study.
                          4.   Upon the occurrence of the Successful Completion of the Part I CD4 Study, as such term
                               is defined in the Drug Studies, identification and enrollment of patient cohort for Part
                               II CD4 Study.
---------------------------------------------------------------------------------------------------------------------------
Deliverables of Encode:   1.   Diagnostic test for use in rheumatoid arthritis that separates Subject Drug therapy
                               non-responders with [**] or greater predictive accuracy ("Test A").
                          2.   Custom DNA array and protocol for performing Test A.
                          3.   Diagnostic test that separates HuMAX CD4 therapy responders with [**] or greater
                               predictive accuracy ("Test B").
                          4.   Custom DNA array and protocol for performing Test B.
---------------------------------------------------------------------------------------------------------------------------
Client's Principal
Scientist:
Address:
Facsimile:
---------------------------------------------------------------------------------------------------------------------------
Timeline for Completion   -    The Drug Studies will be completed in [**] months after study initiation with an
of Study:                      interim report after 6 months.
---------------------------------------------------------------------------------------------------------------------------
Fee, Payment and Cost     Fee: [**] for performance of the Drug Studies (see Budget attached to the Drug Studies for
Terms:                    detailed break down).  The following percentage of the Fee will be paid by Client upon the
                          occurrence of the following events: [**]

                              -

                          Cost: In addition to the Fee, up to a total of [**] will be paid by Client to reimburse Encode
                          for the actual cost of Affymetrix U95A gene chips as and when such costs are actually incurred
                          by Encode during the course of conducting the studies.
---------------------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>   20

ACCEPTED AND AGREED TO:

Encode ehf.

        By:    /s/ Thor Sigthorsson
               ------------------------------------
        Name:  Thor Sigthorsson
        Title: Managing Director

Genmab A/S

        By:    /s/ Dr. Lisa N. Drakeman
               ------------------------------------
        Name:  Dr. Lisa N. Drakeman
        Title: Chief Executive Officer

        By:    /s/ Michael Wolff Jensen
               ------------------------------------
        Name:  Michael Wolff Jensen
        Title: Chief Financial Officer & Head of Legal Department

<PAGE>   21

                                   SCHEDULE B

CONTRACT INFORMATION

<TABLE>
<S>                    <C>
---------------------------------------------------------------------------------------------------------------------
Description of the     The target development plan entitled "Identification of Novel Therapeutic Targets in
Target Development     Rheumatoid Arthritis" dated June 12, 2001 (the "Target Development Plan").
Plan:
---------------------------------------------------------------------------------------------------------------------
Services to be
Performed by Encode:   The Target Development Study as set forth in the Target Development Plan (the "Target
                       Development Study")

---------------------------------------------------------------------------------------------------------------------
Materials and
Information to be
provided by Client:

---------------------------------------------------------------------------------------------------------------------
Deliverables:          1.   Candidate targets for therapeutic human monoclonal antibodies in RA based on gene
                            expression profiles, analysis of genetic association of SNP haplotypes for the
                            candidate targets in RA.

---------------------------------------------------------------------------------------------------------------------
Client's Principal
Scientist:

Address:

Facsimile:
---------------------------------------------------------------------------------------------------------------------
Timeline:              [**] months after identification of selected genes.

---------------------------------------------------------------------------------------------------------------------
Fee and Payment        Fee: $ [**] for performance of the Target Development Study.
Terms:
                          -   The following percentage of the Fee will be paid by Client upon the occurrence of
                              the following events:[**]

---------------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>   22

ACCEPTED AND AGREED TO:

Encode ehf.

        By:    /s/ Thor Sigthorsson
               ------------------------------------
        Name:  Thor Sigthorsson
        Title: Managing Director

Genmab A/S

        By:    /s/ Dr. Lisa N. Drakeman
               ------------------------------------
        Name:  Dr. Lisa N. Drakeman
        Title: Chief Executive Officer

        By:    /s/ Michael Wolff Jensen
               ------------------------------------
        Name:  Michael Wolff Jensen
        Title: Chief Financial Officer & Head of Legal Department<PAGE>   1
                                                                    EXHIBIT 10.6

[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION.
THESE PORTIONS HAVE BEEN MARKED WITH THE CLAUSE "CONFIDENTIAL TREATMENT
REQUESTED" AND/OR TWO ASTERISKS ENCLOSED IN BRACKETS (i.e., [**]). THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

                                  COLLABORATION

                                       AND

                             CROSS-LICENSE AGREEMENT

                                 RE: DIAGNOSTICS

                                     BETWEEN

                           F.HOFFMANN-LA ROCHE LTD. AG
                                       AND

                              DECODE GENETICS, EHF.

                            DATED AS OF JUNE 29, 2001

<PAGE>   2

                                TABLE OF CONTENTS

                                                                            PAGE

1.     DEFINITIONS............................................................2

       1.1      Addendum......................................................2

       1.2      Affiliate.....................................................2

       1.3      Annual Research Plan..........................................2

       1.4      Biological Materials..........................................2

       1.5      Collaborator..................................................2

       1.6      Combination Product...........................................2

       1.7      Commercialization or Commercialize............................3

       1.8      Commercially Reasonable Efforts...............................3

       1.9      Confidential Information......................................3

       1.10     Contract Year.................................................3

       1.11     Copyright.....................................................3

       1.12     Copyrightable Work............................................3

       1.13     Decision......................................................4

       1.14     deCODE Copyrightable Work.....................................4

       1.15     deCODE Generalized Technology.................................4

       1.16     deCODE IT Intellectual Property...............................4

       1.17     deCODE Invention..............................................4

       1.18     deCODE Know-How...............................................4

       1.19     deCODE Patents................................................4

       1.20     deCODE Patent Valid Claim.....................................5

       1.21     deCODE Product ...............................................5

       1.22     deCODE Project................................................5

       1.23     Development Efforts...........................................5

       1.24     Development Program...........................................5

       1.25     Diagnostic Product............................................5

       1.26     Disease Gene..................................................6

       1.27     Diseases......................................................6

       1.28     Dollar or "$".................................................6

       1.29     Effective Date................................................6

       1.30     Elected Project...............................................6

                                      (i)

<PAGE>   3
                                TABLE OF CONTENTS
                                  (continued)

                                                                            PAGE

       1.31     Europe........................................................6

       1.32     Existing Alliance Diseases....................................6

       1.33     Existing Alliance Research Project............................6

       1.34     Existing Roche Diseases.......................................6

       1.35     Existing Roche Research Project...............................6

       1.36     FDA...........................................................6

       1.37     Field.........................................................7

       1.38     First Commercial Sale.........................................7

       1.39     FTE...........................................................7

       1.40     FTE Rate......................................................7

       1.41     IND...........................................................7

       1.42     IND Filing....................................................7

       1.43     Invention.....................................................7

       1.44     IP Trade......................................................8

       1.45     IT Product....................................................8

       1.46     IT Research Project...........................................8

       1.47     Joint Copyrightable Work......................................8

       1.48     Joint Generalized Technology..................................8

       1.49     Joint IT Intellectual Property................................8

       1.50     Joint Invention...............................................8

       1.51     Joint Know-How................................................9

       1.52     Joint Patents.................................................9

       1.53     Joint Patent Valid Claim......................................9

       1.54     Major Country.................................................9

       1.55     Minutes.......................................................9

       1.56     PLA...........................................................9

       1.57     Net Sales.....................................................9

       1.58     New Roche Diseases...........................................11

       1.59     New Roche Research Project...................................11

       1.60     Participants.................................................11

       1.61     Party........................................................11

                                      (ii)

<PAGE>   4
                                TABLE OF CONTENTS
                                  (continued)

                                                                            PAGE

       1.62     Patents......................................................11

       1.63     Product......................................................11

       1.64     Program Copyrightable Work...................................11

       1.65     Program IT Intellectual Property.............................12

       1.66     Program Know-How.............................................12

       1.67     Program Patents..............................................12

       1.68     Program Patent Valid Claim...................................12

       1.69     Registration.................................................12

       1.70     Representative of a Party....................................12

       1.71     Research Projects............................................13

       1.72     Research Program.............................................13

       1.73     Research Term................................................13

       1.74     Roche Copyrightable Work.....................................13

       1.75     Roche Generalized Technology.................................13

       1.76     Roche IT Intellectual Property...............................13

       1.77     Roche Invention..............................................13

       1.78     Roche Know-How...............................................13

       1.79     Roche Patents................................................13

       1.80     Roche Patent Valid Claim.....................................14

       1.81     Royalty Sublicensing Income..................................14

       1.82     Royalty Term.................................................14

       1.83     Shelved Product..............................................15

       1.84     Shelved Project..............................................15

       1.85     Steering Committee...........................................15

       1.86     Sublicensing Income..........................................15

       1.87     Technical Information........................................15

       1.88     Territory....................................................15

       1.89     Third Party..................................................15

       1.90     USA..........................................................15

       1.91     Additional Definitions.......................................15

                                      (iii)

<PAGE>   5
                                TABLE OF CONTENTS
                                  (continued)

                                                                            PAGE

2.     REPRESENTATIONS AND WARRANTIES........................................17

       2.1      Representations and Warranties of Both Parties:..............17

       2.2      Representations of deCODE....................................17

3.     STEERING COMMITTEE....................................................18

       3.1      Members......................................................18

       3.2      Responsibilities of the Chairperson..........................18

       3.3      Responsibilities.............................................18

       3.4      Meetings.....................................................20

       3.5      Decisions....................................................20

       3.6      Minutes......................................................21

       3.7      Expenses.....................................................22

4.     DISCLOSURE OF KNOW-HOW................................................22

       4.1      Disclosure of deCODE Know-How................................22

       4.2      Disclosure of Roche Know-How.................................22

       4.3      Mechanism for Exchange of Know-How...........................22

5.     COLLABORATIVE RESEARCH PROGRAM........................................22

       5.1      Research Program Objectives..................................22

       5.2      Annual Research Plans........................................23

       5.3      Research Projects............................................24

       5.4      Termination of a Research Project............................29

       5.5      Research Program.............................................29

       5.6      Research Funding.............................................30

       5.7      Use of Funds.................................................31

       5.8      Roche Review Right...........................................31

       5.9      Conduct......................................................32

       5.10     Records......................................................33

       5.11     Biological Materials Transfer................................33

       5.12     Exclusivity..................................................34

       5.13     Research Term................................................35

6.     DEVELOPMENT AND COMMERCIALIZATION.....................................35

       6.1      Commercialization of a Research Project......................35

                                      (iv)

<PAGE>   6
                                TABLE OF CONTENTS
                                  (continued)

                                                                            PAGE

       6.2      Commercialization Efforts by Roche for Elected Project.......36

       6.3      Abandonment of a Diagnostic Product for a Disease............37

       6.4      Sale After Registration......................................38

       6.5      Commercialization Efforts by deCODE and its Sublicensees.....39

       6.6      Reports......................................................39

       6.7      Ownership of Regulatory Filings..............................40

7.     GRANT OF LICENSES.....................................................40

       7.1      deCODE Grants to Roche.......................................40

       7.2      Research Programs............................................41

       7.3      Retained Rights..............................................41

       7.4      Option for New Roche Research Projects.......................41

       7.5      Shelved Products.............................................43

8.     PAYMENTS AND ROYALTIES................................................44

       8.1      Access Fees..................................................44

       8.2      Milestone Payments...........................................45

       8.3      Royalties....................................................46

       8.4      Royalty Reductions...........................................46

       8.5      Obligation to Pay Royalties..................................48

       8.6      Roche Supply Obligation......................................49

       8.7      Barred Royalties.............................................49

9.     PAYMENTS AND REPORTS..................................................49

       9.1      Payment......................................................49

       9.2      Mode of Payment..............................................49

       9.3      Records Retention............................................50

       9.4      Audit Request................................................50

       9.5      Taxes........................................................52

       9.6      Blocked Currency.............................................52

       9.7      Interest on Late Payments....................................53

       9.8      Mechanism for Adjustment to Royalties........................53

10.    OWNERSHIP; PATENTS....................................................53

       10.1     Ownership....................................................53

                                      (v)

<PAGE>   7
                                TABLE OF CONTENTS
                                  (continued)

                                                                            PAGE

       10.2     Patent and Copyright Filing, Maintenance and Prosecution
                Regarding Inventions........................................54

11.    PATENT AND COPYRIGHT ENFORCEMENT AND INFRINGEMENT....................58

       11.1     Patent and Copyright Enforcement............................58

       11.2     Notice of Certification.....................................59

       11.3     Infringement Actions by Third Parties.......................60

12.    INDEMNIFICATION......................................................60

       12.1     Research Activities.........................................60

       12.2     Product Liability...........................................60

       12.3     Notice......................................................61

13.    PUBLICATION; NON-DISCLOSURE..........................................61

       13.1     Publication.................................................61

       13.2     Non-Disclosure and Non-use; Exceptions......................62

       13.3     Authorized Disclosure.......................................63

       13.4     Injunctive Relief...........................................63

       13.5     Third Parties...............................................63

14.    TERM; TERMINATION....................................................63

       14.1     Term; Expiration............................................63

       14.2     Effect of Expiration........................................64

       14.3     Termination Without Cause...................................64

       14.4     Breach by Roche Other than Under Section 6.2 or 6.4.........65

       14.5     Breach by deCODE............................................66

       14.6     Obligations.................................................67

       14.7     Termination of Sublicenses..................................67

       14.8     Surviving Obligations.......................................67

       14.9     No Waiver...................................................68

       14.10    Dispute.....................................................68

15.    FORCE MAJEURE........................................................68

       15.1     Events of Force Majeure.....................................68

16.    MISCELLANEOUS........................................................68

       16.1     Relationship of Parties.....................................68

                                      (vi)

<PAGE>   8
                                TABLE OF CONTENTS
                                  (continued)

                                                                            PAGE

       16.2     Assignment..................................................68

       16.3     Disclaimer of Warranties....................................69

       16.4     Further Actions.............................................69

       16.5     Notice......................................................69

       16.6     Use of Name.................................................70

       16.7     Public Announcements........................................70

       16.8     Waiver......................................................71

       16.9     Compliance with Law.........................................71

       16.10    Severability................................................71

       16.11    Amendment...................................................71

       16.12    Governing Law...............................................71

       16.13    Arbitration.................................................72

       16.14    Entire Agreement............................................72

       16.15    Parties in Interest and Bankruptcy..........................72

       16.16    Descriptive Headings........................................73

       16.17    Counterparts................................................73

       16.18    Interpretation..............................................73

                                      (vii)

<PAGE>   9

                                  COLLABORATION
                                       AND
                     CROSS-LICENSE AGREEMENT RE: DIAGNOSTICS

THIS COLLABORATION AND CROSS-LICENSE AGREEMENT RE: DIAGNOSTICS (this
"Agreement") dated as of June 29, 2001 is by and among F. Hoffmann-LaRoche Ltd
AG, and having offices at Grenzacherstrasse 124, CH-4070 Basel, Switzerland
("Roche"), and deCODE genetics, ehf., a corporation duly organized and existing
under the laws of Iceland, having offices at Lynghals 1, IS-110 Reykjavik,
Iceland ("deCODE").

                             PRELIMINARY STATEMENTS

         A. deCODE and Roche have been collaborating on the discovery of
disease-causing genes for numerous diseases pursuant to that certain Research
Collaboration and Cross-License Agreement between the Parties, or affiliates of
the Parties, dated February 1, 1998 (the "1998 Research Agreement").

         B. deCODE and Roche now wish to expand the relationship created under
the 1998 Research Agreement with respect to diagnostic products to include
expansion of their collaboration with respect to the certain of the diseases
covered by the 1998 Research Agreement and the addition of new targets, products
and diseases, pursuant to the terms and conditions set forth in this Agreement.

         C. The Parties desire to work together to identify and validate
molecular targets useful for developing products and services that accurately
establish a patient's current diagnosis, predict future risk of disease, predict
drug response and determine responses to treatment or the health status of
individuals; and to enable early and effective prevention and/or treatment
(whether such treatment is provided by Roche or a Third Party) or any other kind
of action on the health or disease status of an individual.

         D. In addition, the Parties desire to develop informatics products and
services, including software tools and database content that can be provided at
the point of care to facilitate medical decision-making and bundled together
with diagnostic instruments.

         NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual covenants and agreements of the Parties contained in this Agreement, the
Parties agree as follows:

<PAGE>   10

1.       DEFINITIONS.

         As used in this Agreement, the following terms will have those meanings
set forth in this Section 1 unless the context dictates otherwise.

         1.1 "Addendum" shall mean each addendum to this Agreement that is
entered into by the Parties in connection with a Research Project, as provided
for in Sections 5.3(a), (b) or (c), substantially in the form of Exhibit H.

         1.2 "Affiliate", with respect to any Party, shall mean (a) an
organization at least fifty percent (50%) of which is owned and/or controlled
directly or indirectly, by stock ownership or otherwise, by a Party, (b) an
organization which directly or indirectly owns and/or controls a Party, by stock
ownership or otherwise; or (c) an organization, the majority ownership of which
is directly or indirectly common to the majority ownership of a Party.
Genentech, Inc., a Delaware corporation with an address of 460 Point San Bruno
Boulevard, South San Francisco, California, USA, shall not be deemed an
Affiliate for purposes of this Agreement.

         1.3 "Annual Research Plan" shall mean, for each Research Project, a
reasonably detailed description of (i) the annual goals and scope of such
Research Project, (ii) the annual activities, including without limitation
scientific work assigned to, and to be conducted by, each Party for the Disease
that is the subject of such Research Project or, in the case of an IT Research
Project, for the development of an IT Product, and (iii) the criteria to be
achieved to demonstrate satisfaction of research milestones, as approved by the
Steering Committee for each Contract Year, as updated from time to time during
such Contract Year.

         1.4 "Biological Materials" shall mean any and all biological materials
such as tissue samples, plasma samples and cell lines provided by one Party to
the other Party under this Agreement.

         1.5 "Collaborator" shall mean, (i) for Roche, a Third Party with whom
Roche has agreed jointly to research and/or develop one or more Diagnostic
Products who agrees to be bound by the terms and conditions of this Agreement,
and (ii) for deCODE, a Third Party with whom deCODE has agreed jointly to
research and/or develop one or more deCODE Products who agrees to be bound by
the terms and conditions of this Agreement.

         1.6 "Combination Product" shall mean a Diagnostic Product that (i) is
useful in diagnosis, prognosis, prediction or disease management of a Disease
and at least one other disease that is not a Disease, or (ii) contains (1) a
component which causes such Combination Product to be a Diagnostic Product, and
(2) at least one other component that is able to detect and/or quantify the
presence or amount of (A) a gene other than a Disease Gene, or (B) a product of
a gene other than a Disease Gene.

                                      -2-
<PAGE>   11

         1.7 "Commercialization" or "Commercialize" shall mean any and all
activities directed to developing, obtaining regulatory approval for marketing,
promoting, distributing, offering for sale or selling a Product, importing a
Product for sale, conducting Commercial Phase IIIB Studies and Phase IV Studies,
manufacturing for commercial sale, or an IP Trade. When used as a verb,
"Commercialize" means to engage in Commercialization.

         1.8 "Commercially Reasonable Efforts" shall mean efforts consistent
with sound and reasonable business practices and judgment in the industry, which
are comparable with the efforts exerted by a Party for its own products of a
like kind and at a like stage of development and having similar potential,
taking into account scientific, business and marketing considerations.

         1.9 "Confidential Information" shall mean any and all Technical
Information that is (i) disclosed by one Party ("Disclosing Party") to the other
Party ("Receiving Party") under this Agreement, the 1998 Research Agreement or
the Secrecy Agreement between the Parties dated September 5, 1997, and which at
the time of disclosure is clearly marked as "Confidential," but not Technical
Information which is orally or visually disclosed to a Receiving Party unless
such oral or visual disclosure is described or summarized in a writing, marked
as "Confidential" and provided to the Receiving Party within forty-five (45)
days after such oral or visual disclosure, or (ii) Program Know-How.

         1.10 "Contract Year" shall mean (a) with respect to the first Contract
Year, the period beginning on the first day of the month following the Effective
Date and ending twelve (12) months thereafter (the "First Contract Year"), and
(b) with respect to each subsequent Contract Year, the twelve (12) month period
beginning on the day following the end of the First Contract Year and each
succeeding twelve (12) month period thereafter during the Research Term the
"Second, Third, Fourth or Fifth Contract Year", as applicable). Each Contract
Year shall be divided into four (4) "Contract Quarters" comprised of successive
three (3) month periods.

         1.11 "Copyright" shall mean the copyright subsisting in accordance with
the United States Copyright Law, foreign copyright laws and international
agreements in any Copyrightable Work, together with any United States or foreign
Copyright registration application or resulting Copyright registration.

         1.12 "Copyrightable Work" shall mean any original work of authorship
fixed in any tangible medium of expression, now known or later developed, from
which it can be perceived, reproduced, or otherwise communicated, either
directly or with the aid of a machine or device, including without limitation,
computer programs and related documentation, which is authored, prepared or
created by either Party solely or jointly with the other Party, including a
Party's Representatives, as a Work-Made-For-Hire (as that capitalized term is
defined in the United States Copyright Law), for which such

                                      -3-
<PAGE>   12

Party is considered the author and owner solely or jointly with the other Party
or such Party's Representatives.

         1.13 "Decision" shall mean a decision pursuant to Section 3.4 and shall
be effective as of the date the Minutes reflecting the decision are finalized as
provided in Section 3.5.

         1.14 "deCODE Copyrightable Work" shall mean (i) any Technical
Information that constitutes a Copyrightable Work, excluding deCODE Generalized
Technology, which deCODE or its Affiliates, prior to or during the Research
Term, owns or controls (provided that deCODE or its Affiliates has the right to
license or otherwise make available such Technical Information to Roche) which
relates to any of the Research Projects or is necessary to make, have made, use,
offer for sale, sell or import IT Products, or (ii) any Program Copyrightable
Work which deCODE or its Affiliates solely owns or controls.

         1.15 "deCODE Generalized Technology" shall mean any Technical
Information relating to generalized methods for conducting genomics research and
characterizing the function of genes or generalized information relating to the
foregoing which deCODE or its Affiliates, prior to or during the Research Term,
owns or controls (provided that deCODE or its Affiliates has the right to
license or otherwise make available such Technical Information to Roche).

         1.16 "deCODE IT Intellectual Property" shall mean the statutory rights
and protection afforded deCODE Patents, deCODE Copyrightable Works and/or deCODE
Know-How covering any IT Products by the patent, copyright and trade secret laws
of the country where such right is sought, it being understood that any
individual category of intellectual property may be afforded more than one such
statutory right.

         1.17 "deCODE Invention" shall mean an Invention conceived and reduced
to practice developed, made or created solely by one or more Representatives of
deCODE.

         1.18 "deCODE Know-How" shall mean (i) any Technical Information,
excluding deCODE Generalized Technology, which deCODE or its Affiliates, prior
to or during the Research Term, owns or controls (provided that deCODE or its
Affiliates has the right to license or otherwise make available such Technical
Information to Roche) which relates to any of the Research Projects or is
necessary to make, have made, use, offer for sale, sell or import Products, or
(ii) any Program Know-How which deCODE or its Affiliates solely owns or
controls.

         1.19 "deCODE Patents" shall mean (i) any Patents, excluding Patents
claiming deCODE Generalized Technology, which deCODE or its Affiliates, prior to
or during the Research Term, owns or controls (provided that deCODE or its
Affiliates has the right to license or otherwise make available such Patents to
Roche) which relate to any of the Research Projects or are necessary to make,
have made, use, offer for sale, sell or

                                      -4-
<PAGE>   13

import Products, or (ii) any Program Patent which deCODE or its Affiliates
solely owns or controls.

         1.20 "deCODE Patent Valid Claim" shall mean: (i) a claim of any issued
and unexpired deCODE Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a deCODE Patent
that has not been cancelled, withdrawn, or abandoned, or is not pending in a
given country with the applicable patent office for more than three (3) years
from the earliest date from which the patent application was filed or claims
priority in the given country.

         1.21 "deCODE Product" shall mean any Shelved Product licensed by deCODE
to a Third Party pursuant to Section 7.5(a)(iv) or Commercialized by deCODE.

         1.22 "deCODE Project" shall mean those internal research projects being
conducted by deCODE from time to time, in its sole discretion, with respect to
the diseases set forth on Exhibit A, as such Exhibit may be updated from time to
time.

         1.23 "Development Efforts" shall mean the amount of effort made by
deCODE pursuant to any Research Project to contribute to the overall research or
development of Diagnostic Products from such Research Project; and shall be
determined by the Steering Committee at the time of the approval of each Annual
Research Plan for such Research Project, based on the amount of work allocated
to deCODE under such Annual Research Plan and any preceding Annual Research
Plans for a particular Research Project. Such determination shall be described
as "High Development Efforts," "Medium Development Efforts" or "Low Development
Efforts".

         1.24 "Development Program" shall mean the research, discovery and
development activities performed by a Party in accordance with Article 6 to
discover and/or develop Products.

         1.25 "Diagnostic Product" shall mean:

               (a) any product in the form of a device, compound, kit or service
useful in the Field which contains a component which is (a) able to
[CONFIDENTIAL TREATMENT REQUESTED]; or

               (b) any product in the form of a device, compound, kit or service
useful for the measurement or prediction of individual patient response to a
therapeutic product, which device, compound, kit or service contains a component
which is able to [CONFIDENTIAL TREATMENT REQUESTED]; and is discovered,
developed, made or

                                      -5-
<PAGE>   14

created during, or as part of or as a direct result of a Research Project by a
Party, its Affiliates or its Collaborator at any time during the Research Term.

         1.26 "Disease Gene" shall mean a gene that affects the pathogenesis of
a Disease, as determined by the Steering Committee based on the criteria
established in the Annual Research Plan for the Research Project relating to
such Disease.

         1.27 "Disease" shall mean any of the Existing Roche Diseases, the
Existing Alliance Diseases and the New Roche Diseases, and, in the plural, shall
mean the Existing Roche Diseases, the Existing Alliance Diseases and the New
Roche Diseases, collectively.

         1.28 "Dollar" or "$" shall mean USA Dollars.

         1.29 "Effective Date" shall mean June 29, 2001.

         1.30 "Elected Project " shall mean a Research Project to which Roche
has added value to deCODE Know-How by work product or other resources.

         1.31 "Europe" shall mean the United Kingdom, France, Germany, Italy,
and Spain.

         1.32 "Existing Alliance Diseases" shall mean the diseases for which
Existing Alliance Research Projects are being conducted from time to time, as
set forth in Exhibit B, as such Exhibit may be modified from time to time as
provided in this Agreement.

         1.33 "Existing Alliance Research Project" shall mean a research project
that is [CONFIDENTIAL TREATMENT REQUESTED] and which the Parties select as a
Research Project under this Agreement pursuant to Section 5.3(b) and set forth
as Exhibit B, and which list may be modified from time to time as provided in
this Agreement.

         1.34 "Existing Roche Diseases" shall mean the diseases for which
Existing Roche Research Projects are being conducted from time to time, as set
forth in Exhibit C, as such Exhibit may be modified from time to time as
provided in this Agreement.

         1.35 "Existing Roche Research Project" shall mean a research project
selected from time to time by Roche from its internal research programs for
inclusion as a Research Project under this Agreement pursuant to Section 5.3(a).
A list of the Existing Roche Research Projects as of the Effective Date is set
forth in Exhibit C, which Exhibit may be modified from time to time as provided
in this Agreement.

         1.36 "FDA" shall mean the USA Food and Drug Administration, or the
successor thereto, or any corresponding foreign registration or regulatory
authority.

                                      -6-
<PAGE>   15

         1.37 "Field" shall mean the use of any Diagnostic Product that (a)
identifies patients having a particular disease or having a predisposition to a
particular disease, and/or (b) defines the prognosis or monitors the progress of
any disease in a patient and/or (c) is used to select [CONFIDENTIAL TREATMENT
REQUESTED], based on the use of such product or service, to be the most
effective and/or to be the most safe for a patient.

         1.38 "First Commercial Sale" shall mean, with respect to a Product in a
country of the Territory, the first commercial sale to a Third Party (other than
a sublicensee) by a Party, its Affiliates or sublicensees, as the case may be,
of the Product in the country, after obtaining Registration for the Product in
the given country or, if for a country where no Registration for the Product is
required, the date of first commercial sale of such Product by the Party, its
Affiliates or sublicensees to a Third Party (other than a sublicensee) in the
country. In the case of an IP Trade, the "First Commercial Sale" shall be the
effective date of the license agreement pertaining thereto. "First Commercial
Sale" shall not mean the sale of a Product for use in a clinical trial or for
compassionate or similar use.

         1.39 "FTE" shall mean a full time equivalent person year of scientific,
technical or managerial work on or in direct connection with the Research
Program, or any Research Project, carried out by a Representative of deCODE.
Such work on or in direct connection with the Research Program, or any Research
Project, includes, but is not limited to, experimental laboratory work,
recording and writing of results, reviewing literature and references, holding
scientific discussions, managing and leading scientific staff and carrying out
project management duties.

         1.40 "FTE Rate" shall mean [**] per FTE. The FTE Rate shall include all
personnel, equipment, reagents and all other expenses including support staff
and overhead for or associated with an FTE.

         1.41 "IND" shall mean an Investigational New Device application, as
defined in the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the
regulations promulgated thereunder, conducted or sponsored by Roche, its
Affiliates or sublicensees, for initiating in the USA of human clinical testing
for diagnosis, prevention or treatment of a Disease using a Diagnostic Product,
or any corresponding foreign application, registration or certification in
Europe or Japan.

         1.42 "IND Filing" shall mean the filing of an IND based upon which
human clinical testing commences in the USA, Europe or Japan.

         1.43 "Invention" shall mean an invention, discovery, improvement,
process, method, formula, compilation, source code, object code, device, idea or
concept, (whether or not patentable or copyrightable,) which is developed, made
or created by

                                      -7-
<PAGE>   16

one or more Representatives of a Party or jointly by Representatives of the
Parties as a result of a Research Project.

         1.44 "IP Trade" shall mean the license or sublicense, as the case may
be, by Roche of any results and proceeds of an Elected Project either in
exchange for monetary compensation, intellectual property of a Third Party or
other consideration or any combination of the foregoing and evidenced by a
written agreement.

         1.45 "IT Product" shall mean any informatics product in the form of a
product, software tool or service useful for [CONFIDENTIAL TREATMENT REQUESTED]
which is developed, made or created as a result of a Research Project by a
Party, its Affiliate or its Collaborator at any time during the Research Term.

         1.46 "IT Research Project" shall mean a research project directed
toward the development of informatics products and services, including software
tools, and identified from time to time by the Parties for inclusion as a
Research Project under this Agreement pursuant to Section 5.3(d) as set forth in
Exhibit D, and which list may be modified from time to time as provided in this
Agreement.

         1.47 "Joint Copyrightable Work" shall mean (i) any Technical
Information that constitutes a Copyrightable Work, excluding deCODE Generalized
Technology, which deCODE or its Affiliates, prior to or during the Research
Term, owns or controls (provided that deCODE or its Affiliates has the right to
license or otherwise make available such Technical Information to Roche) which
relates to any of the Research Projects or is necessary to make, have made, use,
offer for sale, sell or import IT Products, or (ii) any Program Copyrightable
Work which deCODE or its Affiliates solely owns or controls.

         1.48 "Joint Generalized Technology" shall mean any Technical
Information relating to generalized methods for conducting genomics research and
characterizing the function of genes or generalized information relating to the
foregoing which is developed, made or created jointly by Representatives of both
Parties as a result of a Research Project.

         1.49 "Joint IT Intellectual Property" shall mean the statutory rights
and protection afforded Joint Patents, Joint Copyrightable Works and/or Joint
Know-How covering any IT Products by the patent, copyright and trade secret laws
of the country where such right is sought, it being understood that any
individual category of intellectual property may be afforded more than one such
statutory right.

         1.50 "Joint Invention" shall mean an Invention developed, made or
created jointly by Representatives of both Parties as a result of a Research
Project.

                                      -8-
<PAGE>   17

         1.51 "Joint Know-How" shall mean shall mean any and all Technical
Information, including any Joint Invention, that is developed, made or created
jointly by Representatives of both Parties as a result of a Research Project.

         1.52 "Joint Patents" shall mean any and all Patents claiming a Joint
Invention.

         1.53 "Joint Patent Valid Claim" shall mean: (i) a claim of any issued
and unexpired Joint Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a Joint Patent that
has not been cancelled, withdrawn or abandoned, or is not pending in a given
country with the applicable patent office for more than three (3) years from the
earliest date from which the patent application was filed or claims priority in
the given country.

         1.54 "Major Country" shall mean the [CONFIDENTIAL TREATMENT REQUESTED].

         1.55 "Minutes" shall mean the final minutes of a Steering Committee
meeting, as finalized under Section 3.5.

         1.56 "PLA" shall mean a Product License Application, as the case may
be, for a Diagnostic Product, for diagnosis, prevention or treatment of a
Disease, filed with the FDA in the USA or any corresponding foreign application,
registration or certification in Europe (either in the European Union using a
centralized process or in one of the countries comprising Europe under a
decentralized process) or Japan.

         1.57 "Net Sales" and the related term "Adjusted Gross Sales" shall have
the following meanings:

              (a) As to Roche:

                  (i) "Adjusted Gross Sales" shall mean, with respect to any
Diagnostic Product, the amount of gross sales invoiced by Roche, its Affiliates
or sublicensees to Third Parties for such Diagnostic Product, commencing with
the First Commercial Sale of such Diagnostic Product, less deductions for the
following items which are included in the invoiced amounts and do not exceed
reasonable and customary amounts in the country in which such sale occurred: (1)
returns (including withdrawals and recalls), (2) rebates (price reductions
including Medicaid and similar types of rebates, e.g., chargebacks), (3) volume
(quantity) discounts granted at the time of invoicing, (4) sales taxes and other
taxes directly linked and included in the gross sales amount, as computed in the
Roche's sales statistics for the countries concerned. "Adjusted Gross Sales"
shall also include the amount or fair market value of all other consideration
received by Roche, its Affiliates or sublicensees with respect to Diagnostic
Products, whether such consideration is in cash, payment in kind, exchange or
another form.

                                      -9-
<PAGE>   18

                  (ii) "Net Sales" shall mean the amount calculated by
subtracting from Adjusted Gross Sales [CONFIDENTIAL TREATMENT REQUESTED] of
Adjusted Gross Sales for those sales related deductions which are not accounted
for on a product-by-product basis (e.g. outward freights, postage,
transportation insurance, packing materials for dispatch of goods, custom
duties, discounts granted later than at the time of invoicing, cash discounts
and other direct expenses).

              (b) As to deCODE:

                  (i) "Adjusted Gross Sales" shall mean, with respect to any
deCODE Product, the amount of gross sales invoiced by deCODE or its Affiliates
to Third Parties for such deCODE Product, commencing with the First Commercial
Sale of such deCODE Product, less deductions for the following items which are
included in the invoiced amounts and do not exceed reasonable and customary
amounts in the country in which such sale occurred: (1) returns (including
withdrawals and recalls), (2) rebates (price reductions including Medicaid and
similar types of rebates, e.g., chargebacks), (3) volume (quantity) discounts
granted at the time of invoicing, and (4) sales taxes and other taxes directly
linked and included in the gross sales amount. "Adjusted Gross Sales" shall also
include the amount or fair market value of all other consideration received by
deCODE or its Affiliates with respect to deCODE Products, whether such
consideration is in cash, payment in kind, exchange or another form.

                  (ii) "Net Sales" shall mean the amount calculated by
subtracting from Adjusted Gross Sales [CONFIDENTIAL TREATMENT REQUESTED] for
those sales related deductions which are not accounted for on a
product-by-product basis (e.g. outward freights, postage, transportation
insurance, packing materials for dispatch of goods, custom duties, discounts
granted later than at the time of invoicing, cash discounts and other direct
expenses).

              (c) In the event the price of a Diagnostic Product (including
a Diagnostic Product that becomes a deCODE Product) includes an amount to cover
instrument system costs or amortization recovery under an instrument system
rental plan or similar plan, the Net Sales for such Diagnostic Product shall be
reduced by [CONFIDENTIAL TREATMENT REQUESTED] to reflect the actual value of
such instrument system, calculated in a manner consistent with such Party's
policies and procedures for all such instrument systems, and shall be based upon
supporting documentation and applicable to all Diagnostic Products sold by a
Party, its Affiliates, or sublicensees, and which deduction shall be subject to
an annual review by the Parties; provided that [CONFIDENTIAL TREATMENT
REQUESTED] taken by Roche or deCODE, as applicable, shall be [CONFIDENTIAL
TREATMENT REQUESTED].

              (d) For a Combination Product, the Parties shall meet
approximately three (3) months prior to commercial launch of such Combination
Product to negotiate in good faith and agree to an appropriate adjustment to Net
Sales to reflect the relative significance of each component of the Combination
Product or royalty bearing fraction

                                      -10-
<PAGE>   19

of such Combination Product. If, after good faith negotiations (not to exceed
thirty (30) days, which can be extended by mutual agreement), the Parties cannot
agree to an appropriate adjustment, Net Sales shall be equal to Net Sales of the
Combination Product multiplied by a fraction, the numerator of which is the
reasonable fair market value of the component(s) of said Product, which cause
said product to be a Diagnostic Product, if sold separately and the denominator
of which is the reasonable fair market value of the Combination Product.

By way of clarification, where the Diagnostic Product is included in a kit for
nucleic acid amplification, the Parties shall negotiate in good faith and agree
to an appropriate adjustment to Net Sales to reflect the relative significance
of each component (e.g., sample preparation, amplification and detection) of the
Diagnostic Product.

         1.58 "New Roche Diseases" shall mean the diseases for which New Roche
Research Projects are being conducted from time to time, as set forth in Exhibit
E, as such Exhibit may be modified from time to time as provided in this
Agreement.

         1.59 "New Roche Research Project" shall mean a research project
[CONFIDENTIAL TREATMENT REQUESTED], as set forth on Exhibit E for inclusion as a
research project under this Agreement pursuant to Section 5.3(c). A list of the
New Roche Research Projects will be set forth in Exhibit E, and may be modified
from time to time as provided in this Agreement.

         1.60 "Participants" shall mean those persons who enroll to participate
in harvesting programs or other studies being conducted as part of a Research
Project.

         1.61 "Party" shall mean deCODE or Roche and, when used in the plural,
shall mean deCODE and Roche.

         1.62 "Patents" shall mean all patents and patent applications
throughout the Territory, and any extensions, renewals, continuations,
continuations-in-part, divisions, patents-of-addition, reissues, registrations,
patents of confirmation, patents of importation, and Supplementary Protection
Certificates and foreign counterparts thereof.

         1.63 "Product" shall mean any Diagnostic Product, deCODE Product or IT
Product, and, in the plural, shall mean the Diagnostic Products, deCODE Products
and IT Products, collectively.

         1.64 "Program Copyrightable Work" shall mean any Technical Information
that constitutes a Copyrightable Work, that is developed or conceived and
reduced to practice, made or created solely by a Party, or jointly by both
Parties, as a result of a Research Project; provided, however, that any
Technical Information that is developed or conceived and reduced to practice,
made or created as a result of a Research Project solely by one or more
Representatives of deCODE relating to generalized methods for conducting
genomics research and characterizing the function of genes or

                                      -11-
<PAGE>   20

generalized information relating to the foregoing shall be considered deCODE
Generalized Technology but not Program Copyrightable Work.

         1.65 "Program IT Intellectual Property" shall mean the statutory rights
and protection afforded Program Patents, Program Copyrightable Works and/or
Program Know-How covering any IT Products by the patent, copyright and trade
secret laws of the country where such right is sought, it being understood that
any individual category of intellectual property may be afforded more than one
such statutory right.

         1.66 "Program Know-How" shall mean any and all Technical Information,
including any Invention, that is developed or conceived and reduced to practice,
made or created solely by a Party, or jointly by both Parties, as a result of a
Research Project; provided, however, that any Technical Information that is
developed or conceived and reduced to practice, made or created as a result of a
Research Project solely by one or more Representatives of deCODE relating to
generalized methods for conducting genomics research and characterizing the
function of genes or generalized information relating to the foregoing shall be
considered deCODE Generalized Technology but not Program Know-How.

         1.67 "Program Patents" shall mean any and all Patents claiming an
Invention.

         1.68 "Program Patent Valid Claim" shall mean: (i) a claim of any issued
and unexpired Program Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a Program Patent
that has not been cancelled, withdrawn, or abandoned, or is not pending in a
given country with the applicable patent office for more than three (3) years
from the earliest date from which the patent application was filed or claims
priority in the given country.

         1.69 "Registration" shall mean, for a given country and a given Product
for diagnosing, preventing or treating a Selected Disease, an official approval,
resulting from an application for such official approval in the given country
filed by Roche, its Affiliate or sublicensee, which is required by the
government or health authority of the given country for the Product to be
offered for sale in such country, including authorizations as may be required
for the production, importation, pricing, reimbursement and sale of such Product
in such country, and for subsequent regulatory filings for line extensions
and/or additional indications of such Product.

         1.70 "Representative of a Party" shall mean an employee of a Party or
its Affiliates or any other person who is contractually required to assign or
grant exclusive rights in and to Program Know-How to a Party or its Affiliates.

                                      -12-
<PAGE>   21

         1.71 "Research Projects" shall mean the Existing Roche Research
Projects, the Existing Alliance Research Projects, the New Roche Research
Projects and the IT Research Projects.

         1.72 "Research Program" shall mean all of the Research Projects
collectively.

         1.73 "Research Term" shall mean, subject to Section 5.12, a five (5)
year period commencing on the first day of the First Contract Year and ending on
the last day of the Fifth Contract Year, unless extended or earlier terminated
as otherwise provided in this Agreement.

         1.74 "Roche Copyrightable Work" shall mean (i) any Technical
Information that constitutes a Copyrightable Work which Roche or its Affiliates,
prior to or during the Research Term, owns or controls (provided that Roche or
its Affiliates has the right to license or otherwise make available such
Technical Information to deCODE) which relates to any of the Research Projects
or is necessary to make, have made, use, offer for sale, sell or import IT
Products, or (ii) any Program Copyrightable Work which Roche or its Affiliates
solely owns or controls.

         1.75 "Roche Generalized Technology" shall mean any Technical
Information relating to generalized methods for conducting genomics research and
characterizing the function of genes or generalized information relating to the
foregoing which Roche or its Affiliates, prior to or during the Research Term,
owns or controls (provided that Roche or its Affiliates has the right to license
or otherwise make available such Technical Information to deCODE).

         1.76 "Roche IT Intellectual Property" shall mean the statutory rights
and protection afforded Roche Patents, Roche Copyrightable Works and/or Roche
Know-How covering any IT Products by the patent, copyright and trade secret laws
of the country where such right is sought, it being understood that any
individual category of intellectual property may be afforded more than one such
statutory right.

         1.77 "Roche Invention" shall mean an Invention developed or conceived
and reduced to practice, made or created solely by one or more Representatives
of Roche.

         1.78 "Roche Know-How" shall mean (i) any Technical Information which
Roche or its Affiliates, prior to or during the Research Term, owns or controls
(provided that Roche or its Affiliates has the right to license or otherwise
make available such Technical Information to deCODE) which relates to any of the
Research Projects or is necessary to make, have made, use, offer for sale, sell
or import deCODE Products, or (ii) any Program Know-How which Roche or its
Affiliates solely owns or controls ; provided however, that "Roche Know-How"
specifically excludes Technical Information relating to the polymerase chain
reaction ("PCR") methods and/or technology.

         1.79 "Roche Patents" shall mean (i) any Patents which Roche or its
Affiliates, prior to or during the Research Term, owns or controls (provided
that Roche or its

                                      -13-
<PAGE>   22

Affiliates has the right to license or otherwise make available such Patents to
deCODE) which relate to any of the Research Projects or are necessary to make,
have made, use, offer for sale, sell or import Products, or (ii) any Program
Patent which Roche or its Affiliates solely owns or controls; provided however,
that "Roche Patents" specifically excludes Roche's and its Affiliates' patent
portfolio relating to PCR technology.

         1.80 "Roche Patent Valid Claim" shall mean: (i) a claim of any issued
and unexpired Roche Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a Roche Patent that
has not been cancelled, withdrawn, or abandoned, or is not pending in a given
country with the applicable patent office for more than three (3) years from the
earliest date from which the patent application was filed or claims priority in
the given country.

         1.81 "Royalty Sublicensing Income" shall mean that portion of
Sublicensing Income directly attributable to royalties received by deCODE from
its Third Party licensees with respect to such Third Party licensees' sales of a
given deCODE Product in a given country.

         1.82 "Royalty Term" shall mean:

              (a) As to Roche, for a given Diagnostic Product in a given
country in the Territory, a period of time commencing with respect to Net Sales,
on the First Commercial Sale of the given Diagnostic Product in the given
country and ending on the later of: (i) [**] from the date of the First
Commercial Sale of such Diagnostic Product in such country, or (ii)
[CONFIDENTIAL TREATMENT REQUESTED] on which the making, having made, using,
offering for sale, selling or importing of the Diagnostic Product in the country
of sale by Roche, its Affiliates or sublicensees is claimed by a deCODE Patent
Valid Claim or a Program Patent Valid Claim.

              (b) As to deCODE, for a given deCODE Product in a given
country in the Territory, a period of time commencing (i) with respect to Net
Sales, on the First Commercial Sale of the given deCODE Product in the given
country, and (ii) with respect to Sublicensing Income, on the Effective Date,
and ending on the later of: (1) [CONFIDENTIAL TREATMENT REQUESTED] from the date
of the First Commercial Sale of such deCODE Product in such country, or (2)
[CONFIDENTIAL TREATMENT REQUESTED] on which the making, having made, using,
offering for sale, selling or importing of the deCODE Product in the country of
sale by deCODE, its Affiliates or sublicensees is claimed by a Roche Patent
Valid Claim or a Program Patent Valid Claim.

              (c) If, in a country in the Territory, the above definition of
Royalty Term is unenforceable, then for such country, Royalty Term shall mean
the longest term as may be enforceable under the applicable laws of such
country, provided that in no event shall the Royalty Term in such country exceed
the maximum term above.

                                      -14-
<PAGE>   23

         1.83 "Shelved Product" shall mean any Diagnostic Product or IT Product
developed from a Shelved Project. A "Shelved Product" may become a deCODE
Product.

         1.84 "Shelved Project" shall mean any Research Project to which Roche
(a) relinquished its rights to [CONFIDENTIAL TREATMENT REQUESTED] developed
therefrom in writing; or (b) [CONFIDENTIAL TREATMENT REQUESTED], as determined
by the Steering Committee, for example, by [CONFIDENTIAL TREATMENT REQUESTED];
or (c) has Commercialized any Diagnostic Product or IT Product developed from
such Research Project and thereafter, Roche ceases the sale or other
distribution thereof from all of the Major Countries for a period of at least
[CONFIDENTIAL TREATMENT REQUESTED]. The Steering Committee shall determine
whether a Research Project is a Shelved Project.

         1.85 "Steering Committee" shall mean the body organized and acting
pursuant to Section 3.

         1.86 "Sublicensing Income" shall mean all consideration, including, for
example, up-front payments, milestones, and royalties, received by deCODE from
its Third Party licensees with respect to a given deCODE Product, but excluding
any amounts received from Third Party licensees to reimburse deCODE for research
and development expenses of deCODE which deCODE can reasonably document;
provided, however, that with respect to consideration [CONFIDENTIAL TREATMENT
REQUESTED].

         1.87 "Technical Information" shall mean information, data methods,
trade secrets, know-how or copyrights (whether patentable or not patentable),
including without limitation, ideas, concepts, formulas, manufacture, methods,
procedures, designs, compositions of matter, plans, applications,
specifications, drawings, techniques, materials (including without limitation
biological materials such as Biological Materials, RNA, DNA, DNA fragments,
organisms, proteins, polypeptides, plasmids, vectors and the like) compounds,
products, processes, research, technical data, apparatus, equipment, samples,
inventions, discoveries, and the like, as well as improvements related thereto.

         1.88 "Territory" shall mean the entire world.

         1.89 "Third Party" shall mean any party other than a Party, or an
Affiliate of a Party.

         1.90 "USA" shall mean the United States of America.

         1.91 Additional Definitions. Each of the following definitions is set
forth in the section of this Agreement indicated below:

                                      -15-
<PAGE>   24

           Definition                                    Section
           ----------                                    -------

           "1998 Research Agreement"                     Preliminary Statements

           "AAA"                                         16.13(b)

           "Bankrupt Party"                              16.15(b)

           "Bankruptcy Code"                             16.15 (b)

           "Claims"                                      12.1

           "Cure Period"                                 14.4(a)(ii)

           "deCode Notice"                               7.5(a) (i)

           "Decision Period"                             7.5(a) (ii)

           "Default Notice"                              14.4(a)(i)

           "Disclosing Party"                            1.9

           "Executive Officers"                          3.5(b)

           "Evidence Period"                             6.2(d) and 6.4(b)

           "Exclusivity"                                 5.12(c)

           "intellectual property"                       16.15(b)

           "Initiating Party"                            11.1(c)

           "Lupus Patent"                                7.3(a)

           "Option Notice"                               7.4(a)

           "Original Product"                            8.2(c)

           "owed Party"                                  9.5

           "paying Party"                                9.5

           "Proposed Publication"                        13.1(b)

           "providing Party"                             5.11(a)

           "receiving Party"                             5.11(a)

           "Receiving Party"                             1.9

                                      -16-
<PAGE>   25

           "Replacement Product"                         8.2 (c)

           "Responsible Party"                           11.1(b)

           "Reviewing Party"                             13.1(a)

           "Roche Notice"                                7.5(b) (i)

           "Statements"                                  16.7(b)

           "Sublicensee's Required Efforts"              6.5

           "Suit or Action"                              11.1(c)

           "Third Party License"                         8.4(c)

           "Third Party Product"                         8.4(B) (i)

           "Withdrawal Notice"                           13.1(b)

           "Withholding Taxes"                           9.5

2.       REPRESENTATIONS AND WARRANTIES.

         2.1 Representations and Warranties of Both Parties. Each Party
represents and warrants to the other Party that, as of the Effective Date:

                  (a) such Party is duly organized and validly existing under
the laws of the state or country of its incorporation and has full corporate
power and authority to enter into this Agreement and to carry out the provisions
hereof; and

                  (b) such Party has taken all corporate action necessary to
authorize the execution and delivery of this Agreement and the fulfilling of its
obligations under this Agreement; and

                  (c) such Party is not aware of any impediment which would
inhibit its ability to fulfill the terms and conditions imposed on it by this
Agreement; and

                  (d) such Party has the right to grant the other Party the
rights and licenses hereby granted under this Agreement.

         2.2 Representations of deCODE. deCODE represents and warrants to Roche
that, as of the Effective Date, there are no patents or patent applications that
deCODE owns or controls in the Territory which could preclude Roche from
carrying out its obligations under this Agreement and which deCODE does not have
the right to license or otherwise make available to Roche.

                                      -17-
<PAGE>   26

3.       STEERING COMMITTEE.

         3.1 Members. The Parties shall establish a Steering Committee, which
shall consist of six (6) members, three (3) members from each Party. One (1)
member from each Party must be both (i) a member of senior management and (ii) a
scientist. The initial members of the Steering Committee are set forth on
Exhibit F. Members of the Steering Committee may be represented at any meeting
by a designee appointed by such member for such meeting. The initial chairperson
shall be agreed upon by the Parties and shall be designated on Exhibit F. The
initial chairperson shall serve as chairperson for the First Contract Year.
Thereafter, the chairperson of the Steering Committee for a given Contract Year
shall be selected within thirty (30) days of the beginning of such given
Contract Year on an alternating basis between the Parties, and shall serve as
chairperson during such given Contract Year. The initial secretary shall be
selected by the Party that is not designating the chairperson and shall be
designated on Exhibit F. The initial secretary shall serve as secretary for the
First Contract Year. Thereafter, the secretary of the Steering Committee for a
given Contract Year shall be selected within thirty (30) days of the beginning
of such given Contract Year by the Party not designating the chairperson for the
same given contract year, and shall serve as secretary during such given
Contract Year. Each Party shall be free to change its members, on prior written
notice to the other Party. Each Party may, in its discretion, invite
non-Steering Committee Representatives of such Party, provided that each Party
approves the other Party's invitee(s) in advance.

         3.2 Responsibilities of the Chairperson The chairperson of the Steering
Committee shall have the following responsibilities:

             (a) to call meetings of the Steering Committee, send notice of each
such meeting and designate the time, date and place of each such meeting;

             (b) to convene or poll the member of the Steering Committee by
other permitted means;

             (c) to establish the agenda for each meeting of the Steering
Committee;

             (d) to prepare comments to the draft minutes prepared by the
secretary of the Steering Committee, and communicate with the secretary to
finalize the draft minutes prior to circulation to all members of the Steering
Committee; and

             (e) to execute, along with the secretary of the Steering Committee,
the final minutes of the meetings of the Steering Committee.

         3.3 Responsibilities.  The Steering Committee shall:

                                      -18-
<PAGE>   27

             (a) identify, review, select and oversee all Research Projects;

             (b) evaluate and determine scientific criteria to be implemented
under all Research Projects;

             (c) establish a mechanism by which the Parties will exchange deCODE
Know-How and Roche Know-How, including Program Know-How, and oversee the
exchange of such Know-How;

             (d) commencing on the Effective Date, discuss and prepare an Annual
Research Plan for each Research Project for the First Contract Year of the
Research Term, including determining the priorities among the various Research
Projects and the appropriate number of FTEs to be used to support each Research
Project, and, prior to ninety (90) days after the Effective Date, finalize an
Annual Research Plan for each Research Project for the First Contract Year of
the Research Term and have each such Annual Research Plan signed and dated by a
representative of each Party on the Steering Committee;

             (e) not less than three (3) months prior to the commencement of
each subsequent Contract Year during the Research Term, discuss and prepare an
Annual Research Plan for each ongoing Research Project, including determining
the priorities among the various Research Projects and the appropriate number of
FTEs to be used to support each Research Project, and, prior to the commencement
of each subsequent Contract Year during the Research Term, finalize an Annual
Research Plan for each Research Project for the such Contract Year of the
Research Term and have each such Annual Research Plan signed and dated by a
representative of each Party on the Steering Committee;

             (f) decide upon approval of proposed amendments or modifications to
any Annual Research Plan;

             (g) evaluate data from all Research Projects;

             (h) coordinate the activities of the Parties, and review and
evaluate progress, under the Research Projects, provided that the Steering
Committee shall not have authority to make any determination that either Party
is in breach of its obligations under the Research Projects;

             (i) discuss, prepare and finalize an Annual Research Plan for any
new Research Project;

             (j) determine the research milestones and decide when a research
milestone established for any Research Project is achieved in such Research
Project;

             (k) determine the development milestones, development milestone
payments and the royalty rates applicable to each Diagnostic Product or IP
Trade,

                                      -19-
<PAGE>   28

consistent with, and taking into account the criteria described in, Sections
5.3(f), (g), (h) and (i);

             (l) determine contribution of added value and commensurate eighteen
(18) month period for each Elected Project;

             (m) prepare and approve each Addendum to this Agreement;

             (n) perform any other activities related to the Research Projects
as the Parties may request from time to time, other than deciding that a Party
is in breach of an obligation under this Agreement.

         3.4 Meetings. During the Research Term and until one (1) year after the
end of the Research Term, the Steering Committee shall meet at least four (4)
times every Contract Year, and more frequently as the Parties deem appropriate,
on such dates, places and at such times as the Parties shall agree. Thereafter,
during the term of this Agreement, the Steering Committee shall meet on an as
needed basis on such dates, places and at such times as the Parties shall agree.
The meetings shall alternate between the offices of the Parties unless the
Parties otherwise agree. The chairperson shall, if practicable, send notice of
all meetings to all members of the Steering Committee no less than twenty (20)
days before the date of the meeting. The Steering Committee may also convene or
be polled or consulted from time to time by means of telecommunications, video
conferences or correspondence, as deemed necessary or appropriate; provided,
however, that the Steering Committee meet in person at least twice every
Contract Year during the Research Term and until one (1) year after the end of
the Research Term.

         3.5 Decisions.

             (a) The Steering Committee may decide on any subject matter that is
subject to the Steering Committee's decision-making authority. All decisions of
the Steering Committee shall be made by consensus of the members (or their
designees) present at any meeting. Such consensus shall require that at least
one (1) member of each Party are present at such meeting.

             (b) In the event that consensus cannot be reached by the Steering
Committee after good faith discussions with respect to a matter that is subject
to its decision-making authority, then, the matter shall be referred for further
review and resolution to the head of Roche's molecular diagnostics business
unit, or such other similar position designated by Roche from time to time, and
the Chief Executive Officer at deCODE, or such other similar position designated
by deCODE from time to time (such officers, collectively, the "Executive
Officers"). The Executive Officers of each Party shall use reasonable efforts to
resolve the matter within thirty (30) days after the matter is referred to them.
If the Executive Officers cannot resolve the matter within thirty (30) days,
then: (i) if the matter may violate any statutes, laws, rules or regulations of
Iceland authority in Iceland, the matter shall be decided by the Executive
Officer of

                                      -20-
<PAGE>   29

deCODE in good faith, giving appropriate consideration to the reasonable
business and scientific concerns of Roche; and (ii) for the responsibilities of
the Steering Committee identified in Sections 3.3(a)-(i) and other than set
forth in clause (i) above, the matter shall be decided by the Executive Officer
of Roche in good faith, giving appropriate consideration to the reasonable
business and scientific concerns of deCODE.

             (c) No Decision, either by the Steering Committee or an Executive
Officer, on any matter that is subject to the Steering Committee's
decision-making authority, may have the effect of materially increasing the
economic burdens or the research responsibilities of a Party without the prior
written approval of such Party.

             (d) No Decision regarding Section 3.3 (j), (k), (l), (m) or (n) may
be made by the Steering Committee without consensus of the Steering Committee,
and Section 3.5(b) shall not apply to such Decisions.

         3.6 Minutes. Promptly after each Steering Committee meeting, the
secretary of the Steering Committee shall prepare and distribute to the
chairperson draft minutes of the meeting, which shall provide a description in
reasonable detail of the discussions had at the meeting and a list of any
actions, decisions or determinations approved by the Steering Committee and a
list of any issues to be resolved by the Executive Officers. The chairperson may
then comment on the draft minutes. The secretary shall discuss with the
chairperson any comments of the chairperson and circulate a final draft of the
minutes to all members of the Steering Committee within fifteen (15) days of the
meeting. The members of the Steering Committee shall then have fifteen (15) days
after circulation of the final draft minutes to provide their comments thereon
to the secretary of the Steering Committee. If a member of the Steering
Committee does not comment to the secretary on the draft minutes within the
fifteen (15) day period after circulation, said member is deemed to have agreed
to the final draft minutes. Upon the expiration of the fifteen (15) day period
after circulation, the secretary and the chairperson of the Steering Committee
shall have an additional fifteen (15) days to discuss the other members'
comments and finalize the minutes. The secretary and chairperson shall each sign
and date the final minutes. The signature of the chairperson and the secretary
on the final minutes shall indicate each Party's assent to the minutes. With the
sole exception of specific items of the meeting minutes to which the chairperson
and the secretary cannot agree and which are escalated as provided below, final
minutes of all Steering Committee meetings shall be finalized no later than
forty five (45) days after the meeting to which the minutes pertain. If at any
time during the preparation and finalization of the Steering Committee meeting
minutes the secretary and the chairperson of the committee do not agree on any
issue with respect to the minutes, this issue shall be resolved by the process
provided in Section 3.5(b). The decision resulting from the process shall be
recorded by the secretary of the Steering Committee in an amended finalized
minutes for said meeting. All other issues in the minutes which are not subject
to such escalation shall be finalized within the above-mentioned forty-five (45)
days.

                                      -21-
<PAGE>   30

         3.7 Expenses. Each Party shall be responsible for all travel and
related costs and expenses for its members and non-Steering Committee invitees
to attend meetings of, and otherwise participate on, the Steering Committee.

4.       DISCLOSURE OF KNOW-HOW.

         4.1 Disclosure of deCODE Know-How. Promptly following the Effective
Date, deCODE shall disclose to Roche all existing deCODE Know-How and,
thereafter, deCODE shall disclose to Roche on an ongoing basis during the
Research Term all additional deCODE Know-How.

         4.2 Disclosure of Roche Know-How. Promptly following the Effective
Date, Roche shall disclose to deCODE such Roche Know-How as reasonably
determined by Roche to be necessary for deCODE to carry out the Research
Projects and, thereafter, Roche shall disclose to deCODE on an ongoing basis
during the Research Term all additional Roche Know-How.

         4.3 Mechanism for Exchange of Know-How. The Steering Committee shall
establish a mechanism by which the Parties will exchange deCODE Know-How and
Roche Know-How, including Program Know-How, in accordance with this Agreement,
and oversee the exchange of such Know-How.

5.       COLLABORATIVE RESEARCH PROGRAM.

         5.1 Research Program Objectives

             (a) The overall objective of the Research Program is to develop
Diagnostic Products that accurately establish a patient's current diagnosis,
predict future risk of disease, predict drug response and determine responses to
treatment or the health status of individuals; as part of the primary objective,
the Parties also intend:

                 (i) To develop IT Products which support the marketing of the
other Products developed under the other Research Projects (e.g., to create
software programs and algorithms that provide decision support for the other
Products);

                 (ii) To develop algorithms for establishing diagnostic
patterns;

                 (iii) To develop stand-alone IT Products which aid in medical
decision making;

                 (iv) To create a diagnostics-focused database to be used for
both discovery applications and post marketing studies (e.g., such a database
might combine key datasets from [CONFIDENTIAL TREATMENT REQUESTED]; and

                                      -22-
<PAGE>   31

                 (v) To develop IT Products which use databases (including the
database which may be developed under this Agreement) for aiding in medical
decision support.

             (b) The Parties intend to achieve the objectives set forth in
subsection (a) above by allocating the responsibilities between the Parties in
any Annual Research Plan and seek to leverage the core strengths of each of
Roche and deCODE including the following:

                 (i) With respect to Roche, its core strengths in the areas of
DNA/RNA/proteomics-testing platform, nucleic acid-based diagnostic markers,
disease-causing genes and polymorphisms, diagnostic development and
commercialization know-how, marketing and distribution capabilities,
registration, quality and manufacturing know-how, cash resources and therapies
to support diagnostic decisions.

                 (ii) With respect to deCODE, its core strength in the areas of
identification of disease-causing genes and polymorphisms, know-how for other
potential predictors (expression-based, haplotypes, familial analysis), access
to population-based medical data and samples, bioinformatics, statistics,
genealogy, and associated genealogy software, privacy and decision support
software, and mathematical algorithms for use in data mining.

         5.2 Annual Research Plans.

             (a) For the First Contract Year of the Research Term, commencing on
the Effective Date, the Steering Committee will discuss and prepare an Annual
Research Plan for each Research Project and will finalize an Annual Research
Plan for each Research Project on or prior to thirty (30) days after the
Effective Date. Thereafter, during the Research Term, the Steering Committee
shall (i) commencing not less than three (3) months prior to the commencement of
the subsequent Contract Year, discuss and prepare an Annual Research Plan for
each Research Project for the upcoming Contract Year, and (ii) prior to the
commencement of each Contract Year during the Research Term, finalize an Annual
Research Plan for each Research Project for such Contract Year. Each Annual
Research Plan shall be reviewed on a quarterly basis by the Steering Committee
and may be amended from time to time upon Steering Committee approval. Each
Annual Research Plan, and any amendment thereto, shall be signed and dated by a
representative of each Party on the Steering Committee.

             (b) Each Annual Research Plan shall contain the specific research
objectives to be achieved during the Contract Year, the specific activities to
be performed under the Research Program and the timeline for performing such
activities, and the Party which shall be responsible for performing each of the
activities and, with

                                      -23-
<PAGE>   32

respect to deCODE, the number of FTEs being funded by Roche who are assigned to
each Research Project.

             (c) Each Annual Research Plan shall also contain the specific
criteria to be met for the achievement of research milestones agreed upon by the
Parties in the Addendum relating to such Research Project.

             (d) Each Annual Research Plan shall be consistent with the other
terms and conditions of this Agreement, including the objectives set forth in
Section 5.1.

         5.3 Research Projects.

             (a) Existing Roche Research Projects. From time to time during the
Research Term, Roche shall select research projects from [CONFIDENTIAL TREATMENT
REQUESTED] programs that Roche believes may benefit from inclusion in the
collaboration between the Parties pursuant to this Agreement and shall prepare a
report to the Steering Committee regarding such research projects. At such time,
the Parties shall negotiate and try to reach agreement in the matters described
in Section 5.3(e). Upon reaching an agreement on such matters, the Parties shall
prepare a proposal and shall report the terms of such proposal to the Steering
Committee. The Steering Committee shall then determine whether any such research
project shall become an "Existing Roche Research Project" under this Agreement.
In the event that the Steering Committee determines to make such research
project an "Existing Roche Research Project" under this Agreement, the Steering
Committee shall prepare and the Parties shall execute an Addendum and approve an
Annual Research Plan for such Research Project for the remaining portion of the
then current Contract Year, and any modifications to any other Annual Research
Plans necessary to allocate sufficient resources to such Research Project. At
such time, Exhibit C shall be amended to include such research project as an
Existing Roche Research Project, and Exhibit C shall be amended to include the
Disease which is the subject of such Existing Roche Research Project as an
Existing Roche Disease.

             (b) Existing Alliance Research Projects. The Parties shall
periodically review the status of any research projects which the Parties are
collaborating on pursuant to [CONFIDENTIAL TREATMENT REQUESTED]. From time to
time during the Research Term, the Parties may select certain of such research
projects in which [CONFIDENTIAL TREATMENT REQUESTED] and which the Parties
believe may benefit from inclusion in the further collaboration between the
Parties pursuant to this Agreement, and shall prepare a report to the Steering
Committee regarding such research projects. At such time, the Parties shall
negotiate and try to reach agreement in the matters described in Section 5.3(e).
Upon reaching an agreement on such matters, the Parties, and their appropriate
Affiliates, if necessary, shall prepare a proposal which sets forth such
agreed-upon terms with respect to such research project and shall report the
terms of such proposal to the Steering Committee. The Steering Committee shall
then determine whether any such research project shall [CONFIDENTIAL TREATMENT
REQUESTED]. In the event that the Steering

                                      -24-
<PAGE>   33

Committee determines to [CONFIDENTIAL TREATMENT REQUESTED], the Steering
Committee shall prepare and the Parties shall execute an Addendum and
approve an Annual Research Plan for such Research Project for the remaining
portion of the then current Contract Year, and any modifications to any other
Annual Research Plans necessary to allocate sufficient resources to such
Research Project. At such time, Exhibit B shall be amended to include such
research project as an Existing Alliance Research Project, and Exhibit B shall
be amended to include the Disease which is the subject of such Existing Alliance
Research Project as an Existing Alliance Disease. Any Addendum entered into
pursuant to this Section 5.3(b) shall direct whether any of the provisions of
the [CONFIDENTIAL TREATMENT REQUESTED] apply to such Research Project or whether
the terms of this Agreement shall be wholly applicable to such Research Project.

             (c) New Roche Research Projects. From time to time during the
Research Term, Roche may elect, subject to the consent of deCODE, to include as
a Research Project any of the [CONFIDENTIAL TREATMENT REQUESTED] that Roche
believes may benefit from inclusion in the collaboration between the Parties
pursuant to this Agreement, provided that [CONFIDENTIAL TREATMENT REQUESTED],
and shall prepare a report to the Steering Committee regarding such research
projects. At such time, the Parties shall negotiate and try to reach agreement
in the matters described in Section 5.3(e). Upon reaching an agreement on such
matters, the Parties shall report the terms of such agreement to the Steering
Committee. The Steering Committee shall then determine whether any such research
project shall become a "New Roche Research Project" under this Agreement. In the
event that the Steering Committee determines to make such research project a
"New Roche Research Project" under this Agreement, the Steering Committee shall
prepare and the Parties shall execute an Addendum and approve an Annual Research
Plan for such Research Project for the remaining portion of the then current
Contract Year, and any modifications to any other Annual Research Plans
necessary to allocate sufficient resources to such Research Project. At such
time, Exhibit E shall be amended to include such Research Project as a New Roche
Research Project, and Exhibit E shall be amended to include the Disease which is
the subject of such New Roche Research Project as a New Roche Disease.

             (d) IT Research Projects. From time to time during the Research
Term, the Parties may elect to establish a research project for the development
of IT Products that both Parties believe may benefit from inclusion in the
collaboration between the Parties pursuant to this Agreement and shall prepare a
report to the Steering Committee regarding such research projects. At such time,
the Parties shall negotiate and try to reach agreement in the matters described
in Section 5.3(e). Upon reaching an agreement on such matters, the Parties shall
report the terms of such Agreement to the Steering Committee. The Steering
Committee shall then determine

                                      -25-
<PAGE>   34

whether any such research project shall become an "IT Research Project" under
this Agreement. In the event that the Steering Committee determines to make such
research project an "IT Research Project" under this Agreement, the Steering
Committee shall prepare and the Parties shall execute an Addendum and approve an
Annual Research Plan for such Research Project for the remaining portion of the
then current Contract Year, and any modifications to any other Annual Research
Plans necessary to allocate sufficient resources to such Research Project. At
such time, Exhibit D shall be amended to include such Research Project as an IT
Research Project.

             (e) Prior to the inclusion of any research project set forth in
Section 5.3(a), (b), (c) or (d) as an Existing Roche Research Project, an
Existing Alliance Research Project, a New Roche Research Project or an IT
Research Project, respectively, pursuant to this Agreement, the Parties shall
negotiate and agree upon the following:

                 (i) the criteria to be achieved for the satisfaction of
research milestones, and

                 (ii) the amount of each research milestone to be paid by Roche
to deCODE upon the satisfaction of such milestone criteria for such research
project; provided, however, that the Parties recognize that research milestones
may not be appropriate for some research projects, [**]. The Parties intend
that: (1) these milestones will be research milestones; (2) the Parties
anticipate that there may be [**] such research milestones, depending on the
development stage of the Research Project at the time that it becomes a Research
Project under this Agreement; and (3) the Parties anticipate that each milestone
payment will be [CONFIDENTIAL TREATMENT REQUESTED].

             (f) With respect to the appropriate development milestones and
royalties to be paid on Products developed from a Research Project; the Parties
intend that such milestones and royalties shall be determined: (1) based on the
customary standards in agreements between commercial entities in the diagnostic
industry; (2) taking into account (A) the type of Product that will be developed
from such research project; (B) the level of contribution of deCODE to the
development of the Product from such research project (e.g., High, Medium or Low
Development Efforts); (C) the degree to which the Product will be covered by
deCODE Generalized Technology or Joint Generalized Technology; (D) the degree to
which the Product will contain active components not covered by deCODE Patents,
Joint Generalized Technology, or covered by intellectual property other than
deCODE Generalized Technology, Joint Generalized Technology or Roche Generalized
Technology; (E) the stage of development of the Product at the time that the
research project became a Research Project pursuant to this Agreement, and the
expected stage of development of the

                                      -26-
<PAGE>   35

Product at the time that deCODE has ceased to contribute to its development
pursuant to this Agreement; (F) potential sales volume and profitability of the
Product; and (G) projected expenses to develop and market the Product; (H) with
respect to development milestones, within the aggregate ranges set forth in
Section 5.3(g) for the various kinds of Research Projects, which the Parties
intend will be paid over one, two or three milestone events, as determined by
the parties; and (I) with respect to royalties, within the ranges set forth in
Section 5.3(h) for the various kinds of Research Projects and degrees of
Development Efforts made by deCODE.

             (g) For each Product developed by Roche from a Research Project,
Roche shall pay aggregate development milestones to deCODE, in addition to any
research milestones to be paid pursuant to Section 5.3(e)(ii), negotiated by the
Parties taking into account the criteria described in Section 5.3, which shall
be non-refundable and fully creditable against all future royalties for such
Products, and shall be in the following ranges:

TABLE I

                    AGGREGATE DEVELOPMENT MILESTONE PAYMENTS

           Type of Research Project                                        Range
           ------------------------                                        -----

For Diagnostic Products developed from an Existing
Roche Research Project                                                     [**]

For Diagnostic Products developed from an Existing
Alliance Research Project                                                  [**]

For Diagnostic Products developed from a New Roche
Research Project                                                           [**]

For IT Products                                                            [**]

provided, however, that any such development milestones for Products developed
from an Existing Alliance Research Project shall [CONFIDENTIAL TREATMENT
REQUESTED].

                 (h) For each Diagnostic Product developed from a Research
Project, Roche shall pay royalties to deCODE on Diagnostic Products developed
from such

                                      -27-
<PAGE>   36

Research Project as negotiated by the Parties as provided for in Section 5.3(f),
which shall be in the following ranges:

TABLE II

<TABLE>
<CAPTION>
                                        ROYALTY RATES - DIAGNOSTIC PRODUCTS
                                        -----------------------------------
                            Diagnostic Products
                            developed from an          Diagnostic Products          Diagnostic Products developed
Level of deCODE             Existing Roche Research    developed from an Existing   from a New Roche Research
Development Effort          Project                    Alliance Research Project    Project
------------------          -----------------------    --------------------------   ------------------------------
<S>                         <C>                        <C>                          <C>
High Development Effort              [**]                        [**]                           [**]

Medium Development Effort            [**]                        [**]                           [**]

Low Development Effort               [**]                        [**]                           [**]
</TABLE>

provided, however, that any such royalties for Diagnostic Products developed
from an Existing Alliance Research Project shall (i) be no less than the
aggregate amount of royalties which could have been paid under the 1998 Research
Agreement with respect to such project pursuant to Roche's obligations under
Section 8.3(a) of the 1998 Research Agreement, and (ii) such royalties shall be
in lieu of any additional royalties which would otherwise be due under the 1998
Research Agreement with respect to such project.

                  (i) For each IT Product developed from a Research Project,
Roche shall pay royalties to deCODE on IT Products developed from such Research
Project as negotiated by the Parties as provided for in Section 5.3(f), which
shall be in the following range:

                                      -28-
<PAGE>   37

TABLE III

                           ROYALTY RATES - IT PRODUCTS

Level of deCODE Development Effort                               IT Products
----------------------------------                               -----------

High Development Effort                                             [**]

Medium Development Effort                                           [**]

Low Development Effort                                              [**]

         5.4 Termination of a Research Project. Subject to the terms and
conditions of this Agreement, at any time during the Research Term, Roche may,
for any reason, terminate a Research Project by giving six (6) months' prior
written notice to deCODE. In such event, the effective date of termination shall
be the date six (6) months after Roche provides such written notice to deCODE.
Following a termination of a Research Project pursuant to this Section 5.4, such
project shall become a Shelved Project.

         5.5 Research Program.

             (a) Scope. Each Research Project shall have as its subject an
independent and separate Disease. For each Research Project, each Party shall
conduct those activities that are assigned to such Party in the Annual Research
Plan for such Research Project.

             (b) Oversight. The Steering Committee shall oversee each Research
Project.

             (c) FTE Rate Adjustment. For the first [**] Contract Years, the FTE
Rate shall be [CONFIDENTIAL TREATMENT REQUESTED]. Thereafter, the FTE Rate may
be adjusted upwards at the beginning of each Contract Year during the Research
Term as mutually agreed by the Parties and based upon actual and documented
increased expenses; provided that such rate shall be increased annually to cover
cost-of-living increases to compensation paid to such FTEs by deCODE.

             (d) Use of FTEs. The Parties acknowledge that deCODE's utilization
of Representatives of deCODE during the course of each Research Project may
fluctuate during the Research Term and that deCODE's obligation to allocate a
certain number of FTEs to a Research Project, and satisfaction of such
obligation, will be based on such allocation calculated over the course of a
given Contract Year of the Research Term.

                                      -29-
<PAGE>   38

         5.6 Research Funding.

             (a) First Contract Year. Subject to the terms and conditions of
this Agreement, Roche shall pay to deCODE [CONFIDENTIAL TREATMENT REQUESTED] for
the funding of the Research Program during the First Contract Year, which shall
be due and payable on a calendar quarterly basis within thirty (30) days after
receipt by Roche of an invoice for such sum.

             (b) Second Contract Year. Subject to the terms and conditions of
this Agreement, Roche shall pay to deCODE [CONFIDENTIAL TREATMENT REQUESTED] for
the funding of the Research Program during the Second Contract Year, which shall
be due and payable on a calendar quarterly basis within thirty (30) days after
receipt by Roche of an invoice for such sum.

             (c) Third, Fourth and Fifth Contract Years.

                 (i) In the event Roche elects to continue Exclusivity for any
of the Third, Fourth and/or Fifth Contract Years, and subject to the terms and
conditions of this Agreement, Roche shall pay to deCODE [CONFIDENTIAL TREATMENT
REQUESTED] for the funding of the Research Program during each of the Third,
Fourth and/or Fifth Contract Years, which shall be due and payable on a calendar
quarterly basis within thirty (30) days after receipt by Roche of an invoice for
such sum.

                 (ii) In the event Roche elects not to continue Exclusivity in
the Third, Fourth or Fifth Contract Years, and subject to the term of this
Agreement, Roche shall pay to deCODE [CONFIDENTIAL TREATMENT REQUESTED] for the
funding of the Research Program during each of the Third, Fourth and/or Fifth
Contract Years, which shall be due and payable on a calendar quarterly basis
within thirty (30) days after receipt by Roche of an invoice for such sum.

             (d) Adjustment to Amount of Payment. The Parties acknowledge and
agree that the amount of each quarterly payment set forth in Sections 5.6 are
determined based on [CONFIDENTIAL TREATMENT REQUESTED] of the number of FTEs to
be allocated to the Research Program by deCODE for a Contract Year during the
Research Term, multiplied by the FTE Rate.

             (e) Other Expenses. Subject to this Section 5.6, each Party shall
be responsible for its own costs and expenses related to the Research Program.

                                      -30-
<PAGE>   39

             (f) Method of Payment. Payments under this Section 5.6 shall be
made by Roche to deCODE by wire transfer to:

                 State Street Bank and Trust Co.
                 225 Franklin Street
                 Boston, MA  02110-2804
                 Account No. 94262524
                 ABA No. 011000028

or such other account as deCODE may, from time to time, designate to Roche in
writing.

             (g) FTE Support. At any time during the First Contract Year, Roche
shall not be required to provide funding for more than [**] FTEs for all
Research Projects. At any time during the Second Contract Year, Roche shall not
be required to provide funding for more than [CONFIDENTIAL TREATMENT REQUESTED]
FTEs for all Research Projects. At any time during the remaining three (3)
Contract Years: (i) if Roche elects to continue the restrictions contained in
Section 5.12 in their entirety pursuant to Section 5.12(d), then Roche shall be
required to provide funding for at least [CONFIDENTIAL TREATMENT REQUESTED] FTEs
for all Research Projects; (ii) if Roche elects not to continue the restrictions
contained in Section 5.11 pursuant to Section 5.12(d), then Roche shall be
required to provide funding for no more than [CONFIDENTIAL TREATMENT REQUESTED]
FTEs for all Research Projects.

         5.7 Use of Funds. deCODE will use funding provided by Roche under this
Section 5 only in support of the Research Program. deCODE will not use any Third
Party funding in direct support of any Research Project. The use of any Third
Party funding by deCODE in indirect support of a Research Program shall not
adversely impact Roche's rights and licenses under this Agreement.

         5.8 Roche Review Right.

             (a) Within thirty (30) days following the end of each quarter of
the Research Term, deCODE shall prepare and submit to Roche a statement
setting forth for each Research Project the number of deCODE scientists who
actually worked on such Research Project during the previous quarter and the
portion of an FTE that each such deCODE scientist worked on such Research
Project.

             (b) deCODE shall keep full, true and accurate books of account
containing all information necessary to determine the correctness of the number
of deCODE scientists who actually worked on any Research Project during any
period of the Research Term and the portion of an FTE that each such deCODE
scientist worked on any such Research Project. Such books of account shall be
kept at deCODE's principal place of business. Not more than once per Contract
Year during the Research Term, Roche or its authorized independent public
accountant shall have the right to engage deCODE's independent public
accountant, at reasonable times and upon

                                      -31-
<PAGE>   40

reasonable notice, to examine on deCODE's premises, such records of deCODE.
Results of any such examination shall be made available to both Parties. Roche
shall bear the cost of such audit, unless such audit indicates an overstatement
of the number of FTEs that worked on any Research Project by [CONFIDENTIAL
TREATMENT REQUESTED] or more, in which event deCODE shall bear the costs of such
audit.

         5.9 Conduct.

             (a) Each Party. Each Party shall for each Research Project:

                 (i) conduct such Research Project as described in each Annual
Research Plan for such Research Project;

                 (ii) use reasonable diligence to (1) perform the activities
assigned to such Party under the Annual Research Plan for such Research Project
and (2) complete such activities on a timely basis;

                 (iii) conduct such Research Project in good scientific manner,
and in compliance in all material respects with all requirements of applicable
laws, rules and regulations, and all other requirements of any applicable good
laboratory practices to attempt to achieve its objectives efficiently and
expeditiously;

                 (iv) periodically during the Research Term (but not less than
once per quarter by deCODE), furnish to the Steering Committee written reports
summarizing (1) all scientific work performed by such Party; and (2) Program
Know-How developed by such Party (including without limitation a summary of
Inventions and results and data generated), in the conduct of the Research
Project;

                 (v) promptly disclose Inventions to the other Party in
accordance with Section 10; and

                 (vi) during the Research Term, allow Representatives of the
other Party, during normal business hours and with reasonable frequency, to
visit the offices and laboratories of such Party where such Research Program is
being conducted, and consult informally, during such visits or by telephone,
with such Party's Representatives performing scientific work on or in direct
connection with such Research Program; provided, however, that (1) such
Representatives of the other Party are under an agreement binding such
Representatives to protect Confidential Information to at least the same extent
or greater as is required of such other Party under this Agreement and (2) the
Party allowing any such visit approves in writing prior to such visit the other
Party's Representatives, which approval shall not be unreasonably withheld. Any
such visit shall not unreasonably interrupt the operations of the Party that is
visited.

             (b) Dedicated Efforts. Each Party shall dedicate Commercially
Reasonable Efforts to the collaboration and conduct of the Research Program, and
the

                                      -32-
<PAGE>   41

management and oversight of the Research Program. In connection with the
foregoing, deCODE shall dedicate the personnel necessary for this purpose, and
Roche shall dedicate an internal venture group for this purpose.

         5.10 Records.

              (a) During the Research Term and for each Research Project, deCODE
shall maintain records in sufficient detail and in such good scientific manner
as to, in all material aspects, completely and accurately reflect all scientific
work performed and results achieved in the conduct of such Research Project
(including all Inventions and results and data generated in the conduct of such
Research Project). Such records shall be maintained in separate, bound
laboratory notebooks for each Research Project. deCODE shall maintain such
records in a form required under all applicable laws and regulations of the
Major Countries.

              (b) During the Research Term and for each Research Project, Roche
shall have the right, during normal business hours and upon reasonable notice,
and subject to such reasonable procedures as deCODE may require, to inspect all
such records of deCODE relating to the Research Project. Roche shall maintain
such records of deCODE contained therein as Confidential Information in
accordance with Section 13 and shall not use such records except to the extent
otherwise permitted by this Agreement.

         5.11 Biological Materials Transfer.

              (a) For any Biological Materials provided by a Party (the
"providing Party") to the other Party (the "receiving Party"), the providing
Party shall provide the receiving Party with all related Know-How of the
providing Party pertaining to such Biological Materials, and shall inform the
receiving Party of any hazards or precautions which need to be taken with
respect to the Biological Materials that the providing Party is aware of, or
becomes aware of, during the term of this Agreement. The providing Party shall
properly label, package, and transport the Biological Materials in accordance
with all applicable laws and regulations and as reasonably requested by the
receiving Party. Nothing herein shall be construed as giving the receiving Party
any title or ownership to any Biological Materials. The receiving Party may not
use any Biological Materials except in the conduct of a Research Project or a
Development Program without the prior written consent of the providing Party.
The receiving Party shall not supply any Biological Materials to any Third
Party, other than Collaborators, without the prior written consent of the
providing Party. In no event shall the receiving Party use any Biological
Materials to harvest DNA. Upon the providing Party's written request during the
Research Term or one (1) year thereafter, the receiving Party shall destroy all
unused Biological Materials.

              (b) Biological Materials obtained in Iceland shall not be
transported outside of Iceland. The Parties shall determine the most desirable
methods, for each Research Project, to collect, use and retain such Biological
Materials.

                                      -33-
<PAGE>   42

             (c) THE BIOLOGICAL MATERIALS ARE PROVIDED BY THE PROVIDING PARTY
"AS IS" AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF
FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE
BIOLOGICAL MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER
PROPRIETARY RIGHTS OF ANY THIRD PARTY.

         5.12 Exclusivity.

              (a) During the First Contract Year, the Second Contract Year, and
any additional Contract Years in which Roche elects to continue the restrictions
contained in this Section 5.12 pursuant to Section 8.1(c), [CONFIDENTIAL
TREATMENT REQUESTED]

              (b) Notwithstanding the foregoing exclusivity provision, this
Agreement shall not prohibit deCODE or any of its Affiliates, either alone or in
collaboration with a Third Party: (i) from engaging in any activities relating
(1) to any disease where the express goal and focus of such activities is to
identify or develop products or services for use outside of the Field; (2) to
any disease to which Roche has provided its written consent and the Parties have
reached agreement on licensing rights and revenue sharing; or (3) to any disease
to which rights have been granted to a Third Party for use in the Field pursuant
to Section 7.4; (ii) from engaging in the development, marketing and sales of
any database products, or other software products and services for general use
for bioinformatics information; or (iii) from engaging in any activity with
respect to any elements of any IT Research Project, or with respect to any IT
Research Project as a whole, which is not specifically prohibited pursuant to
Section 5.12(a)(ii).

              (c) The foregoing restrictions shall apply [CONFIDENTIAL TREATMENT
REQUESTED] and, in the event that Roche elects to extend the restrictions for
[CONFIDENTIAL TREATMENT REQUESTED].

              (d) Roche shall have the right, in its sole discretion, to elect
to extend the Exclusivity. At least [CONFIDENTIAL TREATMENT REQUESTED] prior to
the end of the [CONFIDENTIAL TREATMENT REQUESTED] and [CONFIDENTIAL TREATMENT
REQUESTED], Roche shall notify deCODE whether it is electing to extend the
Exclusivity or not. If Roche notifies deCODE that it elects to extend the
Exclusivity, then Roche shall be obligated to provide the access fees set forth
in Section 8.1(c) and the research funding set forth in Section 5.6(c), and
deCODE and its Affiliates shall be bound by the foregoing restrictions for
[CONFIDENTIAL

                                      -34-
<PAGE>   43

TREATMENT REQUESTED]. Notwithstanding the foregoing, for any Research Project
that has become an Elected Project during the Research Term, the Exclusivity
shall be retained with respect to those projects regardless of whether Roche
elects to provide access fees for [CONFIDENTIAL TREATMENT REQUESTED].

         5.13 Research Term.

              (a) End of Research Term. Subject to Sections 5.13(b), the
Research Term shall end on the expiration of the Fifth Contract Year.

              (b) Extensions. The Parties may mutually agree to extend the
Research Term after the expiration of the Fifth Contract Year for such number of
Diseases, and on such terms, as the Parties may mutually agree. In the event
that Roche is interested in such an extension, Roche shall so notify deCODE in
writing no later than ninety (90) days prior to the expiration of the
then-current Contract Year of the Research Term. The level of funding to be
provided by Roche to deCODE, the number of FTEs to be provided by deCODE, the
FTE Rate to be paid by Roche to deCODE for such extension period and, if the
Exclusivity shall apply, shall be determined by the Parties at such time of any
such mutual agreement of extension. Such extensions shall be deemed to be
included in the Research Term for all purposes under this Agreement except as
certain terms may be modified by the mutual agreement of the Parties.

6.       DEVELOPMENT AND COMMERCIALIZATION.

         6.1 Commercialization of a Research Project.

             (a) At any time prior to the conclusion of a Research Project,
Roche may advise the Steering Committee of contributions to a Research Project
and/or its intent to Commercialize a product that is the subject of a Research
Project, (each, an "Elected Project").

             (b) Upon a Research Project becoming an Elected Project, Roche
shall have the exclusive right and license under the Inventions, Program
Know-How; Program Copyrighted Works and Program Patents relating to or resulting
from the given Research Product, and the non-exclusive right to use deCODE
Generalized Technology and deCODE IT Intellectual Property, and deCODE shall
grant to Roche the exclusive and non-exclusive licenses provided in Section 7
hereof and subject to the other provisions of this Agreement.

             (c) If, for a [CONFIDENTIAL TREATMENT REQUESTED], as determined by
the Steering Committee, Roche fails to [CONFIDENTIAL TREATMENT REQUESTED] as
determined by the Steering Committee, the Elected Project, or any Research
Project may be designated a Shelved Project by the Steering Committee.

                                      -35-
<PAGE>   44

             (d) In the event that an Elected Project subsequently has been
designated a Shelved Project, either Party may restore the status of an Elected
Project by any of the following: (i) in the case of Roche, [CONFIDENTIAL
TREATMENT REQUESTED], by payment to deCODE of [CONFIDENTIAL TREATMENT REQUESTED]
of any value contributed to the Shelved Project by deCODE up to the time of
restoration to Elected Project status; or (ii) in the case of deCODE, by
continuing with development of such project either on its own or with a Third
Party, in which case, [CONFIDENTIAL TREATMENT REQUESTED], and in accordance with
the criteria set forth in Section 5.3(f). At the conclusion of the [CONFIDENTIAL
TREATMENT REQUESTED], Roche shall relinquish any rights with respect to such
Shelved Project, except that in no event shall [CONFIDENTIAL TREATMENT
REQUESTED] upon terms not inconsistent with the terms of this Agreement.

         6.2 Commercialization Efforts by Roche for Elected Project.

             (a) Upon a Research Project becoming an Elected Project, Roche,
directly or through an Affiliate or sublicensee, will use Commercially
Reasonable Efforts directed to Commercialization of the Elected Project.

             (b) Prior to the first Registration of a Diagnostic Product
developed from an Elected Project for a given Disease in any Major Country,
Roche's exercise of Commercially Reasonable Efforts is to be determined by
judging Roche's Commercially Reasonable Efforts taken as a whole in the Major
Countries.

             (c) After the first Registration of a Diagnostic Product developed
from an Elected Project for a given Disease in any Major Country, Roche's
exercise of Commercially Reasonable Efforts is to be determined by judging
Roche's Commercially Reasonable Efforts taken as a whole taken on a Major
Country-by-Major Country basis.

             (d) For a given Disease, prior to the first Registration in any
Major Country of a Diagnostic Product developed from an Elected Project for such
Disease, if deCODE reasonably believes that Roche is not using Commercially
Reasonable Efforts, deCODE may provide Roche written notice specifying the
reasons deCODE believes that Roche, at the time, is not using Commercially
Reasonable Efforts with respect to such Disease. Upon receipt of such notice,
Roche shall have a period of ninety (90) days (an "Evidence Period") to present
evidence to deCODE that Roche, its Affiliate or sublicensee is using
Commercially Reasonable Efforts with respect to such Disease. If Roche presents
evidence acceptable to deCODE that Roche, its Affiliate or sublicensee is using
Commercially Reasonable Efforts with respect to such Disease, deCODE's notice
shall be deemed withdrawn and of no effect. Should there be a dispute as to
whether Roche has, within the Evidence Period, presented evidence reasonably
acceptable to demonstrate that Roche, its Affiliate or sublicensee is using
Commercially Reasonable Efforts with respect to such Disease, the Parties shall
conduct good faith discussions directed toward resolution of the dispute. If the
Parties

                                      -36-
<PAGE>   45

do not resolve the dispute after good faith discussions have been conducted for
a period of thirty (30) days following the Evidence Period, the Parties shall
submit such dispute for resolution in accordance with Section 16.13. If it is
agreed by the Parties, or if it is resolved in accordance with Section 16.13,
that Roche, within the Evidence Period, has not presented evidence reasonably
acceptable to demonstrate that Roche, its Affiliate or sublicensee is using
Commercially Reasonable Efforts with respect to such Disease, then the licenses
and rights granted to Roche shall be governed by Section 7.2 of this Agreement.

             (e) For a given Disease, after the first Registration in any Major
Country of a Diagnostic Product developed from an Elected Project for such
Disease, if deCODE reasonably believes that Roche is not using Commercially
Reasonable Efforts in any Major Country, deCODE may provide Roche written notice
specifying the reasons deCODE believes that Roche, at the time, is not using
Commercially Reasonable Efforts with respect to such Disease in the Major
Country. Upon receipt of such notice, Roche shall have a period of ninety (90)
days (an "Evidence Period") to present evidence to deCODE that Roche, its
Affiliate or sublicensee is using Commercially Reasonable Efforts with respect
to such Disease in the Major Country. If Roche presents evidence acceptable to
deCODE that Roche, its Affiliate or sublicensee is using Commercially Reasonable
Efforts with respect to such Disease in the Major Country, deCODE's notice shall
be deemed withdrawn and of no effect. Should there be a dispute as to whether
Roche has, within the Evidence Period, presented evidence reasonably acceptable
to demonstrate that Roche, its Affiliate or sublicensee is using Commercially
Reasonable Efforts with respect to such Disease in the Major Country, the
Parties shall conduct good faith discussions directed toward resolution of the
dispute. If the Parties do not resolve the dispute after good faith discussions
have been conducted for a period of thirty (30) days following the Evidence
Period, the Parties shall submit such dispute for resolution in accordance with
Section 16.13. If it is agreed by the Parties, or if it is resolved in
accordance with Section 16.13, that Roche, within the Evidence Period, has not
presented evidence reasonably acceptable to demonstrate that Roche, its
Affiliate or sublicensee is using Commercially Reasonable Efforts with respect
to such Disease in the Major Country, then the rights and licenses granted to
Roche and deCODE shall be governed by Section 7.6 of this Agreement.

         6.3 Abandonment of a Diagnostic Product for a Disease.

             (a) For a given Disease, at any time during the term of this
Agreement prior to the first Registration in any Major Country of a Diagnostic
Product developed from an Elected Project for such Disease, Roche may, for any
reason, terminate this Agreement with respect to all Diagnostic Products for the
Disease by giving six (6) months' prior written notice to deCODE. In such event,
the effective date of termination shall be the date six (6) months after Roche
provides such written notice to deCODE. The effects of such termination shall be
governed by Section 14.4(a).

                                      -37-
<PAGE>   46

             (b) For a given Disease, at any time during the term of this
Agreement after the first Registration in any Major Country of a Diagnostic
Product developed from an Elected Project for such Disease, Roche may, for any
reason, terminate this Agreement in a given Major Country with respect to all
Diagnostic Products for the Disease by giving six (6) months' prior written
notice to deCODE. In such event, the effective date of termination shall be the
date six (6) months after Roche provides such written notice to deCODE. The
effects of such termination shall be governed by Section 14.4(b).

             (c) If Roche terminates this Agreement pursuant to this Section
6.3(a) and (b) with respect to all Diagnostic Products for a Disease, such
Disease shall no longer be considered a Disease under this Agreement, and all
Joint Generalized Technology relating to such Diagnostic Products shall
thereafter be governed by Section 14.3.

         6.4 Sale After Registration.

             (a) Time Period. For a given a Diagnostic Product developed from an
Elected Project and which is the subject of a Registration in a given country,
Roche, its Affiliate or sublicensee shall, within one (1) year after such
Registration make a First Commercial Sale of the given Diagnostic Product in the
given country.

             (b) Notice of Failure. If Roche, its Affiliate or sublicensee has
not, within one (1) year after Registration of a Diagnostic Product in a given
country, made a First Commercial Sale of the given Diagnostic Product in the
given country, deCODE may provide Roche written notice to Roche specifying the
same. Upon receipt of such notice, Roche shall have a period of ninety (90) days
(an "Evidence Period") to present evidence to deCODE that Roche, its Affiliate
or sublicensee, for reasons beyond their control, has not or is unable to make a
First Commercial Sale of the given Diagnostic Product in the given country
within one (1) year after such Registration. If Roche presents evidence
acceptable to deCODE that Roche, its Affiliate or sublicensee, for reasons
beyond their control, has not or is unable to make a First Commercial Sale of
the given Diagnostic Product in the given country within one (1) year after such
Registration, deCODE's notice shall be deemed withdrawn and of no effect. Should
there be a dispute as to whether Roche has, within the Evidence Period,
presented evidence reasonably acceptable to demonstrate that Roche, its
Affiliate or sublicensee, for reasons beyond their control, has not or is unable
to make a First Commercial Sale of the given Diagnostic Product in the given
country within one (1) year after such Registration, the Parties shall conduct
good faith discussions directed toward resolution of the dispute. If the Parties
do not resolve the dispute after good faith discussions have been conducted for
a period of thirty (30) days following the Evidence Period, the Parties shall
submit such dispute for resolution in accordance with Section 16.13. If it is
agreed by the Parties, or if it is resolved in accordance with Section 16.13,
that Roche, within the Evidence Period, has not presented evidence reasonably
acceptable to demonstrate that Roche, its Affiliate or sublicensee, for reasons
beyond their control,

                                      -38-
<PAGE>   47

has not or is unable to make a First Commercial Sale of the given Diagnostic
Product in the given country within one (1) year after such Registration, then
the rights and licenses granted to Roche and deCODE shall be governed by
Section 7.2 of this Agreement.

             (c) Abandonment of a Diagnostic Product after Registration.
Notwithstanding anything to the contrary herein, at any time during the term of
this Agreement, Roche may, for any reason, terminate its rights to use the Joint
Generalized Technology under Section 6.1(b) and licenses under Section 7.1 in a
given country with respect to a given Diagnostic Product that was the subject of
a Registration in the given country by giving six (6) months' prior written
notice to deCODE. In such event, the effective date of such termination shall be
the date six (6) months after Roche provides such written notice to deCODE. The
effects of such termination shall be governed by Section 14.3(c).

             6.5 Commercialization Efforts by deCODE and its Sublicensees.
During the term of this Agreement, deCODE shall have no diligence obligation
with respect to Shelved Products for a Disease other than using Commercially
Reasonable Efforts to identify and obtain a licensee for such Shelved Products
in the event deCODE determines not to develop Shelved Products for the Disease
directly or through an Affiliate. In the event that deCODE grants rights to any
Shelved Products for a Disease to a licensee, deCODE shall require such licensee
to use Commercially Reasonable Efforts, in the Major Countries as a whole,
directed to the Commercialization of at least one (1) deCODE Product for such
Disease ("Sublicensee's Required Efforts").

         6.6 Reports.

             (a) By Roche. For each Disease, Research Project and Elected
Project: (i) at least once per year during the term of this Agreement, Roche
will inform deCODE as to the goals and scope of each project; (ii) commencing at
the end of the Research Program for each Disease, and until the Registration of
a Diagnostic Product in a given Major Country for such Disease, within sixty
(60) days after the end of each calendar year, Roche shall provide to deCODE a
written summary of Roche's, its Affiliates' and sublicensee's Commercially
Reasonable Efforts during such previous calendar year, provided that Roche is
permitted by any such sublicensee to share such information with deCODE. All
such summaries shall be treated by deCODE as Confidential Information under
Section 13.

             (b) By deCODE. For a Disease, commencing at the end of the Research
Program for such Disease, and until the first registration of a deCODE Product
in any Major Country, within sixty (60) days after the end of each calendar
year, provide written summary of Commercially Reasonable Efforts and provided
deCODE determines not to develop Shelved Products for the Disease directly or
through an Affiliate, deCODE shall provide to Roche a written summary of: (i)
deCODE's and its Affiliates' efforts to identify and obtain a licensee for
Shelved Products for the Disease,

                                      -39-
<PAGE>   48

and (ii) the Sublicensee's Required Efforts of deCODE's licensees in the Major
Countries during such previous year; provided that deCODE is permitted by such
sublicensee to share such information with Roche. All such summaries shall be
treated by Roche as Confidential Information under Section 13.

         6.7 Ownership of Regulatory Filings. Other than as explicitly provided
for in this Agreement, nothing herein shall be construed as giving deCODE any
title or ownership to any IND, NDA or other regulatory filings related to a
Diagnostic Product. Other than as explicitly provided for in this Agreement,
nothing herein shall be construed as giving Roche any title or ownership to any
IND, NDA or other regulatory filings related to a deCODE Product.

7.       GRANT OF LICENSES.

         7.1 deCODE Grants to Roche. Subject to the terms and conditions of this
Agreement, deCODE grants to Roche and its Affiliates:

             (a) Upon a Research Project becoming an Elected Project, (i) a sole
and exclusive worldwide right and license under Joint Know-How and Joint
Patents, (ii) sole and exclusive worldwide right and license to use deCODE
Know-How and all deCODE Patents, and (iii) a non-exclusive right and license to
use deCODE Generalized Technology, to make, have made, use, offer for sale,
sell, have sold, and import Diagnostic Products developed a result of the
Elected Project, in the Field throughout the Territory. The rights and licenses
granted to Roche pursuant to this Section 7.1(a) shall include the right to
grant sublicenses thereto. Roche shall advise deCODE of all sublicenses granted
under this Agreement. Roche guarantees and assumes responsibility for the
performance of all obligations so imposed on such sublicensee by reason of
operation of any such sublicense. The milestones and royalties for such products
shall be set forth in the appropriate Addendum and determined by the Steering
Committee as provided in Section 3.3(k).

             (b) Upon a Research Project becoming an Elected Project, a
non-exclusive right and license under deCODE IT Intellectual Property, solely to
the extent necessary to make, have made, use, offer for sale, sell, have sold
and import Diagnostic Products in the Field throughout the Territory. The rights
and licenses granted to Roche pursuant to this Section 7.1(b) shall include the
right to grant sublicenses thereto. Roche shall advise deCODE of all sublicenses
granted under this Agreement. Roche guarantees and assumes responsibility for
the performance of all obligations so imposed on such sublicensee by reason of
operation of any such sublicense. The licenses granted to Roche in this Section
7.1(b) shall be subject to the negotiation and agreement of the Parties as to
the applicable access fees to be paid by Roche to deCODE pursuant to the
provisions set forth in Section 5.3.

                                      -40-
<PAGE>   49

             (c) A royalty-free, non-exclusive worldwide right and license under
deCODE Know-How and deCODE Patents, and (ii) a non-exclusive right and license
to use deCODE Generalized Technology, solely for Roche's internal research
purposes relating to the development of Diagnostic Products in the Field
throughout the Territory. The rights and licenses granted pursuant to this
Section 7.1(c) shall not include the right to grant sublicenses thereto.

             (d) A world-wide, [CONFIDENTIAL TREATMENT REQUESTED] license and
immunity from suit to practice, make, have made, use and sell and have sold, any
products or other materials but for the license granted herein would infringe a
Valid Claim under the deCODE Patent commonly known as the "Lupus Patent"); and
[**], world-wide license [CONFIDENTIAL TREATMENT REQUESTED] to deCODE's database
commonly known as the "Clinical Genome Miner", subject to terms substantially in
the form of Exhibit I hereto, and evidenced by a license agreement between the
Parties in form and substance satisfactory to Roche.

         7.2 Research Programs. During the Research Term, each Party grants to
the other Party and its Affiliates a fully paid-up, non-royalty bearing
non-exclusive right and license, without the right to grant sublicenses, under
such Party's respective Know-How and Patents, for the sole and exclusive purpose
of the other Party fulfilling its research obligations under any and all
Research Projects under this Agreement.

         7.3 Retained Rights.

             (a) Each Party shall retain its rights to use all Joint Patents and
Joint Know-How, without obligation to the other Party, for internal research and
development purposes, and for all other purposes subject only to the license
grants made by each Party in Sections 7.1 and 7.2.

             (b) Neither Party shall have the right to use Joint Inventions,
Joint Know-How, Joint Patents or Joint IT Intellectual Property except as
provided in this Agreement.

             (c) Each Party shall retain all rights to use its respective
know-how, generalized technology and patents for all purposes outside the Field.

         7.4 Option for [CONFIDENTIAL TREATMENT REQUESTED]. deCODE shall have an
option to licensing [CONFIDENTIAL TREATMENT REQUESTED] developed from any
[CONFIDENTIAL TREATMENT REQUESTED] as follows:

             (a) If, at any time during the term of this Agreement, deCODE is
interested in offering rights to [CONFIDENTIAL TREATMENT REQUESTED] developed
from any [CONFIDENTIAL TREATMENT REQUESTED] with respect to such Disease,

                                      -41-
<PAGE>   50

or with respect to [CONFIDENTIAL TREATMENT REQUESTED], to a Third Party to whom
deCODE has granted such Third Party any rights or licenses with respect to
[CONFIDENTIAL TREATMENT REQUESTED], deCODE shall give written notice ("Option
Notice") to Roche of its interest.

             (b) In the case of a [CONFIDENTIAL TREATMENT REQUESTED], in the
event that at the time of such Option Notice (i) there have been [CONFIDENTIAL
TREATMENT REQUESTED] by Roche with respect to discoveries or developments under
the [CONFIDENTIAL TREATMENT REQUESTED], and (ii) deCODE and/or such Third Party
agree to reimburse Roche for [CONFIDENTIAL TREATMENT REQUESTED] for the
[CONFIDENTIAL TREATMENT REQUESTED], then deCODE shall have the option to license
[CONFIDENTIAL TREATMENT REQUESTED] relating to such [CONFIDENTIAL TREATMENT
REQUESTED] developed from such [CONFIDENTIAL TREATMENT REQUESTED] by giving
written notice of its exercise of such option within sixty (60) days after
receipt of such cost information from Roche, except as provided in Section
7.4(d). Roche shall provide such cost information with respect to such
[CONFIDENTIAL TREATMENT REQUESTED] within thirty (30) days after receipt of the
deCODE Notice pertaining to such [CONFIDENTIAL TREATMENT REQUESTED].

             (c) In the case of a [CONFIDENTIAL TREATMENT REQUESTED], then
deCODE shall have the option to license [CONFIDENTIAL TREATMENT REQUESTED] with
respect to such diagnostic products relating to such disease developed from such
[CONFIDENTIAL TREATMENT REQUESTED] within thirty (30) days after the date of the
deCODE Notice pertaining to such [CONFIDENTIAL TREATMENT REQUESTED], except as
provided in Section 7.4(d).

             (d) In the event that deCODE exercises its option pursuant to this
Section 7.4, Roche shall have the right to elect to retain [CONFIDENTIAL
TREATMENT REQUESTED] in the Field, or to such diagnostic products relating to
such disease developed from such [CONFIDENTIAL TREATMENT REQUESTED] in the
Field, by notifying deCODE of such election with ninety (90) days after receipt
of the Option Notice pertaining to such [CONFIDENTIAL TREATMENT REQUESTED]. In
such case, deCODE shall only grant such Third Party a [CONFIDENTIAL TREATMENT
REQUESTED] right to such [CONFIDENTIAL TREATMENT REQUESTED] and/or other
intellectual property with respect to such Diagnostic Products in the Field
relating to such [CONFIDENTIAL TREATMENT REQUESTED], or with respect to such
diagnostic products in the Field relating to such disease developed from such
[CONFIDENTIAL TREATMENT REQUESTED], and, with respect to Diagnostic Products
relating to a [CONFIDENTIAL TREATMENT REQUESTED] developed from a [CONFIDENTIAL
TREATMENT REQUESTED], deCODE and/or such Third Party shall [**] of the costs
incurred in connection with such [CONFIDENTIAL TREATMENT REQUESTED], and the
license grants in Section 7.1 shall be modified to reflect the foregoing.

                                      -42-
<PAGE>   51

         7.5 Shelved Products.

             (a) deCODE Interest.

                 (i) At any time during the term of this Agreement, deCODE may
offer rights to a Shelved Product to a Third Party, provided that Roche does not
elect to restore the Shelved Product to [CONFIDENTIAL TREATMENT REQUESTED].
deCODE shall give written notice ("deCODE Notice") to Roche of its interest.
Such deCODE Notice shall include sufficient information regarding such Shelved
Product as deCODE, in good faith, deems reasonably necessary for Roche to make a
reasonably informed decision regarding whether or not Roche wishes to acquire or
reacquire the rights [CONFIDENTIAL TREATMENT REQUESTED].

                 (ii) Decision Period. Roche shall have a period of sixty (60)
days, extendible by mutual agreement of the Parties, said period to commence on
the receipt by Roche of the deCODE Notice to respond to such notice ("Decision
Period").

                 (iii) Negotiations. In the event that Roche, within such
Decision Period, provides written notice to deCODE that it is interested in
acquiring or reacquiring such rights, then the Parties shall conduct good faith
negotiations [CONFIDENTIAL TREATMENT REQUESTED].

                 (iv) Third Party Terms. In the event that deCODE enters into an
agreement with a Third Party, the Parties shall promptly enter into good faith
negotiations with respect [CONFIDENTIAL TREATMENT REQUESTED] to be paid by
deCODE to Roche for such Shelved Product, and deCODE shall be free to offer such
rights to any Third Party on any terms and conditions. Such [CONFIDENTIAL
TREATMENT REQUESTED] shall be determined by the Parties shall take into account
the following criteria: (1) customary standards in agreements between commercial
entities in the molecular diagnostics industry; (2) taking into account (A) the
type of Product that will be developed from such research project; (B) the level
of contribution of Roche to the development of the Product from such research
project (e.g., High, Medium or Low Development Efforts); (C) the degree to which
the Product will be covered by Roche Generalized Technology, or Joint
Generalized Technology; (D) the degree to which the Product will contain active
components not covered by Roche Patents or Joint Generalized Technology or
covered by intellectual property other than deCODE Generalized Technology, Joint
Generalized Technology or Roche Generalized Technology; (E) the stage of
development of the Product at the time that the research project became a
Research Project pursuant to this Agreement, and the stage of development of the
Product at the time that Roche ceases to contribute to its development pursuant
to this Agreement; (F) potential sales volume and profitability of the Product;
and (G) projected expenses to develop and market the Product. If deCODE executes
an agreement to license such rights relating to a Shelved Product to a Third
Party, such Shelved Product shall thereafter be referred to as a "deCODE
Product".

                                      -43-
<PAGE>   52

                 (v) New Opportunity. In the event that Roche, within such
Decision Period, does not provide written notice to deCODE that it is interested
in pursuing negotiations for such rights, (i) deCODE shall be free to offer such
rights to any Third Party under any terms and conditions, and (ii) in the event
additional material new findings not yet presented to Roche are developed during
a two (2) year period commencing on the date that is the end of the Decision
Period, and unless prohibited by agreement or ongoing negotiations with a Third
Party, deCODE shall give Roche the opportunity to review such additional data
and to reconsider its interest in such negotiation.

             (b) Roche Interest.

                 (i) Roche. If, at any time during the term of this Agreement,
Roche is interested in rights to a Shelved Product, Roche shall give written
notice ("Roche Notice") to deCODE of its interest. Such Roche Notice shall
include sufficient information regarding such Shelved Product as Roche in good
faith, deems reasonably necessary for deCODE to make a reasonably informed
decision regarding Roche's interest in such rights.

                 (ii) Negotiations. Upon receipt by deCODE of such Roche Notice,
the Parties shall conduct good faith negotiations [CONFIDENTIAL TREATMENT
REQUESTED].

                 (iii) Failure to Agree. In the event that within three (3)
months after commencing negotiations, the Parties fail to execute an agreement
related to such rights, then the provisions of Section 16.13(a) shall apply.

8.       PAYMENTS AND ROYALTIES.

         8.1 Access Fees. In connection with the restrictions on deCODE pursuant
to Section 5.11 and in consideration for rights granted to Roche pursuant to
Section 7.1, Roche shall pay deCODE the following non-refundable, non-creditable
payments:

             (a) [CONFIDENTIAL TREATMENT REQUESTED] due and payable within
thirty (30) days after the later of (i) the Effective Date and (ii) receipt by
Roche of an invoice for such sum;

             (b) [CONFIDENTIAL TREATMENT REQUESTED] due and payable within
thirty (30) days after the later of (i) the first day of the Second Contract
Year and (ii) receipt by Roche of an invoice for such sum; and

             (c) In the event that Roche elects to continue the restrictions
pursuant to Section 5.12, [CONFIDENTIAL TREATMENT REQUESTED] due and payable
within thirty (30) days after (i) the first day of each of the Third Contract
Year, the Fourth Contract Year and the Fifth Contract Year, as applicable.

                                      -44-
<PAGE>   53

         8.2 Milestone Payments.

             (a) With respect to any research milestones arising with respect to
a Research Project, Roche shall pay deCODE such nonrefundable and fully
creditable against all future royalties for Products developed from such
Research Project, payments, within thirty (30) days after the satisfaction of
the criteria identified in the Annual Research Plan for such Research Project
with respect to each research milestone.

             (b) For a given Diagnostic Product resulting from a Research
Project, Roche shall pay to deCODE the milestone payments agreed to pursuant to
Section 5.3(g) within thirty (30) days after the occurrence of the development
milestones set forth in the applicable Addendum.

             (c) For a given Diagnostic Product, Roche will make each of such
payments under Section 8.2(b) only once, for the first occurrence of a
development milestone for the Diagnostic Product, independent of the number of
occurrences of the development milestone for the Diagnostic Product. In the
event that Roche's clinical development of any Diagnostic Product for a Disease
(an "Original Product") terminates and, at or after the time of such
termination, Roche is engaged or subsequently becomes engaged in clinical
development of any other Diagnostic Product for such Disease (a "Replacement
Product") and both the Original Product and the Replacement Product diagnose or
prevent the same Disease, then Roche shall [CONFIDENTIAL TREATMENT REQUESTED]
development milestone payments due pursuant to Section 8.2(b) with respect to
the Replacement Product [CONFIDENTIAL TREATMENT REQUESTED] to all milestone
payments [CONFIDENTIAL TREATMENT REQUESTED] with respect to the Original Product
prior to termination of development thereof.

                                      -45-
<PAGE>   54

         8.3 Royalties.

             (a) Royalty Rates Paid by Roche. For a given Diagnostic Product,
during the Royalty Term for the Diagnostic Product, Roche shall pay to deCODE a
royalty on Net Sales of the given Diagnostic Product, on a country-by-country
basis, at the royalty rates set forth in the applicable Addendum. Royalties
payable for all Products Commercialized shall be recoupable against [**]
research and development milestones paid by Roche pursuant to this Agreement
provided, however, that for each calendar year, no more than [**] of the
royalties due to deCODE shall be credited against any such milestone payments
[CONFIDENTIAL TREATMENT REQUESTED], at which time, [CONFIDENTIAL TREATMENT
REQUESTED] of the royalties will be payable.

             (b) Royalty Rates Paid by deCODE.

                 (i) For a given deCODE Product, during the Royalty Term, deCODE
shall pay to Roche a royalty on Net Sales of the given deCODE Product, on a
country-by-country basis, at the royalty rates set forth in the applicable
Addendum.

                 (ii) If for a given deCODE Product, deCODE licenses rights to
such deCODE Product to a Third Party in a given country, then during the Royalty
Term for such deCODE Product, deCODE shall pay to Roche the percentage of
Sublicensing Income received by deCODE from its sublicensees in the given
country with respect to the given deCODE Product at the rates set forth in the
applicable Addendum.

         8.4 Royalty Reductions.

             (a) Reductions for no Valid Claim.

                 (i) Reduction for Roche. The royalties otherwise due under
Section 8.3(a) shall be reduced, on a country-by-country basis, by [**] with
respect to a given Diagnostic Product in a given country if Roche's (i) making,
having made or using Disease Genes to make, have made, use, offer for sale, sell
and import the Diagnostic Product, or (ii) making, having made, using, offering
for sale, selling or importing the Diagnostic Product, is not covered by a
deCODE Patent Valid Claim, a Joint Patent Valid Claim or a Program Valid Claim
in such country.

                 (ii) Reduction for deCODE. The royalties or percentage of
Royalty Sublicensing Income otherwise due under Section 8.3(b) shall be reduced,
on a country-by-country basis, by [**] with respect to a given deCODE Product in
a given country if, deCODE's (i) making, having made or using Disease Genes to
make, have made, use, offer for sale, sell and import the deCODE Product, and
(ii) making, having made, using, offering for sale, selling or importing the
deCODE Product is not covered by a Joint Patent Valid Claim, a Program Patent
Valid Claim or a deCODE Patent Valid Claim in such country.

                                      -46-
<PAGE>   55

             (b) Reduction for Generic Competition.

                 (i) By Roche. Roche may reduce the royalties otherwise due
under Section 8.3(a), on a country-by-country basis, by [**] with respect to a
given Diagnostic Product in a given country if, in such country, in any calendar
quarter, one or more Third Parties markets a product ("Third Party Product")
having as a component the same component as the Diagnostic Product, where (1)
the manufacture, use or sale of such Third Party Product is not claimed by a
deCODE Patent Valid Claim of an issued deCODE Patent or a Joint Patent Valid
Claim of an issued Joint Patent in such country, and (2) such Third Party
Product(s), in aggregate, have at least [CONFIDENTIAL TREATMENT REQUESTED] of
the aggregate unit volume of sales for such Diagnostic Product and such Third
Party Product in any calendar year in such country, as measured by IMS published
data or such other index as the Parties may agree upon.

                 (ii) By deCODE. deCODE may reduce the royalties or percentage
of Royalty Sublicensing Income otherwise due under Section 8.3(b), on a
country-by-country basis, by [**] with respect to a given deCODE Product in a
given country if, in such country, in any calendar quarter, one or more Third
Parties markets a Third Party Product having as a component the same component
as the deCODE Product, or its salt, where (1) the manufacture, use or sale of
such Third Party Product is not claimed by a in a deCODE Patent Valid Claim of
an issued deCODE Patent or a Roche Joint Valid Claim of an issued Joint Patent
in such country, and (2) such Third Party Product(s), in aggregate, have at
least [CONFIDENTIAL TREATMENT REQUESTED] of the aggregate unit volume of sales
for such deCODE Product and such Third Party Product in any calendar year in
such country, as measured by IMS published data or such other index as the
Parties may agree upon.

             (c) Third Party Royalties. If, for a given Product in a given
country, a Party believes that the making, having made, using, offering for
sale, selling or importing the given Product in the given country would
represent a significant risk of infringement of a Third Party Patent, the Party
shall notify the other Party in writing, and the Parties will in good faith
discuss the need to obtain a license from the Third Party ("Third Party
License"). If the Parties fail to agree as to the need for such Third Party
License, the Parties will submit the matter to patent counsel acceptable to both
Parties for a legal opinion about the need to obtain such Third Party License.
The Parties will [CONFIDENTIAL TREATMENT REQUESTED] associated with such legal
opinion.

                  If the Parties agree on the need for the Third Party License,
or if patent counsel provides reasons as to why the making, having made,
offering for sale, selling or importing of the given Product in the given
country would represent a significant risk of infringement of the Third Party
Patent, the Party may reduce the royalties or percentage of Royalty Sublicensing
Income otherwise due under Section 8.3 for the given Product by an amount equal
to [**] of the royalties and payments paid by the Party to such Third Party
under the Third Party License.

                                      -47-
<PAGE>   56

Notwithstanding the above, for a given Product, in no event shall such reduction
apply to a Third Party License from a Collaborator where the Third Party License
results from a collaboration having as its subject the Product.

             (d) Limit of Reductions to Royalties. Notwithstanding anything to
the contrary, a Party may not reduce the royalties or percentage of Royalty
Sublicensing Income due to the other Party for any calendar quarter on account
of any reductions in royalties or percentage of Royalty Sublicensing Income
provided for in Subsections 8.4(a)-(c) by an amount which would reduce the
amount of royalties or the amount of Royalty Sublicensing Income, as the case
may be, otherwise due under Section 8.3 by more than [CONFIDENTIAL TREATMENT
REQUESTED]. Any amount of reductions in royalties or percentage of Royalty
Sublicensing Income which exceed the foregoing limits for a given calendar
quarter may be applied by the Party in subsequent calendar quarters, subject
again to the foregoing limitations. The limitations to the royalty and Royalty
Sublicensing Income reductions provided in this Section 8.4(d) shall not apply
against additional credits or reductions or deductions under any other
provisions of this Agreement.

             (e) Additional Limitation. Prior to the First Commercial Sale of
any Diagnostic Product, if such product is a combination of a deCODE Invention
and one or more other active component(s) subject to intellectual property
rights of Roche or a Third Party, such as multiple nucleotide sequences
("Components") the Parties shall negotiate in good faith, and agree to
appropriately prorate the amount of Net Sales and the royalty payable thereon in
accordance with Section 5.3(b), to reflect the relative significance of the
deCODE Invention and the other Components contained in such product. At no time
shall deCODE receive royalty payments in excess of the amount that would
otherwise be payable in accordance with Section 5.3(b).

         8.5 Obligation to Pay Royalties.

             (a) Sales Among Roche and its Affiliates and Sublicensees. The
obligation to pay royalties to deCODE under Section 8.3 is imposed only once
with respect to the same unit of Diagnostic Product, regardless of the number of
deCODE Patents pertaining thereto. There shall be no obligation to pay royalties
on Net Sales to deCODE under Section 8.3 on sales or transfers of Diagnostic
Products among Roche and its Affiliates and its sublicensees, but in such
instances the obligation to pay royalties on Net Sales shall arise only upon the
sale by Roche, its Affiliates or its sublicensees to Third Parties (other than
sublicensees of Roche).

             (b) Sales Among deCODE and its Affiliates. The obligation to pay
royalties to Roche under Section 8.3 is imposed only once with respect to the
same unit of deCODE Product, regardless of the number of Roche Patents
pertaining thereto. There shall be no obligation to pay royalties on Net Sales
or a percentage of Royalty Sublicensing Income to Roche under Section 8.3 on
sales of deCODE Products among deCODE and its Affiliates and its sublicensees,
but in such instances the obligation to

                                      -48-
<PAGE>   57

pay royalties on Net Sales shall arise only upon the sale by deCODE or its
Affiliates to Third Parties (other than sublicensees of deCODE) and the
obligation to pay a percentage of Royalty Sublicensing Income shall arise only
upon the sale by deCODE's sublicensees to Third Parties.

         8.6 Roche Supply Obligation. During the Royalty Term, Roche shall
provide quantities of Diagnostic Products reasonably necessary or required by
the persons who are both citizens and residents of Iceland for the prevention,
diagnosis and/or treatment of the Diseases at no charge.

         8.7 Barred Royalties. If the royalties set out in this Section 8, after
giving effect to all reductions and credits to such royalties allowable under
this Agreement, are higher than the maximum royalties permitted by the law or
regulations of a given country, the royalty payable for such country shall be
equal to the maximum permitted under such law or regulations.

9.       PAYMENTS AND REPORTS.

         9.1 Payment. Except as otherwise provided in this Agreement, all
royalties on Net Sales of Diagnostic Products shall be calculated quarterly as
of March 31, June 30, September 30 and December 31 (each as being the last day
of a calendar quarter) and shall be paid by Roche within ninety (90) days after
the end of each calendar quarter for which such Net Sales are calculated. Each
such payment shall be accompanied by a statement, Product-by-Product and
country-by-country, of the amount of Net Sales during such calendar quarter and
the amount of royalties due on such Net Sales.

         Except as otherwise provided in this Agreement, all royalties on Net
Sales of deCODE Products and the amount of Sublicensing Income due shall be
calculated quarterly as of March 31, June 30, September 30 and December 31 (each
as being the last day of a calendar quarter) and shall be paid by deCODE within
ninety (90) days after the end of each calendar quarter for which such Net Sales
or Sublicensing Income are calculated. Each such payment shall be accompanied by
a statement, Product-by-Product and country-by-country, of the amount of Net
Sales, the amount of royalties due on such Net Sales, or the amount of
Sublicensing Income due, as the case may be.

         9.2 Mode of Payment. A Party shall make all payments required under
this Agreement as directed by the other Party from time to time in United States
Dollars or such other currency as the Parties may mutually agree.

             (a) For Roche and its Affiliates. For Roche and its Affiliates,
whenever for the purpose of calculating royalty conversion from any foreign
currency shall be required, such conversion shall be made as follows: when
calculating the Adjusted Gross Sales, the amount of such sales in foreign
currencies shall be converted into

                                      -49-
<PAGE>   58

Swiss Francs as computed in the central Roche's Swiss Francs Sales Statistics
for the countries concerned, in accordance with Roche's customary practice and
procedures for consolidating its Affiliates' sales into Swiss Francs; and in
accordance with Roche's customary practice and procedures for conversion from
Swiss Francs to Dollars when calculating royalties on Net Sales.;

             (b) For a Sublicensee of Roche in a Country. For a sublicensee of
Roche, whenever for the purpose of calculating royalty conversion from any
foreign currency shall be required, such conversion shall be made as follows:
when calculating the Adjusted Gross Sales, the amount of such sales shall be
reported by the sublicensee to Roche within thirty (30) days from the end of the
calendar quarter, after having converted each applicable monthly sales in
foreign currency into the Dollar using the average rates of exchange published
in The Wall Street Journal (or some other source agreed upon in writing by the
Parties for the country) for each respective month of the applicable calendar
quarter.

             (c) For deCODE and its Affiliates. For deCODE and its Affiliates,
whenever for the purpose of calculating royalty conversion from any foreign
currency shall be required, such conversion shall be made as follows: when
calculating the Adjusted Gross Sales and Net Sales, the amount of such sales in
foreign currencies shall be converted into Dollars, as computed for the country
concerned using the average monthly rate of exchange listed in The Wall Street
Journal (or some other source agreed upon in writing by the Parties for the
country) for each applicable month of the applicable calendar quarter.

             (d) For a Sublicensee of deCODE in a Country. For a sublicensee of
deCODE, the Sublicensing Income shall be calculated by conversion of such amount
from the currency in which it was paid to deCODE into Dollars as computed for
the country concerned using the average monthly rate of exchange listed in The
Wall Street Journal (or some other source agreed upon in writing by the Parties
for the country) for each applicable month of the applicable calendar quarter.

         9.3 Records Retention. Each Party shall keep, and require its
Affiliates and sublicensees to keep, full, true and accurate books of account in
accordance with generally accepted accounting principles, consistently applied
("Books of Account") containing all particulars that may be necessary for the
purpose of calculating all royalties and Sublicensing Income payable to the
other Party under this Agreement for a period of three calendar (3) years after
the end of the calendar year in which such sales occurred. Such Books of Account
shall be kept at the principal place of business of the Party, its Affiliates or
its sublicensees, as the case may be.

         9.4 Audit Request.

             (a) By deCODE. At deCODE's expense, deCODE or its authorized
independent public accountant has the right to engage Roche's independent public
accountant to perform, on behalf of deCODE or its independent public accountant,
an

                                      -50-
<PAGE>   59

audit, conducted in accordance with generally accepted auditing standards in
the USA, of such Books of Account of Roche, its Affiliates and sublicensees that
are deemed necessary by Roche's independent public accountants to report on
Adjusted Gross Sales and Net Sales of the Diagnostic Products for the period or
periods requested by deCODE. Results of any such examination shall be made
available to both Parties. deCODE or its authorized independent public
accountant shall have the right to review the reports prepared by Roche's
independent public accountant and make inquiries of Roche's independent public
accountant regarding such reports.

             Such audit shall not be performed more frequently than once per
calendar year nor more frequently than once with respect to Books of Account
covering any specific period of time, upon at least thirty (30) working days'
prior written notice, and shall be conducted during regular business hours in
such a manner as to not unnecessarily interfere with Roche's normal business
activities.

             All Books of Account referred to under this Section 9.4(a) shall be
used only for the purpose of verifying royalty statements or compliance with the
royalty provisions of this Agreement and (ii) shall be treated by deCODE as
Confidential Information under Section 13.

             The failure of deCODE to request verification of any royalty
calculation during the period under Section 9.3 when Books of Account have to be
retained shall be considered acceptance of the accuracy of such reporting.

             In the event that such audit shall indicate that in any calendar
year the royalties which should have been paid by Roche are greater than those
which were actually paid by Roche, then Roche shall promptly pay the underpaid
amount to deCODE and, if the royalties which should have been paid by Roche are
[CONFIDENTIAL TREATMENT REQUESTED] greater than those which were actually paid
by Roche, then Roche shall also reimburse deCODE for the reasonable cost of such
audit. In the event that such audit shall indicate that in any calendar year the
royalties which were actually paid by Roche are greater than those which should
have been paid, then, at Roche's option, deCODE shall promptly reimburse to
Roche the overpaid amount or Roche shall deduct the overpaid amount from the
next royalty payment to be paid deCODE, without regard to the limitations set
forth in Section 8.4(d).

             (b) By Roche. At Roche's expense, Roche or its authorized
independent public accountant has the right to engage deCODE's independent
public accountant to perform, on behalf of Roche or its independent public
accountant, an audit, conducted in accordance with generally accepted auditing
standards in the USA, of such Books of Account of deCODE, its Affiliates and
sublicensees that are deemed necessary by deCODE's independent public
accountants to report on Adjusted Gross Sales, Net Sales and Sublicensing Income
of the deCODE Products for the period or periods requested by Roche. Results of
any such examination shall be made available to both Parties. Roche or its
authorized independent public accountant shall have the

                                      -51-
<PAGE>   60

right to review the reports prepared by deCODE's independent public accountant
and make inquiries of deCODE's independent public accountant regarding such
reports.

             Such audit shall not be performed more frequently than once per
calendar year nor more frequently than once with respect to Books of Account
covering any specific period of time, upon at least thirty (30) working days'
prior written notice, and shall be conducted during regular business hours in
such a manner as to not unnecessarily interfere with deCODE's normal business
activities.

             All Books of Account referred to under this Section 9.4(b) shall be
used only for the purpose of verifying royalty statements or compliance with
this Agreement and (ii) shall be treated by Roche as Confidential Information
under Section 13.

             The failure of Roche to request verification of any royalty
calculation during the period under Section 9.3 when Books of Account have to be
retained shall be considered acceptance of the accuracy of such reporting.

             In the event that such audit shall indicate that in any calendar
year the royalties which should have been paid by deCODE are greater than those
which were actually paid by deCODE, then deCODE shall promptly pay the underpaid
amount to Roche and, if the royalties which should have been paid by deCODE are
[CONFIDENTIAL TREATMENT REQUESTED] greater than those which were actually paid
by deCODE, then deCODE shall also reimburse Roche for the reasonable cost of
such audit. In the event that such audit shall indicate that in any calendar
year the royalties which were actually paid by deCODE are greater than those
which should have been paid, then, at deCODE's option, Roche shall promptly
reimburse to deCODE the overpaid amount or deCODE shall deduct the overpaid
amount from the next royalty payment to be paid Roche.

         9.5 Taxes. All amounts owing to a Party ("owed Party") specified in
this Agreement shall be paid by the other Party ("paying Party") net of all
applicable taxes, fees, and other charges excluding only taxes on the paying
Party's income. In particular, any tax required to be withheld by a paying Party
under the laws of any country for the account of the Owed Party ("Withholding
Taxes"), shall be promptly paid by the paying Party for and on behalf of the
owed Party to the appropriate governmental authority, and the paying Party shall
furnish the owed Party with proof of payment of such tax. Any such tax actually
paid on the owed Party's behalf shall be deducted from royalty payments due the
owed Party. The Paying Party will reasonably assist the owed Party in minimizing
the Withholding Taxes applicable to any payment made by the paying Party and in
claiming tax refund at the owed Party's request.

         9.6 Blocked Currency. In each country where the local currency is
blocked by applicable law and cannot be removed from such country, royalties
accrued in that country shall be paid to the owed Party in such country in local
currency by deposit in a local bank designated by the owed Party.

                                      -52-
<PAGE>   61

         9.7 Interest on Late Payments. Any payment under this Agreement that is
not paid on or before the date such payment is due shall bear interest, to the
extent permitted by applicable law, at the average one-month London Interbank
Offered Rate (=LIBOR) as reported by Datastream from time to time, or such other
index as the Parties may agree in writing, plus two percent (2%), calculated in
the number of days such a payment is overdue.

         9.8 Mechanism for Adjustment to Royalties. For the first calendar
quarter of each calendar year during the term of this Agreement, a Party shall
be entitled to deduct from the royalties owed to the other Party for that
quarter any reductions, deductions or credits on royalties allowed under this
Agreement during the previous calendar year provided the Party did not otherwise
previously take such reductions or credits. In the event that any reductions,
deductions or credits otherwise allowable to a Party in the last calendar year
during the term of the Agreement have not been fully utilized by such Party upon
the expiration of this Agreement, then the other Party shall reimburse such
Party for the allowable amount.

10.      OWNERSHIP; PATENTS.

         10.1 Ownership.

              (a) Technical Information. Except as otherwise provided in this
Agreement, this Agreement does not grant either Party any rights in or to
Technical Information, or any Patents related thereto, owned or controlled by
the other Party.

              (b) Existing Intellectual Property. Subject to the license grants
in Section 7.1(a), each Party shall retain ownership of any Patents, Know-How,
Technical Information and Copyrightable Works owned solely (with respect to the
other Party) by such Party prior to the Research Term which relate to any of the
Research Projects or are necessary to make, have made, use, offer for sale, sell
or import Products except as to deCODE Patents and Know-How licensed to Roche
under Section 7.1(a).

              (c) Inventions. Except as otherwise provided in Sections 10.1(d)
and (e), deCODE shall solely own deCODE Inventions and resulting Patents. Roche
shall solely own Roche Inventions and resulting Patents. The Parties shall
jointly own Joint Inventions and resulting Patents. The determination of
inventorship shall be made in accordance with the patent laws of the United
States.

              (d) Inventions from Existing Roche Research Projects. With respect
to Inventions developed pursuant to with any Existing Roche Research Project,
Roche shall solely own all such Inventions, and deCODE shall assign its rights
in any such Inventions to Roche, at Roche's expense, except as follows:

                  (i) deCODE shall own any Inventions (whether patentable or
otherwise) developed, made or created solely by deCODE which comprises
Generalized Technology;

                                      -53-
<PAGE>   62

                  (ii) deCODE and Roche shall jointly own any Inventions
(whether patentable or otherwise) developed jointly by deCODE and Roche which
comprises Generalized Technology;

                  (iii) deCODE shall own any Inventions (whether patentable or
otherwise) developed solely by deCODE in the course of conducting an Existing
Roche Project that is agreed to by the Parties to be a significant improvement
or invention, and such inventions shall be deemed to be deCODE Patents or deCODE
Know-How; and

                  (iv) Any Inventions (whether patentable or otherwise) relating
to IT shall be owned in the manner set forth in Section 10.1(c).

              (e) Inventions from Existing Alliance Research Projects and New
Roche Research Projects. With respect to Inventions developed pursuant to any
Existing Alliance Research Project or New Roche Research Project, each Party
shall own any Inventions (whether patentable or otherwise) developed solely by
that Party which comprises Generalized Technology.

         10.2 Patent and Copyright Filing, Maintenance and Prosecution Regarding
Inventions.

              (a) Disclosure. As soon as a Party concludes that an Invention has
been made, it shall promptly inform the Steering Committee, and provide a
summary of the Invention pursuant to Section 13 herein. Should a Party be faced
with a possible loss of rights in a Major Country, such communication may take
place promptly after filing a priority patent application for the Invention.

              (b) Filing.

                  (i) deCODE Inventions and Roche Inventions. For deCODE
Inventions and Roche Inventions, the Party owning the Invention shall have the
first right of election to prepare and file a priority patent application for
the Invention or a Copyright, as the case may be, at its own cost. Should the
Party owning the Invention elect not to prepare and/or file any such patent
application or Copyright, it shall (i) provide the other Party with written
notice as soon as reasonably possible after making such election but in any
event no later than sixty (60) days before the other Party would be faced with a
possible loss of rights in a Major Country, (ii) give the other Party the right,
at the other Party's election and sole expense, to prepare and file the priority
patent application or Copyright, and (iii) offer reasonable assistance to the
other Party in connection with such preparation and filing at no cost to the
other Party except for [CONFIDENTIAL TREATMENT REQUESTED] incurred by the Party
owning the Invention in rendering such assistance.

                  The filing Party shall perform corresponding foreign filings
at its own cost, after having discussed the countries for foreign filings with
the non-filing Party within nine (9) months after the priority filing or
Copyright filing. Should the Parties not agree on the countries for foreign
filings, either Party will have the right to file the subject of the priority
application or Copyright in [CONFIDENTIAL TREATMENT

                                      -54-
<PAGE>   63

REQUESTED] in any country of its own choice at [CONFIDENTIAL TREATMENT
REQUESTED] in any country where the Parties do not agree as to filing.

                  (ii) Joint Inventions. For Joint Inventions, the Parties shall
consult and agree upon (i) which Party shall have the first right of election to
prepare and file a priority patent application or Copyright for the Joint
Invention, in the name of both Parties, and (ii) sharing of costs, although the
presumption is that Roche will prepare, file and prosecute such patent
application.

                  The Party having the first right of election may elect to
prepare and file any such patent application or Copyright at its own cost.
Notwithstanding anything to the contrary, if the Parties agreed to share costs,
the non-filing Party shall reimburse the filing Party in an amount equal to
[CONFIDENTIAL TREATMENT REQUESTED] incurred by the filing Party in preparing and
filing such patent application or Copyright, within thirty (30) days after
receipt of an itemized invoice from the filing Party.

                  Should the Party having the first right of election elect not
to prepare and/or file any such patent application or Copyright, as the case may
be, it shall (i) provide the other Party with written notice as soon as
reasonably possible after making such election but in any event no later than
sixty (60) days before the other Party would be faced with a possible loss of
rights in a Major Country, (ii) give the other Party the right, at the other
Party's election and sole expense, to prepare and file the priority application
or Copyright in the name of both Parties, and (iii) offer reasonable assistance
to the other Party in connection with such preparation and filing at no cost to
the other Party except for [CONFIDENTIAL TREATMENT REQUESTED] incurred by the
Party owning the Invention in rendering such assistance.

                  The filing Party shall perform corresponding foreign filings,
at [CONFIDENTIAL TREATMENT REQUESTED], after having discussed the countries for
foreign filings with the non-filing Party within nine (9) months after the
priority filing or Copyright filing. Notwithstanding anything to the contrary,
for corresponding foreign filings filed in agreed upon countries, if the Parties
agreed to share costs, the non-filing Party shall reimburse the filing Party in
an amount equal to [CONFIDENTIAL TREATMENT REQUESTED] incurred by the filing
Party in preparing and filing such corresponding foreign filings, within thirty
(30) days after receipt of an itemized invoice from the filing Party. Should the
Parties not agree on the countries for foreign filings, either Party will have
the right to file the subject of the priority application or Copyright in
[CONFIDENTIAL TREATMENT REQUESTED] in any country of its own choice at
[CONFIDENTIAL TREATMENT REQUESTED] in any country where the Parties do not agree
as to filing.

              (c) Prosecution and Maintenance.

                  (i) deCODE Inventions and Roche Inventions. The filing Party
shall prosecute and reasonably maintain applications filed under Section
10.2(b)(i) and

                                      -55-
<PAGE>   64

patents and Copyrights resulting therefrom at its own expense. On request of the
filing Party, the non-filing Party will cooperate in all reasonable ways in
connection with the prosecution and maintenance of such applications and patents
and Copyrights resulting therefrom, at the expense of the filing Party for all
out-of-pocket expenses incurred by the non-filing Party as a result of such
cooperation. Upon written request, the filing Party shall inform the non-filing
Party of the issuance of such patent application or Copyright, initiation of an
appeal of a rejection of such patent application or Copyright, or initiation of
an interference involving or an opposition to any such patent or Copyright
application or patent or Copyright resulting therefrom. The filing Party shall
provide the non-filing Party, upon the non-filing Party's written request, with
copies of substantive communications to and from patent and copyright offices
regarding such patent and Copyright applications and patents and Copyrights
resulting therefrom in sufficient time before the due date for response in order
to give the non-filing Party an opportunity to comment on the content thereof.

                  Should the filing Party no longer wish to prosecute and/or
maintain any such patent or Copyright application or patent or Copyright
resulting therefrom, the filing Party shall (i) provide the non-filing Party
with written notice of its wish no later than sixty (60) days before the patent
or Copyright, or patent or Copyright application, would otherwise become
abandoned, (ii) give the non-filing Party the right, at the non-filing Party's
election and sole expense (subject to the credit set forth below), to prosecute
and/or maintain such patent or Copyright, or patent or Copyright application,
and (iii) offer reasonable assistance to the non-filing Party in connection with
such prosecution and/or maintenance at no cost to the non-filing Party except
for reimbursement of the filing Party's reasonable out-of-pocket expenses
incurred by the filing Party in rendering such assistance. The non-filing Party
shall be entitled to recoup [CONFIDENTIAL TREATMENT REQUESTED] of such Party's
documented reasonable out-of-pocket expenses incurred to prosecute and/or
maintain such patents, Copyrights and/or patent or Copyright applications by
taking a credit against any royalty payment otherwise due, as shown on the Net
Sales statement provided under Section 9.1, up to a maximum credit, when
combined with the credit provided pursuant to Section 10.2(c)(ii), in any given
calendar quarter equal to [CONFIDENTIAL TREATMENT REQUESTED] of such royalty
payments otherwise due, until such amount has been fully credited.

                  (ii) Joint Inventions. The filing Party shall prosecute and
reasonably maintain patent and Copyright applications filed under Section
10.2(b)(ii) and patents and Copyrights resulting therefrom.

                  For a given patent or Copyright application filed under
Section 10.2(b)(ii), should the non-filing Party have had an obligation under
Section 10.2(b)(ii) to reimburse the filing Party in an amount equal to
[CONFIDENTIAL TREATMENT REQUESTED] incurred by the filing Party in preparing and
filing such patent or Copyright application, then the non-filing Party shall
reimburse the filing Party in an amount equal to [CONFIDENTIAL TREATMENT
REQUESTED] incurred by the filing Party in prosecuting and maintaining such
application and patents or Copyrights

                                      -56-
<PAGE>   65

resulting therefrom, within thirty (30) days after receipt of an itemized
invoice from the filing Party. For a given patent or Copyright application filed
under Section 10.2(b)(ii), should the non-filing Party have had no obligation
under Section 10.2(b)(ii) to reimburse the filing Party in an amount equal to
[CONFIDENTIAL TREATMENT REQUESTED] incurred by the filing Party in preparing and
filing such patent or Copyright application, then the filing Party shall
prosecute and reasonably maintain such application and patents or Copyrights
resulting therefrom at its own cost.

                  On request of the filing Party, the non-filing Party will
cooperate in all reasonable ways in connection with the prosecution and
maintenance of such applications and patents or Copyrights resulting therefrom,
at the expense of the filing Party for [CONFIDENTIAL TREATMENT REQUESTED]
incurred by the non-filing Party as a result of such cooperation. Upon written
request, the filing Party shall inform the non-filing Party of the issuance of
such patent or Copyright application, initiation of an appeal of a rejection of
such patent or Copyright application, or initiation of an interference involving
or an opposition to any such patent or Copyright application or patent or
Copyright resulting therefrom. The filing Party shall provide the non-filing
Party, upon the non-filing Party's written request, with copies of substantive
communications to and from patent offices regarding such patent or Copyright
applications and patents or Copyrights resulting therefrom in sufficient time
before the due date for response in order to give the non-filing Party an
opportunity to comment on the content thereof.

                  Should the filing Party no longer wish to prosecute and/or
maintain any such patent or Copyright application or patent resulting therefrom,
the filing Party shall (i) provide the non-filing Party with written notice of
its wish no later than sixty (60) days before the patent, Copyright or patent or
Copyright application would otherwise become abandoned, (ii) give the non-filing
Party the right, at the non-filing Party's election and sole expense (subject to
the credit set forth below), to prosecute and/or maintain such patent, Copyright
or patent or Copyright application, and (iii) offer reasonable assistance to the
non-filing Party in connection with such prosecution and/or maintenance at no
cost to the non-filing Party except for [CONFIDENTIAL TREATMENT REQUESTED] of
the filing Party's [CONFIDENTIAL TREATMENT REQUESTED] incurred by the filing
Party in rendering such assistance. The non-filing Party shall be entitled to
recoup [CONFIDENTIAL TREATMENT REQUESTED] of such Party's documented
[CONFIDENTIAL TREATMENT REQUESTED] incurred to prosecute and/or maintain such
patents, Copyright and/or patent or Copyright applications as the filing Party
had agreed was its share of costs relating thereto pursuant to the first
paragraph of Section 10.2(b)(ii). Such amount shall be [**] by the non-filing
Party by [CONFIDENTIAL TREATMENT REQUESTED], as shown on the [CONFIDENTIAL
TREATMENT REQUESTED] provided under [CONFIDENTIAL TREATMENT REQUESTED], up to a
[CONFIDENTIAL TREATMENT REQUESTED], when [CONFIDENTIAL TREATMENT REQUESTED]
provided pursuant to [CONFIDENTIAL TREATMENT REQUESTED], in any given calendar
quarter equal to [CONFIDENTIAL TREATMENT REQUESTED] of such royalty payments
otherwise due, until such amount has been [CONFIDENTIAL TREATMENT REQUESTED].

                                      -57-
<PAGE>   66

11.      PATENT AND COPYRIGHT ENFORCEMENT AND INFRINGEMENT.

         11.1 Patent and Copyright Enforcement.

              (a) Notice. Each Party shall promptly provide written notice to
the other Party during the term of this Agreement of any (i) known infringement
or suspected infringement of a Program Patent or Program Copyright, (ii)
institution by a Third Party of a proceeding for the purpose of revoking or
holding unpatentable, invalid or unenforceable a claim of a Program Patent or
Program Copyright, or (ii) unauthorized use or misappropriation of any Program
Know-How by a Third Party of which it becomes aware.

              (b) Responsible Party. For Program Patents, Program Copyrights and
Program Know-How solely owned by a Party, the Party owning such Program Patent,
Program Copyright or Program Know-How shall have the first right of election to
(i) initiate an infringement suit or (ii) take such appropriate action as is
reasonably required to defend against such potential revoking or holding
unpatentable, invalid or unenforceable a claim of a Program Patent or Program
Copyright, or (iii) take such other appropriate action as is required to
restrain or otherwise prevent such known or suspected infringement or
unauthorized use or misappropriation ("Responsible Party"). For Program Patents,
Program Copyrights and Program Know-How jointly owned by the Parties, within
thirty (30) days after written notice under Section 11.1(a), the Parties shall
consult and agree upon which Party shall be the Responsible Party.

              (c) Initiation of Suit or Action. Within a period of one hundred
and twenty (120) days after the Responsible Party provides or receives written
notice under Section 11.1(a), the Responsible Party, in its sole discretion,
shall decide whether or not to (i) initiate an infringement suit, (ii) take such
appropriate action as is reasonably required to defend against such potential
revoking or holding unpatentable, invalid or unenforceable a claim of a Program
Patent or Program Copyright, or (iii) take such other appropriate action as is
reasonably required to restrain or otherwise prevent such known or suspected
infringement or unauthorized use or misappropriation ("Suit or Action",
collectively).

              If, within the one hundred and twenty (120) day period, the
Responsible Party advises the other Party of a decision to initiate a Suit or
Action, the Responsible Party, at its own cost, shall promptly initiate such
Suit or Action and provide written notice to the other Party of such initiation.

              For Program Patents, Program Copyrights and Program Know-How owned
solely by deCODE, and for Program Patents, Program Copyrights and Program
Know-How jointly owned and for which deCODE has been designated the Responsible
Party, in the event deCODE does not advise Roche within the one hundred and
twenty (120) day period of a decision to initiate such Suit or Action, or if
deCODE advises Roche within the one hundred and twenty (120) day period of a
decision not to initiate such Suit or Action, then Roche shall thereafter have
the right, [**], to initiate such Suit

                                      -58-
<PAGE>   67

or Action. The Party initiating the Suit or Action ("Initiating Party") shall
provide written notice to the other Party of such Suit or Action. The Initiating
Party shall keep the other Party informed of the status of any such Suit or
Action and, upon the other Party's written request, shall provide the other
Party with copies of all substantive documents filed in, and all substantive
communications relating to such Suit or Action. If necessary, the other Party
shall join as a party to the Suit or Action but shall be under no obligation to
participate except to the extent such participation is required as the result of
being named party to the suit or proceeding. At the Initiating Party's written
request, the other Party shall offer reasonable assistance to the Initiating
Party at no charge except for [CONFIDENTIAL TREATMENT REQUESTED] incurred by the
other Party in rendering such assistance. Reasonable assistance shall include,
without limitation, the execution of such legal papers as are reasonably
necessary for the prosecution, settlement or compromise of such Suit or Action.

              Each Party shall have the right to be represented in any such Suit
or Action by counsel of its own choice at its own expense.

              (d) Recovery. Any recovery obtained by any Party as a result of
any Suit or Action shall be applied first to reimburse each Party for all costs
and expenses related to such Suit or Action, and if after such reimbursement any
funds shall remain from such recovery, such remaining funds shall be
[CONFIDENTIAL TREATMENT REQUESTED] to the Initiating Party, and [CONFIDENTIAL
TREATMENT REQUESTED] to the other Party, but in no event shall the other Party
be entitled to receive more than the amount of royalties such other Party would
have received if the infringing Third Party's sales were deemed to be Net Sales
under this Agreement.

              (e) Settlement. Neither Party shall settle or compromise any such
Suit or Action in a manner which would restrict the scope or enforceability of
any Program Patent, Program Copyright or Program Know-How jointly owned by the
Parties without the prior written consent of the other Party, which consent
shall not be unreasonably withheld.

         11.2 Notice of Certification. Notwithstanding anything to the contrary
in Section 11.1, for a Program Patent claiming the making, having made, using,
offering for sale, selling or importing of a Product, should either Party
receive a certification from a Third Party under the "Drug Price Competition and
Patent Term Restoration Act of 1984" (Public Law 98-417), as amended, or its
comparable law in a country other than the USA, then such Party shall
immediately give written notice to the other Party of such certification. The
Responsible Party shall have twenty-one (21) days from the date such Party
received the certification to initiate suit. In the event the twenty-one (21)
day period expires without the Responsible Party having initiated a suit, the
other Party shall have the right, but not the obligation, to immediately bring
suit against the Third Party that filed the certification. If either Party
initiates such a suit, it will immediately notify the other Party.

                                      -59-
<PAGE>   68

         11.3 Infringement Actions by Third Parties. Each Party shall promptly
notify the other Party in the event that a Third Party at any time provides
written notice to, or commences an action, suit or proceeding against such Party
or such Party's Affiliates or sublicensees accusing infringement of patent
rights or unauthorized use or misappropriation of its technology owned or
controlled by such Third Party, based on an assertion or claim arising out of
(i) Roche's, its Affiliate's or its sublicensees making, having made, using,
offering for sale, selling or importing Diagnostic Products in the Territory
under deCODE Know-How or deCODE Patents ; (ii) Roche, its Affiliates or its
Collaborators research and/or develop Diagnostic Products; (iii) deCODE's, its
Affiliate's or its sublicensees making, having made, using, offering for sale,
selling or importing deCODE Products in the Territory under Roche Know-How or
Roche Patents; (iv) deCODE, its Affiliates or its Collaborators research and/or
develop deCODE Products; (v) either Party's fulfilling its obligations under any
and all Research Projects under this Agreement. The accused Party shall defend,
settle or compromise such action, suit or proceeding at its own discretion,
provided any rights of the other Party are not effected, and at its own cost;
provided, however, that at the accused Party's written request, the other Party
shall offer reasonable assistance to the accused Party at no charge except for
[CONFIDENTIAL TREATMENT REQUESTED] incurred by the other Party in rendering such
assistance. Reasonable assistance shall include, without limitation, the
execution of such legal papers as are reasonably necessary for the defense,
settlement or compromise of such action, suit or proceeding. Each party shall
have the right to be represented in any such action, suit or proceeding by
counsel of its own choice at its own expense.

12.      INDEMNIFICATION.

         12.1 Research Activities. Each Party agrees to indemnify, defend and
hold the other Party, its Affiliates and its sublicensees, if any, and their
respective directors, officers, employees and agents, harmless from and against
any and all liabilities, damages, losses, or reasonable costs and expenses
(including the reasonable fees of attorneys and other professionals)
(collectively "Claims") asserted by a Third Party and arising out of the
activities of the indemnifying Party in the conduct of any Research Program,
except to the extent such Claims arose out of or resulted from the negligence,
recklessness or wrongful intentional acts or omissions of the indemnified Party,
its Affiliates, or its sublicensees, if any, and their respective directors,
officers, employees and agents.

         12.2 Product Liability. Each Party shall indemnify, defend and hold the
other Party, its Affiliates and its sublicensees, if any, and their respective
directors, officers, employees and agents, harmless from and against any and all
Claims asserted by a Third Party arising out of the manufacture, use,
distribution or sale of any Product by the indemnifying Party, its Affiliates or
its sublicensees due to any negligence, recklessness or wrongful intentional
acts or omissions by, or strict liability of, the indemnifying Party, its
Affiliates or its sublicensees, if any, and their respective directors,
officers, employees and agents, except, in each case, to the extent such

                                      -60-
<PAGE>   69

Claims are due to the negligence, recklessness or wrongful intentional acts or
omissions of the indemnified Party, its Affiliates or its sublicensees, if any,
and their respective directors, officers, employees and agents.

         12.3 Notice. In the event that either Party is seeking indemnification
under Section 12.1 or 12.2, such Party shall inform the indemnifying Party of a
Claim as soon as reasonably practicable after it receives notice of the Claim,
shall permit the indemnifying Party to assume direction and control, at its
expense, of the defense of the Claim (including the sole right to settle the
claim at the sole discretion of the indemnifying Party, provided that such
settlement does not impose any material financial obligation on the indemnified
Party), and shall cooperate as requested (at the expense of the indemnifying
Party) in the defense of the Claim. The indemnified Party may, at its option and
expense, be represented in the defense of the Claim by counsel of its own
choice.

13.      PUBLICATION; NON-DISCLOSURE.

         13.1 Publication.

              (a) Manuscript. Both Parties recognize that each may wish to
publish the results of their scientific work relating to the Research Projects.
However, both Parties also recognize the importance of acquiring patent
protection and of maintaining Confidential Information as proprietary.
Consequently, subject to any applicable laws or regulations obligating either
Party to do otherwise, any proposed publication or oral presentation by either
Party shall comply with this Section 13.1. At least ninety (90) days before a
manuscript is to be submitted to a publisher, the publishing Party will provide
the chairperson and secretary of the Steering Committee with a copy of the
manuscript. If the publishing Party wishes to make an oral presentation, it will
provide the other Party ("Reviewing Party") with a copy of the abstract (if one
is submitted) at least forty (40) days before it is to be submitted. The
publishing Party will also provide to the Reviewing Party a copy of the text of
the presentation, including all slides, posters, and any other visual aids, at
least forty (40) days before the presentation is made.

              (b) Review of Manuscript. The Reviewing Party in good faith will
review the manuscript, abstract, text or any other material provided under
Section 13.1(a) ("Proposed Publication") to determine whether the Proposed
Publication (i) contains an Invention for which the Reviewing Party desires
patent protection or (ii) could reasonably be expected to have a material
adverse effect on the commercial value of any Confidential Information that the
Reviewing Party reasonably wishes to have remain proprietary. The Reviewing
Party will notify (each, a "Withdrawal Notice") the publishing Party within
thirty (30) days of receipt of the Proposed Publication if the Reviewing Party,
in good faith, determines that the Proposed Publication (i) contains an
Invention for which the Reviewing Party desires patent protection or (ii) could
reasonably be expected to have a material adverse effect on the commercial value
of

                                      -61-
<PAGE>   70

any Confidential Information that the Reviewing Party reasonably wishes to have
remain proprietary.

              (c) Delay or Withdrawal. If the Reviewing Party provides a
Withdrawal Notice that the Proposed Publication contains an Invention for which
the Reviewing Party desires patent protection, the publishing Party shall delay
its publication or presentation for a period of ninety (90) days from the date
of such Withdrawal Notice, extendible upon mutual agreement, to allow for the
filing of a priority patent application claiming the Invention. If the Reviewing
Party provides a Withdrawal Notice that the Proposed Publication could
reasonably be expected to have a material adverse effect on the commercial value
of any Confidential Information that the Reviewing Party reasonably wishes to
have remain proprietary, the Reviewing Party shall recommend changes it
reasonably believes necessary to preserve the Confidential Information as
proprietary. If the Proposed Publication contains Confidential Information that
was disclosed by the Reviewing Party to the publishing Party under this
Agreement, the publishing Party shall incorporate such recommended changes. For
all other Confidential Information, the Parties will consult in good faith and
agree on mutually acceptable modifications to the Proposed Publication to avoid
disclosure of such Confidential Information.

         13.2 Non-Disclosure and Non-use; Exceptions. During the term of this
Agreement and for five (5) years thereafter, a Receiving Party shall (i) treat
Confidential Information provided by a Disclosing Party under this Agreement as
it would treat its own Confidential Information of a similar nature and take all
reasonable precautions not to disclose such Confidential Information to Third
Parties except Affiliates or potential sublicensees who agree to be bound by the
same terms and conditions as found in this Section 13, without the Disclosing
Party's prior written authorization and (ii) not use such Confidential
Information for other than fulfilling its obligations under this Agreement. The
provisions of this Section 13.2 shall not apply to such Confidential Information
which the Receiving Party can demonstrate by written documentation:

              (a) was known or used by the Receiving Party or its Affiliates
prior to the date of disclosure to the Receiving Party or its Affiliates by the
Disclosing Party; or

              (b) either before or after the date of the disclosure to the
Receiving Party or its Affiliates, is lawfully disclosed to the Receiving Party
or its Affiliates by a third party rightfully in possession of such Confidential
Information and not under an obligation of confidentiality to the Disclosing
Party with respect to such Confidential Information; or

              (c) either before or after the date of the disclosure to the
Receiving Party or its Affiliates, becomes published or generally known to the
public through no fault or omission on the part of the Receiving Party or its
Affiliates, but such inapplicability applies only after such Confidential
Information is published or becomes generally known; or

                                      -62-
<PAGE>   71

              (d) is independently developed by the Receiving Party or its
Affiliates without reference to or reliance upon Confidential Information of the
Disclosing Party or its Affiliates; or

              (e) is required to be disclosed by the Receiving Party, its
Affiliates or its sublicensees to comply with applicable laws, to defend or
prosecute litigation or to comply with governmental regulations or court orders;
provided, however, the Receiving Party, its Affiliate or sublicensee provides
prior written notice of such disclosure to the Disclosing Party or its
Affiliates and, to the extent practicable, takes reasonable and lawful actions
to avoid and/or minimize the degree of such disclosure.

         13.3 Authorized Disclosure. The provisions of Section 13.2 shall not
prevent either Party from (i) preparing, filing, prosecuting or maintaining
patent applications or patents related to an Invention or a Product, or (ii)
disclosing Confidential Information to persons working on behalf of the
Receiving Party (and subject to confidentiality provisions set forth herein) or
to governmental agencies, to the extent the Receiving Party reasonably believes
it is required or desirable to secure government approval for the development or
marketing of a Product, or (iii) upon imminent Registration of a Product in a
country, disclosing Confidential Information to the extent reasonably necessary
to promote the use and sale of the Product in the country.

         13.4 Injunctive Relief. The Parties acknowledge that monetary damages
alone may not adequately compensate the Disclosing Party in the event of a
breach by the Receiving Party of this Section 13, and that, in addition to all
other remedies available to the Disclosing Party at law or in equity, it may be
entitled to seek injunctive relief for the enforcement of its rights under this
Section 13.

         13.5 Third Parties. Unless otherwise agreed to in writing, each Party
shall require all Third Parties, including consultants, Collaborators,
subcontractors, sublicensees or agents involved in fulfilling its obligations
under this Agreement, to be bound by the same terms and conditions as found in
this Section 13.

14.      TERM; TERMINATION.

         14.1 Term; Expiration. This Agreement shall commence as of the
Effective Date and, unless sooner terminated as provided hereunder, shall expire
as follows:

              (a) As to each Diagnostic Product in each country in the
Territory, this Agreement shall expire upon the expiration of the Royalty Term
with respect to such Diagnostic Product in such country.

              (b) As to each deCODE Product in each country in the Territory,
this Agreement shall expire upon the expiration of the Royalty Term with respect
to such deCODE Product in such country.

                                      -63-
<PAGE>   72

              (c) This Agreement shall expire in its entirety upon the
termination of the Royalty Term with respect to all Diagnostic Products and all
deCODE Products throughout the Territory.

         14.2 Effect of Expiration.

              (a) Following expiration of the term of this Agreement with
respect to a Diagnostic Product in a country in the Territory pursuant to
Section 14.1(a), Roche shall have the fully-paid, royalty-free, perpetual right
and license to continue to make, have made, use, offer for sale, sell and import
such Diagnostic Product in the Field in such country. Following expiration of
the term of this Agreement in its entirety with respect to all Diagnostic
Products pursuant to Section 14.1(c), Roche shall have the fully-paid,
worldwide, royalty-free, perpetual right and license to continue to make, have
made, use, offer for sale, sell and import all Diagnostic Products in the Field
throughout the Territory.

              (b) Following expiration of the term of this Agreement with
respect to a deCODE Product in a country in the Territory pursuant to Section
14.1(b), deCODE shall have the fully-paid, royalty-free, perpetual right and
license to continue to make, have made, use, offer for sale, sell and import
such deCODE Product in such country. Following expiration of the term of this
Agreement in its entirety with respect to all deCODE Products pursuant to
Section 14.1(c), deCODE shall have the fully-paid, worldwide, royalty-free,
perpetual right and license to continue to make, have made, use, offer for sale,
sell and import all deCODE Products in the Territory.

         14.3 Termination Without Cause.

              (a) After the Research Term.

                  (i) By Roche. Subject to Section 14.8, [CONFIDENTIAL TREATMENT
REQUESTED], at any time during the term of this Agreement, Roche may, for any
reason, without affecting or altering Roche's other obligations under this
Agreement, terminate all rights and licenses by deCODE to Roche under this
Agreement with respect to a Disease on a country-by-country basis by giving six
(6) months' prior written notice to deCODE. In such event deCODE shall be
entitled to continue to exercise the rights granted to it under this Agreement.
The effective date of such termination shall be the date six (6) months after
Roche provides such written notice to deCODE.

                  (ii) By deCODE. [CONFIDENTIAL TREATMENT REQUESTED], deCODE
may, at any time and for any reason, without affecting or altering deCODE's
other obligations under this Agreement, terminate all rights and licenses by
Roche to deCODE under this Agreement with respect to a Disease on a country by
country basis by giving six (6) months' prior written notice to Roche. In such
event Roche shall be entitled to continue to exercise the rights granted to it
under this

                                      -64-
<PAGE>   73

Agreement. The effective date of such termination shall be the date six (6)
months after deCODE provides such written notice to Roche.

              (b) Obligations. Termination of this Agreement by a terminating
Party under Section 14.3(a) shall not release the terminating Party, or its
Affiliates or sublicensees from any obligation to make payments or to pay
royalties or the percentage of Sublicensing Income to the other Party under this
Agreement that accrue prior to the effective date of such termination.

              (c) Inventory. In the event of termination by a Party under
Section 14.3(a), the terminating Party, its Affiliates and sublicensees shall
have the right for one (1) year after the effective date of such termination to
sell or otherwise dispose of all Products then in its inventory, and shall pay
royalties and the percentage of Royalty Sublicensing Income thereon, in
accordance with the provisions of this Agreement, as though the Agreement had
not terminated. After the first anniversary of the effective date of a
termination by a terminating Party under Section 14.3(a), in no event shall the
terminating Party, its Affiliates or sublicensees sell or otherwise dispose of a
Product that is covered by the terminated licenses.

         14.4 Breach by Roche Other than Under Section 6.2 or 6.4.

              (a) Procedure.

                  (i) Failure by Roche to comply with any of its material
obligations contained in this Agreement, other than an obligation under Section
6.2 or 6.4, shall entitle deCODE to give to Roche written notice ("Default
Notice") specifying the nature of the default and specifically stating that
deCODE intends to terminate this Agreement in the event Roche should fail to
cure the default.

                  (ii) Roche shall have a period ("Cure Period") of thirty (30)
days after a Default Notice to cure such default in the case of a payment
default, and ninety (90) days after a Default Notice in the case of all other
defaults. Such ninety (90) day period shall be extended to end one hundred and
twenty (120) days after a Default Notice, or otherwise as the Parties may agree,
if Roche within sixty (60) days after such Default Notice in good faith
commences and diligently continue actions to cure such default.

                  (iii) If, after a Cure Period, Roche does not cure the
specified default, deCODE shall be entitled, without prejudice to any of its
other rights conferred on it by this Agreement, and in addition to any other
remedies available to it by law or in equity, to give a written notice either:

                        (1) terminating this Agreement in its entirety; or

                        (2) without affecting or altering Roche's other
obligations under this Agreement, terminating all rights licensed by deCODE to
Roche

                                      -65-
<PAGE>   74

under this Agreement, in which event deCODE shall be entitled to continue to
exercise the rights granted to it under this Agreement.

                  (iv) The effective date of any such termination shall be the
date that Roche receives such notice pursuant to the preceding clause.

              (b) Effect of Such Breach.

                  (i) If deCODE terminates this Agreement in its entirety, after
the effective date of termination, in no event shall either Party, its
Affiliates or sublicensees make, have made, use, offer for sale, sell or import
any Product for any Disease covered by Valid Claims of Patents owned by the
other Party.

                  (ii) If deCODE, without affecting or altering Roche's other
obligations under this Agreement, terminates all rights licensed by deCODE to
Roche under this Agreement (in which event deCODE shall be entitled to continue
to exercise the rights granted to it under this Agreement), then after the
effective date of such termination in no event shall Roche, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any Diagnostic
Product covered by Valid Claims of deCODE Patents.

         14.5 Breach by deCODE.

              (a) Procedure.

                  (i) Failure by deCODE to comply with any of its material
obligations contained in this Agreement, shall entitle Roche to give to deCODE a
Default Notice specifying the nature of the default and specifically stating
that Roche intends to terminate this Agreement in the event deCODE should fail
to cure the default.

                  (ii) deCODE shall have a period a Cure Period after a Default
Notice to cure such default in the case of a payment default, and ninety (90)
days after a Default Notice in the case of all other defaults. Such ninety (90)
day period shall be extended to end one hundred and twenty (120) days after a
Default Notice, or otherwise as the Parties may agree, if deCODE within sixty
(60) days after such Default Notice in good faith commences and diligently
continue actions to cure such default.

                  (iii) If, after a Cure Period, deCODE does not cure the
relevant default, Roche shall be entitled, without prejudice to any of its other
rights conferred on it by this Agreement, and in addition to any other remedies
available to it by law or in equity, to give a written notice either:

                        (1) terminating this Agreement in its entirety; or

                                      -66-
<PAGE>   75

                        (2) without affecting or altering deCODE's other
obligations under this Agreement, terminating all rights licensed by Roche to
deCODE under this Agreement in whole, in which event Roche shall be entitled to
continue to exercise the rights granted to it under this Agreement.

                  (iv) The effective date of termination shall be the date that
deCODE receives such notice pursuant to the preceding clause.

              (b) Effect of Such Breach.

                  (i) If Roche terminates this Agreement in its entirety, after
the effective date of termination, in no event shall deCODE, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any Diagnostic
Product for any Disease covered by Valid Claims of Joint Patents (or deCODE
Patents).

                  (ii) If Roche, without affecting or altering deCODE's other
obligations under this Agreement, terminates all rights licensed by Roche to
deCODE under this Agreement in whole (in which event Roche shall be entitled to
continue to exercise the rights granted to it under this Agreement), after the
effective date of such termination in no event shall deCODE, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any deCODE
Product for any Disease.

         14.6 Obligations. In no event shall a termination under Section 5.4,
Section 6 or under this Section 14 release a Party or its Affiliates or
sublicensees from any obligation to make payments or to pay royalties or a
percentage of Sublicensing Income to the other Party under this Agreement that
accrued prior to the effective date of termination.

         14.7 Termination of Sublicenses. Upon any termination by Roche under
Section 14.3(a)(i) or by deCODE under Section 14.3(a)(ii), all sublicenses
granted by Roche under this Agreement with respect to the rights and license
being terminated shall terminate simultaneously, subject, nevertheless, in the
case of termination by Roche under Section 14.3(a)(i), to Section 14.3(c). Upon
any termination by deCODE under Section 14.3(a)(ii) or by Roche under Section
14.3.(a)(i), all sublicenses granted by deCODE under this Agreement with respect
to the rights and license being terminated shall terminate simultaneously,
subject, nevertheless, in the case of termination by deCODE under Section
14.3(a)(ii), to Section 14.3(c).

         14.8 Surviving Obligations. Termination of this Agreement in its
entirety or expiration of this Agreement shall not terminate the Parties' rights
and obligations under Sections 5.8, 5.9(a)(v), 5.10, 5.11(b), 8, 9, 10.1,
10.2(b)(c), 11 (only to the extent that a Suit or Action has been commenced
prior to the date of such termination or expiration), 12, 13, 14, and 16, which
shall survive termination or expiration hereof, as well as any other provision
intended by the Parties to survive any such termination or expiration hereof.

                                      -67-
<PAGE>   76

         14.9 No Waiver. The right of deCODE to terminate under Section 14.4,
and of Roche to terminate under Section 14.5, shall not be affected in any way
by a waiver or failure to take action with respect to any previous default. An
election of remedy by a Party for a material breach of this Agreement under this
Section on one occasion shall not constitute a waiver as to any other remedy
that may be available to such Party under this Section 14 as to any material
breach on another occasion.

         14.10 Dispute. And any dispute concerning whether a Party is in default
under the terms of this Agreement shall be referred for resolution in accordance
with Section 16.13. The effectiveness of any notice given pursuant to this
Section shall be tolled during and until such resolution of such dispute.

15.      FORCE MAJEURE.

         15.1 Events of Force Majeure. Neither Party shall be held liable or
responsible to the other Party nor be deemed to be in default under or in breach
of any provision of this Agreement for failure or delay in fulfilling or
performing any obligation of this Agreement when such failure or delay is due to
force majeure, and without the fault or negligence of the Party so failing or
delaying. For purposes of this Agreement, force majeure is defined as causes
beyond the control of the Party, including, without limitation, acts of God;
acts, regulations, or laws of any government; war; civil commotion; destruction
of production facilities or materials by fire, flood, earthquake, explosion or
storm; labor disturbances; epidemic; and failure of pubic utilities or common
carriers. In such event Roche or deCODE, as the case may be, shall immediately
notify the other Party of such inability and of the period for which such
inability is expected to continue. The Party giving such notice shall thereupon
be excused from such of its obligations under this Agreement as it is thereby
disabled from performing for so long as it is so disabled and the thirty (30)
days thereafter. The disabled Party shall also give notice immediately upon the
termination of the force majeure. To the extent possible, each Party shall use
reasonable efforts to minimize the duration of any force majeure.

16.      MISCELLANEOUS.

         16.1 Relationship of Parties. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties. Each Party's performance under this
Agreement is that of a separate entity.

         16.2 Assignment. Neither Party shall be entitled to assign its rights
hereunder without the express written consent of the other Party hereto, except
that both Roche and deCODE may otherwise assign their respective rights and
transfer their respective duties hereunder to any assignee of all or
substantially all of their respective businesses (or that portion thereof to
which this Agreement relates) or in the event of their respective merger or
consolidation or similar transaction. No assignment and transfer shall be valid
or effective unless and until the assignee/transferee shall agree in writing

                                      -68-
<PAGE>   77

to be bound by the provisions of this Agreement. Notwithstanding anything to the
contrary, during the Research Term, in no event shall deCODE be entitled to
assign its rights or delegate its obligations hereunder without the express
written consent of Roche. Notwithstanding anything to the contrary, without
notice to the other Party and without consent of the other Party, either Party
may at any time and for any reason assign all or certain rights and obligations
to its Affiliates who agree to be bound by the terms and conditions of this
Agreement; provided that such Party shall remain liable for all obligations
assigned to its Affiliates.

         16.3 Disclaimer of Warranties. THE PARTIES EXPRESSLY DISCLAIM ALL
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD
PARTY RIGHTS, UNLESS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT.

         16.4 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

         16.5 Notice. Any notice or request required or permitted to be given
under or in connection with this Agreement shall be deemed to have been
sufficiently given if in writing and personally delivered or sent by certified
mail (return receipt requested), or overnight express courier service (signature
required), prepaid, to the Party for which such notice is intended, at the
address set forth for such Party below:

              (a) In the case of Roche, to:

                  F. Hoffmann-LaRoche Ltd.
                  Diagnostics Division DL
                  Grenzacherstrasse 124
                  CH-4070 Basel
                  Switzerland
                  Attention: Head of Division

                  With a copy to:

                  Roche Molecular Systems, Inc.
                  4300 Hacienda Drive
                  Pleasanton, CA 94588 USA
                  Attention: President

              (b) In the case of deCODE, to:

                  deCODE genetics, Inc.
                  Hlidarsmari 15

                                      -69-
<PAGE>   78

                  200  Kopavogur
                  ICELAND
                  Attention:  President

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof. If delivered personally, the date of
delivery shall be deemed to be the date on which such notice or request was
given, unless otherwise set forth in this Agreement. If sent by overnight
express courier service, the date of delivery shall be deemed to be the next
business day after such notice or request was deposited with such service,
unless otherwise set forth in this Agreement. If sent by certified mail, the
date of delivery shall be deemed to be the third business day after such notice
or request was deposited with the U.S. Postal Service, or the foreign equivalent
thereto, unless otherwise set forth in this Agreement.

         16.6 Use of Name. Except as otherwise provided herein, neither Party
shall have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party for any purpose, without the prior written consent of the other Party.

         16.7 Public Announcements.

              (a) Disclosure of Agreement and Press Release. Except as required
by law (including, without limitation, disclosure requirements of the U.S.
Securities and Exchange Commission, NASDAQ or any other stock exchange on which
securities issued by deCODE are traded) and as permitted by Section 13.1,
neither Party shall make any public announcement concerning this Agreement, or
the subject matter hereof or thereof, without the prior written consent of the
other Party, which shall not be unreasonably withheld. It shall not be
unreasonable for a Party to withhold consent with respect to any public
announcement containing any Confidential Information of such Party or the
financial terms of this Agreement. In the event of a required public
announcement, the Party making such announcement shall provide the other Party
with a copy of the proposed text prior to such announcement sufficiently in
advance of the scheduled release of such announcement to afford such other Party
a reasonable opportunity to review and comment upon the proposed text, which
comment shall be incorporated unless prohibited by law, as determined by counsel
to the Party required to make such public announcements. The Parties agree that
each may make an initial public announcement consistent with the form of
announcement contained as Exhibit G.

              (b) Exceptions. Nothing in Section 13 or this Section 16.7 shall
prevent deCODE in connection with efforts to secure financing at any time during
the term of this Agreement, from issuing statements as to achievements made or
the status of the work being done by the Parties under this Agreement
("Statements"), so long as such Statements do not jeopardize the ability to
obtain patent protection on Inventions

                                      -70-
<PAGE>   79

or disclose Confidential Information; provided (except in the case of a public
offering) the recipients of such Statements agree in writing to maintain such
Statements in confidence.

              Nothing in Section 13 or this Section 16.7 shall prevent deCODE
from issuing Statements solely to the extent necessary to comply with applicable
law (including the disclosure requirements of the U.S. Securities and Exchange
Commission, NASDAQ or any other stock exchange on which securities issued by
deCODE are traded); provided that deCODE shall provide Roche with a copy of the
proposed text of such Statements sufficiently in advance of the scheduled
release thereof to afford Roche a reasonable opportunity to review and comment
upon the proposed text and discuss any disagreements thereon.

         16.8 Waiver. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for the future, or of any subsequent
breach hereof. All rights, remedies, undertakings, obligations and agreements
contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of
either Party.

         16.9 Compliance with Law. Nothing in this Agreement shall be deemed to
permit a Party to export, reexport or otherwise transfer any Technical
Information or Product under this Agreement without compliance with applicable
laws.

         16.10 Severability. When possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or
invalid under applicable law, such provision will be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of
this Agreement.

         16.11 Amendment. No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

         16.12 Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of Delaware.

                                      -71-
<PAGE>   80

         16.13 Arbitration.

              (a) Escalation. In the event the Parties are unable to resolve any
dispute, controversy or claim arising out of this Agreement, or the breach,
termination or invalidity thereof ("Dispute"), the Parties shall refer such
Dispute for further review and resolution to the Executive Officers of each
Party. The Executive Officers of each Party shall use reasonable efforts to
resolve the matter within thirty (30) days after the matter is referred to them.

              (b) Binding Arbitration. If the Executive Officers cannot resolve
the Dispute within thirty (30) days, then such Dispute shall be settled by final
and binding arbitration pursuant to the then current commercial arbitration
rules of the American Arbitration Association ("AAA") as provided below:

                  (i) The Arbitration Tribunal shall consist of three (3)
arbitrators. Each Party shall nominate in the request for arbitration and the
answer thereto one (1) arbitrator and the two (2) arbitrators so named will then
jointly appoint the third arbitrator as chairman of the Arbitration Tribunal. If
one Party fails to nominate its arbitrator or, if the Party's arbitrators cannot
agree on the person to be named as chairman within sixty (60) days, the AAA
shall make the necessary appointments of arbitrator or chairman.

                  (ii) The place of arbitration shall be in New York, New York
and the arbitration proceedings shall be held in English.

                  (iii) The award of the Arbitration Tribunal shall be final and
judgment upon such an award may be entered in any competent court or application
may be made to any competent court for juridical acceptance of such an award and
order of enforcement.

              (c) Injunctive Relief. Section 16.13(b) shall not prohibit a Party
from seeking injunctive relief from a court of competent jurisdiction in the
event of a breach or prospective breach of this Agreement by the other Party
which would cause irreparable harm to the first Party.

         16.14 Entire Agreement. This Agreement, together with the Exhibits,
which are attached hereto and made a part hereof, sets forth the entire
agreement and understanding between the Parties as to the subject matter hereof
and merges all prior discussions and negotiations between them, and neither of
the Parties shall be bound by any conditions, definitions, warranties,
understandings or representations with respect to such subject matter other than
as provided herein or as duly set forth on or subsequent to the date hereof in
writing and signed by a proper and duly authorized officer or representative of
the Party to be bound thereby.

         16.15 Parties in Interest and Bankruptcy.

                                      -72-
<PAGE>   81

              (a) All the terms and provisions of this Agreement shall be
binding upon, inure to the benefit of and be enforceable by the Parties hereto
and their respective permitted successors and assigns under Section 16.2.

              (b) Notwithstanding anything to the contrary, in the event that
either Party shall become insolvent, shall make an assignment to the benefit of
creditors, or shall have a petition in bankruptcy filed for or against it
(which, in the case of an involuntary petition, is not dismissed or stayed
within sixty (60) days after such petition is filed) ("Bankrupt Party"), the
other Party shall have the right to terminate this entire Agreement immediately
upon written notice of such termination and the provisions of Section 14.5 or
Section 14.8, as the case may be, shall apply. All rights and licenses granted
by the Bankrupt Party under this Agreement are, and shall otherwise be deemed to
be, for purposes of Section 365(n) of Title 11, US Code (the "Bankruptcy Code"),
licenses of rights to "intellectual property" as defined under Section 101(60)
of the Bankruptcy Code. Unless the other Party elects to terminate this
Agreement under this Section 16.15(b), the Parties agree that the other Party,
as a licensee of such rights under this Agreement, shall retain and may fully
exercise all of its rights and elections under the Bankruptcy Code, subject to
the continued fulfillment of its obligations under this Agreement.

         16.16 Descriptive Headings. The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

         16.17 Counterparts. This Agreement may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature of
more than one Party but all such counterparts taken together shall constitute
one and the same agreement. This Agreement may be executed by facsimile
signatures and such signatures shall be deemed to bind each Party as if such
were an original signature. The Parties may agree to substitute original
signature for any facsimile signature following execution hereof.

         16.18 Interpretation. All defined terms used in this Agreement shall
have the meaning assigned to such term under this Agreement whether used in the
singular or plural.

                                      -73-
<PAGE>   82

         IN WITNESS WHEREOF, each Party has caused this Agreement to be executed
by its duly authorized representative as of the date first set forth above.

                                         F.HOFFMANN-LA ROCHE LTD. AG

                                         By:  /s/ Heino von Prondzynski

                                         Name: Heino von Prondzynski

                                         Title: Head of Roche Diagnostics DL

                                         DECODE GENETICS, EHF

                                         By: /s/ Kari Stefansson

                                         Name: Kari Stefansson

                                         Title: Chief Executive Officer

                                      -74-
<PAGE>   83

                                    EXHIBIT A

                                 DECODE PROJECTS

[CONFIDENTIAL TREATMENT
REQUESTED]

<PAGE>   84

                                    EXHIBIT B

                EXISTING ALLIANCE DISEASES AND RESEARCH PROJECTS

--------------------------------------------------------------------------------
            DISEASE                       DESCRIPTION OF RESEARCH PROJECT
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

To be provided in accordance with the Agreement.

<PAGE>   85

                                    EXHIBIT C

                  EXISTING ROCHE DISEASES AND RESEARCH PROJECTS

--------------------------------------------------------------------------------
            DISEASE                       DESCRIPTION OF RESEARCH PROJECT
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

To be provided in accordance with the Agreement.

<PAGE>   86

                                    EXHIBIT D

                              IT RESEARCH PROJECTS

To be provided in accordance with the Agreement.

<PAGE>   87

                                    EXHIBIT E

                    NEW ROCHE DISEASES AND RESEARCH PROJECTS

--------------------------------------------------------------------------------
            DISEASE                       DESCRIPTION OF RESEARCH PROJECT
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

To be provided in accordance with the Agreement.

<PAGE>   88

                                    EXHIBIT F

                           INITIAL STEERING COMMITTEE

Initial Steering Committee Members from Roche:
         Heinrich Dreismann Ph.D., Head of Roche Molecular Systems
         Thomas Metcalfe, Ph.D., Vice President
         Henry Erlich Ph.D., Vice President

Initial Steering Committee Members from deCODE:
         Kari Stefansson, Chief Executive Officer
         Jeffrey R. Gulcher, Vice President, Research & Development
         Hakon Gudbjartsson, VP, Information Technology

Initial Steering Committee Chairperson:

Initial Steering Committee Secretary:

<PAGE>   89

                                    EXHIBIT G

                           FORM OF PUBLIC ANNOUNCEMENT

deCODE AND ROCHE SIGN LANDMARK ALLIANCE TO DEVELOP INTEGRATED DNA-BASED
DIAGNOSTIC TOOLS AND RELATED SERVICES AND SOFTWARE

The alliance has a total potential value to deCODE of over $300 million

Reykjavik, ICELAND, July 2, 2001 - deCODE genetics (Nasdaq/Nasdaq Europe:DCGN)
today announced that, effective June 29, 2001, it has signed with F.
Hoffmann-LaRoche Ltd. AG the definitive terms of their landmark five-year
alliance to develop and market DNA-based diagnostics for major diseases. The
companies announced the signing of a letter of intent to establish this alliance
in March.

The worldwide market for genomic diagnostics is estimated to grow to $4 billion
over the next ten years, and Roche aims to build on its global leadership in the
field of diagnostics to capture a significant share of this market. Roche's
alliance with deCODE is a key component of its long-term strategy. The companies
estimate that the total value of the collaboration to deCODE could exceed $300
million.

The alliance is also a central element in deCODE's ongoing strategy of creating
value by turning its unique research platform and achievements into products on
the market. The alliance builds on key deCODE and Roche assets: deCODE's
comprehensive population genomics resources and bioinformatics expertise, and
Roche's preeminence in the development and marketing of molecular diagnostics.
In addition to the development of novel DNA-based diagnostic and predisposition
screening products, the companies hope to develop point-of-care informatics
products that can assist doctors in evaluating the results of DNA-based
diagnostic tests.

Kari Stefansson, CEO of deCODE genetics, said, "We are very excited to be able
to bring together our gene research and bioinformatics know-how with the
development and marketing expertise of the world's leading diagnostics company.
We believe that these tools and decision-support systems will become a
fundamental component of future medicine, and that this alliance will create
significant value for deCODE going forward."

deCODE genetics (www.decode.com), based in Reykjavik, Iceland, is conducting
research into the inherited causes of common diseases. The company has three
main business units: discovery services - including disease-gene research, drug
target identification and pharmacogenomic services; database services; and
bioinformatics tools and services. deCODE is using its population approach to
turn raw genomics data into products and services for the global healthcare
industry.

Any statements contained in this press release that relate to future plans,
events or

<PAGE>   90

performance are forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and product
development, market acceptance, government regulation and regulatory approval
processes, intellectual property rights and litigation, dependence on strategic
partners, ability to obtain financing, competitive products and other risks
identified in deCODE's filings with the Securities and Exchange Commission.
Actual results, events or performance may differ materially. deCODE undertakes
no obligation to publicly release any revisions to these forward-looking
statements resulting from events or circumstances after the date hereof.

deCODE AND ROCHE DIAGNOSTICS: DECODE CLINICAL GENOME MINER TO PLAY KEY ROLE IN
SPEEDING GENOMIC DISCOVERY AND PRODUCT DEVELOPMENT

Reykjavik, ICELAND, and Basel, SWITZERLAND, July 16, 2001- At a press conference
held today in Reykjavik, executives from deCODE genetics (Nasdaq/Nasdaq
Europe:DCGN) and Roche Diagnostics underscored the important role deCODE's
Clinical Genome Miner will play in speeding the development of novel DNA-based
diagnostics for major diseases. As part of the companies' broad diagnostics
alliance signed and announced two weeks ago, Roche Diagnostics will become the
first diagnostics company to apply the Clinical Genome Miner's unique
combination of resources for linking together validated population data on human
genetics and common diseases.

The Clinical Genome Miner is a unique, in silico platform for genomic research,
bringing together a comprehensive collection of genetic markers and genealogical
and disease data with cutting edge bioinformatics for analyzing the genetic
basis of more than 30 common diseases. Using this powerful tool, deCODE and
Roche researchers will be able to perform - in real time - experiments that
would take months or even years in the laboratory. The companies will employ the
Clinical Genome Miner to accelerate the identification and validation of markers
for use in DNA-based diagnostic tests. It will also be employed in developing
the point-of-care informatics products that the companies plan to develop and
market to assist doctors in evaluating the results of DNA-based tests.

Kari Stefansson, CEO of deCODE genetics, said, "We are pleased that we and Roche
will be putting the power of the Clinical Genome Miner to work to speed our
discovery efforts and the development of new products. As a longstanding
corporate partner familiar with the quality and results of our research, Roche's
decision to utilize the

                                       2
<PAGE>   91

Clinical Genome Miner is an important validation of the value of our population
approach, data and bioinformatics tools."

"The partnership with deCODE is one in a series of alliances Roche is
establishing to pursue our global objectives in the areas of genetics and
genomics," stated Heino von Prondzynski, member of the Roche Executive Committee
and Head of Roche's global Diagnostics Division. "Working together with deCODE,
and leveraging the power of the Clinical Genome Miner, we will actively explore
new and innovative diagnostics and data management solutions. Physicians will
increasingly depend on bioinformatics knowledge in the prevention, diagnosis,
and management of disease. We believe that our collaboration with deCODE will
provide useful, efficient resources for point of care diagnostics, an area which
represents one of the most important concepts in the future of healthcare." "By
combining the powerful datamining resources of deCODE and the strategic
development strength of Roche, this alliance will emerge as the leading effort
of its kind in the world. This collaboration is unique in that we are working
with a genealogical database of unprecedented quality and size," said Heiner
Dreismann, Head of Roche Molecular Diagnostics. "This is the key ingredient that
will facilitate the rapid identification of the function of newly discovered
disease genes. The medical community has a need for new, informatics-based
diagnostic tools, and it is our objective to provide them as quickly and
cost-effectively as possible."

deCODE genetics, based in Reykjavik, Iceland, is conducting research into the
inherited causes of common diseases. The company has three main business units:
discovery services - including disease-gene research, drug target identification
and pharmacogenomic services; database services; and bioinformatics tools and
services. deCODE is using its population approach to turn raw genomics data into
products and services for the global healthcare industry.

Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-oriented healthcare groups in the fields of pharmaceuticals,
diagnostics and vitamins. Roche's products and services address prevention,
diagnosis and treatment of diseases, thus enhancing well-being and quality of
life. Roche has approximately 64,000 employees and sells its products in over
170 countries. In 2000 the Roche Group posted sales of 28,7 billion Swiss francs
and an adjusted net income of 5,0 billion Swiss francs. Roche's Diagnostics
Division supplies a wide array of innovative testing products and services to
researchers, physicians, patients, hospitals and laboratories worldwide.
Molecular Diagnostics, a business area of Roche Diagnostics, has made the
polymerase chain reaction (PCR) the leading DNA probe technology in the world.
PCR technology allows minute amounts of genetic material to be amplified into
billions of copies in just a few hours, thereby facilitating detection of the
DNA or RNA of pathogenic organisms even before antibodies to these organisms are
formed.

Any statements contained in this press release that relate to future plans,
events or performance are forward-looking statements that involve risks and
uncertainties

                                       3
<PAGE>   92

including, but not limited to, those relating to technology and product
development, market acceptance, government regulation and regulatory approval
processes, intellectual property rights and litigation, dependence on strategic
partners, ability to obtain financing, competitive products and other risks
identified in deCODE's filings with the Securities and Exchange Commission.
Actual results, events or performance may differ materially. deCODE undertakes
no obligation to publicly release any revisions to these forward-looking
statements resulting from events or circumstances after the date hereof.

                                       4
<PAGE>   93

                                    EXHIBIT H

                                ADDENDUM NO. (X)

                                       RE:
                           [ ______ Research Project ]

THIS addendum (the "Addendum") is entered into this ______________, 200X by and
among F.Hoffmann-LaRoche Ltd AG, having offices at Grenzacherstrasse 124,
CH-4070 Basel, Switzerland ("Roche"), and deCODE genetics, ehf., a corporation
duly organized and existing under the laws of Iceland, having offices at
Lynghals 1, IS-110 Reykjavik, Iceland ("deCODE"), and collectively referred to
as the "Parties".

PRELIMINARY STATEMENT
A.       WHEREAS, the Parties have entered into that certain Collaboration and
Cross-License Agreement re: Diagnostics, effective June 29, 2001, as amended
from time to time (the "Agreement");

B.       WHEREAS, pursuant to the Agreement, the Parties have agreed to commence
research and development in connection with a Research Project, as defined in
the Agreement;

C.       WHEREAS, pursuant to the Agreement, the Parties enter into this
Addendum and agree to the following terms with respect to the Research Project.

NOW THEREFORE, the Parties agree as follows:

1.     All capitalized used herein and not otherwise defined herein shall have
       the respective meanings given to them in the Agreement. To the extent a
       term is defined herein and also appears in the Agreement, the definition
       provided herein shall supersede that provided in the Agreement.

2.     The research project described below in this Section 2 shall become an
       [Existing Roche Research Project, Existing Alliance Research Project, New
       Roche Research Project; IT Research Project] and shall be designated as a
       Research Project with respect to the Disease, [Disease] and shall be
       known as the ["______ Research Project"]. The description of the research
       project:
       [_______________________________________________]

3.     Research milestone payments applicable to the [______ Research Project]
       shall be paid in accordance with the following schedule:

<PAGE>   94

<TABLE>
<CAPTION>
      -----------------------------------------------------------------------------------------------------------------
                     AMOUNT TO BE PAID BY                                  RESEARCH MILESTONE
                    ROCHE IN THE EVENT THE                               DELIVERABLE ITEM(S) OR     RESEARCH MILESTONE
                    RESEARCH MILESTONE IS       RESEARCH MILESTONE        OTHER CRITERIA TO BE       DELIVERY DUE DATE
           NO.             ACHIEVED              PAYMENT DUE DATE               ACHIEVED                 (IF ANY)
       -----------------------------------------------------------------------------------------------------------------
       <S>          <C>                         <C>                      <C>                        <C>

       -----------------------------------------------------------------------------------------------------------------

       -----------------------------------------------------------------------------------------------------------------

       -----------------------------------------------------------------------------------------------------------------

       -----------------------------------------------------------------------------------------------------------------
</TABLE>

4.     The development plan for the [______ Research Project] shall be as
       follows:

              a.  Development milestone payments applicable to the Diagnostic
                  Product(s) that have been, are or will be developed in
                  connection with the [Research Project] shall be paid in
                  accordance with the following schedule:

<TABLE>
<CAPTION>
       --------------------------------------------------------------------------------------------------------------------
                      AMOUNT TO BE PAID BY                                  DEVELOPMENT MILESTONE
                     ROCHE IN THE EVENT THE                                 DELIVERABLE ITEM(S) OR    DEVELOPMENT MILESTONE
                    DEVELOPMENT MILESTONE IS     DEVELOPMENT MILESTONE       OTHER CRITERIA TO BE       DELIVERY DUE DATE
           NO.              ACHIEVED               PAYMENT DUE DATE               ACHIEVED                  (IF ANY)
       --------------------------------------------------------------------------------------------------------------------
       <S>          <C>                          <C>                        <C>                       <C>

       --------------------------------------------------------------------------------------------------------------------

       --------------------------------------------------------------------------------------------------------------------

       --------------------------------------------------------------------------------------------------------------------

       --------------------------------------------------------------------------------------------------------------------

       --------------------------------------------------------------------------------------------------------------------
</TABLE>

              b.  Royalty rates payable on the Diagnostic Product(s) arising
                  from the [______ Research Project] shall be as follows:

       -------------------------------------------------------------------------
                                              ROYALTY RATE
       Diagnostic Product(s)
       -------------------------------------------------------------------------

       -------------------------------------------------------------------------

5.     The number of FTEs assigned to [_____ Research  Project] and amount of
       research funding for the [______ Research  Project] shall be as follows:

       -------------------------------------------------------------------------
                                              RESEARCH FUNDING AMOUNT (ANNUAL)
       Number of FTEs
       -------------------------------------------------------------------------

       -------------------------------------------------------------------------

6.     Each of the Parties shall list the name, overnight mailing address, email
       address, telephone number and fax number for each of their respective
       project managers and principal scientists working on the [_____ Research
       Project].

                                       2
<PAGE>   95

7.     The Parties may mutually agree to additional terms and conditions not
       addressed in this Addendum which, when so agreed, shall be attached
       hereto and become part hereof.

8.     The [______ Research Project] and the terms of this Addendum have been
       reviewed and duly approved (in accordance with the Agreement) by the
       Steering Committee at its [date] meeting.

In witness hereof, the Parties have entered into this Addendum No. ___ on the
date first written above.

                                        F.HOFFMANN-LA ROCHE LTD. AG
                                        DIAGNOSTICS DIVISION DL

                                        By: ____________________________________

                                        Name: __________________________________

                                        Title: _________________________________

                                        DECODE GENETICS, EHF

                                        By: ____________________________________

                                        Name: __________________________________

                                        Title: _________________________________

                                       3
<PAGE>   96

                                    EXHIBIT I

                            TERMS FOR "CGM DATABASE'

                  Subscription to deCODE Clinical Genome Miner
                                   Term Sheet

This term sheet ("Term Sheet") summarizes the principal terms and conditions of
the proposed arrangement regarding subscription to the deCODE Clinical Genome
Miner between F. Hoffmann-La Roche Ltd. AG ("Roche") and deCODE genetics, Inc.
("deCODE"), jointly known as the parties ("Parties") of this Term Sheet, dated
June 29, 2001.

Introduction and Background

Roche and deCODE have or will enter into that certain Collaboration and
Cross-License Agreement RE: Diagnostics of even date with this Term Sheet, (the
"Diagnostics Agreement"). Pursuant to the Diagnostics Agreement, Roche will be
granted access to the deCODE Clinical Genome Miner, a bioinformatics tool
developed by deCODE to facilitate more rapid and effective research into the
genetic basis for diseases and other clinical phenotypes.

The Term Sheet sets forth the general terms and conditions upon which the
Parties will negotiate and execute a mutually acceptable definitive agreement
substantially in accordance with the terms and conditions set forth in this Term
Sheet. This Term Sheet is a commitment to enter into a definitive agreement.
This Term Sheet constitutes a legally binding commitment and obligation of both
Parties, until a definitive Agreement has been executed by both Parties, with
respect to the subject matter contemplated by this Term Sheet.

Agreement:                    Subscription to deCODE Clinical Genome Miner
                              ("CGM")

Field:                        Analysis of genes, micro-satellite markers,
                              polymorphisms, SNPs and their association with
                              diseases, symptoms, drug response and other
                              phenotypes for the purposes of developing know-how
                              for the research, development and
                              commercialisation of products within agreed
                              classes to include diagnostic, therapeutic and
                              pharmacogenetic products.

<PAGE>   97

CGM License:                  DeCODE shall grant Roche and its Affiliates as
                              defined in the Diagnostics Agreement, a
                              non-exclusive non-transferable license to the CGM,
                              as described in Appendix A, for Roche's use in the
                              conduct of its internal research and development
                              programs in the Field.

                              Roche shall not have the right to sub-license or
                              to use the CGM to develop or commercialise
                              products which are deemed to involve [CONFIDENTIAL
                              TREATMENT REQUESTED] from its use of the CGM (to
                              be defined).

                              Roche shall be responsible for obtaining any
                              licenses necessary for the use of third party
                              software incorporated into the CGM, including

                              [CONFIDENTIAL TREATMENT REQUESTED].

Authorised Use:               Roche shall have the right to design and run
                              queries which analyse

                              [CONFIDENTIAL TREATMENT REQUESTED]

                              contained in the CGM, and to view, save and
                              download the results of those queries to computers
                              at Roche facilities for further copying,
                              manipulation and analysis by Roche.

Restrictions as to            Notwithstanding the above, Roche's usage of the
Roche use                     CGM shall be subject to certain restrictions to be
                              agreed upon in order to comply with privacy
                              requirements ("Privacy Requirements"). Such
                              restrictions to potentially include the following:

                                    i)      Roche shall not be able to access,
                                            view, download or save Primary Data
                                            in any way, directly or indirectly.

                                    ii)     Roche shall not be able to undertake
                                            analysis the results of which might
                                            contain personally identifiable
                                            information.

                                    iii)    Roche shall not be able to download
                                            Results data which contains any
                                            individual data, including encrypted
                                            identifiers of patients with defined
                                            phenotype, encrypted identifiers of
                                            relatives in any pedigree, and
                                            genotypes whether encrypted or

                                       2
<PAGE>   98

                                            otherwise.

                                    iv)     Any software developed in
                                            partnership or on behalf of Roche
                                            for analysing Primary Data shall be
                                            subject to approval by deCODE (and
                                            any other entities required by
                                            Icelandic law) in order to ensure
                                            that they comply with the above
                                            restrictions.

Privacy Requirements          The Privacy Requirements shall be determined by
                              deCODE prior to the Agreement in order to ensure
                              the protection of privacy of all individuals,
                              alive or dead, for whom phenotypic, genealogic or
                              genotypic data can be accessed through queries by
                              Roche.

Number of User                Roche shall have the right to access the CGM
Connections                   through up to [CONFIDENTIAL TREATMENT REQUESTED]
                              User Connections at the same time. Roche shall be
                              free to authorise [**] for each User Connection.
                              The number of users is [CONFIDENTIAL TREATMENT
                              REQUESTED].

Limits to Usage               deCODE shall allocate to Roche certain
                              computational capacity defined in terms of network
                              connections, CPUs, memory, and storage space. This
                              capacity shall support normal usage levels by [**]
                              simultaneous Roche Users using the deCODE query
                              software and interfaces without regard to the
                              number.

Related Services:             deCODE shall provide to Roche the following
                              services relating to use of the CGM during the
                              Term of the Agreement:

Training                      deCODE shall provide all necessary documentation
                              and information for utilisation of the CGM. DeCODE
                              shall also provide reasonable training to an
                              agreed number of Roche personnel. Such training
                              shall be provided at locations to be agreed by the
                              Parties. Each Party shall bear the costs relating
                              to its own employees, including wages and
                              out-of-pocket expenses. Roche shall have the right
                              to request additional training from deCODE. The
                              cost of such additional training, including a per
                              diem rate for each deCODE employee and any related
                              out-of-pocket expenses, shall be borne by Roche.

User Support                  deCODE shall provide support to CGM users in
                              relation to questions and problems relating to use
                              of the CGM. Routine User Support shall be provided
                              by telephone or e-mail access to support
                              technicians located in Iceland between 8am and
                              10pm Icelandic time. Outside of these hours,
                              routine user

                                       3
<PAGE>   99

                              support requests shall be logged and responded to
                              by telephone or e-mail on the next business day.

                              Critical User Support shall be provided by
                              telephone, e-mail or at deCODE's site
                              [CONFIDENTIAL TREATMENT REQUESTED], except during
                              public holidays, (which shall be disclosed in
                              advance) for certain types of requests as mutually
                              defined by deCODE and Roche, for example
                              correction of equipment malfunctions at deCODE
                              which prevent Roche from accessing the CGM.

IT Support                    deCODE shall provide and maintain the IT
                              infrastructure at deCODE's site that is necessary
                              to support use of the CGM and meet reasonable
                              standards of security and performance, including
                              the average time required for a submitted query of
                              a given complexity to be processed and the results
                              reported. deCODE shall not be responsible for loss
                              of performance due to disturbances and
                              malfunctions in public and third party networks.

                              Such infrastructure shall include the deCODE
                              computer network which undertakes CGM queries
                              requested by Roche, a server dedicated to managing
                              and storing Roche specific CGM queries (the "Roche
                              Server"), and the communication systems necessary
                              for connecting Roche Users to the Roche Server and
                              deCODE computer networks and facilitating the
                              transmission of query requests from Roche to
                              deCODE and the transmission of query results from
                              deCODE to Roche in a reliable and timely manner.

                              deCODE shall also assist Roche to determine the
                              minimum specifications for hardware and software
                              required at designated Roche sites for effective
                              use of the CGM by Roche Users. Roche will be
                              responsible for providing such hardware and
                              software to the Roche Users at Roche's sites.

Maintenance of Roche          deCODE shall maintain the Roche Server at deCODE's
Servers                       site in reasonable working condition at all times,
                              except for scheduled periods of maintenance
                              requiring the equipment to be off-line.

                              Roche shall be responsible for maintaining the
                              Roche Servers at the Roche sites.

Updates to CGM                deCODE shall provide updates to Primary Data (as
                              defined in Appendix A) at least every
                              [CONFIDENTIAL TREATMENT

                                       4
<PAGE>   100

                              REQUESTED].

                              deCODE shall periodically provide updates to debug
                              and enhance the analysis and visualisation tools
                              of the CGM (as defined in Appendix A), as deCODE
                              determines is necessary or desirable.

Term:                         The term of the Agreement shall be [CONFIDENTIAL
                              TREATMENT REQUESTED].

Subscription Fee:             N/A provided Roche pays all amounts set forth in
                              the Diagnostic Agreement and in accordance with
                              the terms of the Diagnostic Agreement . If Roche
                              breaches the Diagnostic Agreement, the Agreement
                              will terminate.

                              Roche's subscription shall also entitle it to
                              request from deCODE Additional Services (described
                              below). Such Additional Services will be provided
                              at costs mutually agreed by Roche to deCODE. Any
                              such Additional Services shall be subject to a
                              separate agreement.

Royalties:                    Roche shall pay to deCODE a royalty of [**]on all
                              net sales received by Roche from products or
                              services that have been developed by Roche which
                              incorporates Roche Intellectual Property for which
                              a patent has been granted to Roche or its
                              licensees whose claims are supported by or
                              otherwise incorporate information or data
                              contained in the CGM.

                              Roche shall be required to notify deCODE from time
                              to time of such Roche Intellectual Property, and
                              of any such products or services developed by
                              Roche thereon
Exclusivity:                  Roche's subscription to the CGM shall be
                              non-exclusive.

                              Additional data generated by deCODE specifically
                              for Roche in the course of providing Additional
                              Services shall be exclusive to Roche.

Intellectual Property:

Existing IP                   deCODE shall own all Intellectual Property,
                              patentable or otherwise ("IP") that it has created
                              in the course of developing the CGM and providing
                              it to Roche.

                              deCODE shall own all IP that deCODE and/or Roche
                              have created in the course of modifying the CGM to
                              meet the

                                       5
<PAGE>   101

                              specifications of Roche prior to or during the
                              Term of the Agreement.

IP arising from Roche         Roche shall own all intellectual property,
Subscription                  patentable or otherwise, that it creates as a
                              result of its use of the CGM ("Roche Intellectual
                              Property"). Roche Intellectual Property for which
                              a patent (as defined above[royalty section]) has
                              been granted to Roche shall be royalty-bearing as
                              provided above. All other Roche Intellectual
                              Property shall be royalty-free.

                              Roche shall own all IP that it provides to deCODE
                              in the course of developing and using the CGM, and
                              deCODE shall not have any right to use such IP
                              without the express written consent of Roche.

                              deCODE shall own all IP developed by deCODE and/or
                              Roche in the course of deCODE providing Additional
                              Services to Roche.

Additional Services:          During the Term of the Agreement, Roche shall have
                              the right to request from deCODE services
                              involving the Customisation of Software and
                              Generation of Additional Data for use in
                              combination with the CGM. The provision of each
                              such Additional Services shall be governed by a
                              separate agreement between the parties. DeCODE
                              shall have no obligation to provide any such
                              services unless and until a definitive agreement
                              regarding the provision of such services, mutually
                              acceptable to both Parties, is entered into by the
                              Parties.

Software Customisation        Modification of CGM software provided by deCODE
                              for the use of Roche data, algorithms,
                              visualisation tools and software in connection
                              with the CGM and any Additional Data.

Generation of                 Generation of [**] data [CONFIDENTIAL TREATMENT
Additional Data               REQUESTED] as specified by Roche for [CONFIDENTIAL
                              TREATMENT REQUESTED] defined by Roche. Such data
                              to be confidential to Roche and accessed in the
                              same manner as data contained in the CGM.

                              Generation of [CONFIDENTIAL TREATMENT REQUESTED]
                              data [CONFIDENTIAL TREATMENT REQUESTED] as
                              specified by Roche for [CONFIDENTIAL TREATMENT

                                       6
<PAGE>   102

                              REQUESTED] defined by Roche and accessed in the
                              same manner as data contained in the CGM.

Publication of Results:       Each party shall have the right to review any
                              proposed publication of the results of any
                              development work, in a manner mutually agreed to
                              by the Partiesprior to publication.

Governing Law &               The Agreement shall be governed by the laws of the
Jurisdictions:                State of Delaware, U.S., without regard to its
                              conflict of law principles, and all actions
                              arising from the Agreement, including
                              arbitrations, shall be conducted in New York, New
                              York. The Parties shall agree to use binding
                              arbitration to resolve disputes between the
                              Parties, other than disputes where either Party is
                              seeking injunctive relief, in accordance with the
                              commercial arbitration rules of the AAA.

Miscellaneous                 The Agreement shall include customary provisions
Provisions:                   to address payment terms, patent prosecution,
                              enforcement and infringement, confidentiality,
                              representations and warranties, indemnification,
                              early termination and effect, and such other
                              provisions as the parties deem appropriate.

                                       7
<PAGE>   103

Appendix A - Clinical Genome Miner Description

The Clinical Genome Miner has two integrated components, the Disease Miner and
the Genome Miner.

The Disease Miner contains genealogical, phenotypic and genotypic information
[CONFIDENTIAL TREATMENT REQUESTED] and allows Roche to analyse the degree and
location of genetic sharing across [CONFIDENTIAL TREATMENT REQUESTED] selected
by Roche [CONFIDENTIAL TREATMENT REQUESTED].

The Genome Miner contains sequence level data and a range of sophisticated
analysis and visualisation tools to allow in-depth analysis of individual genes
highlighted by the Disease Miner. Attractive features of the Genome Miner
include a genome scaffold based on deCODE's proprietary high resolution
physical and genetic map, integrated view of third party exon-predicting tools,
location of deCODE's microsatellite marker map and the locations of 1.3
million SNP's from the public domain.

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]